Any feedback?
Information on EC 2.1.1.354 - [histone H3]-lysine4 N-trimethyltransferase and Organism(s) Homo sapiens and UniProt Accession Q9H7B4
for references in articles please use BRENDA:EC2.1.1.354Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
2.1.1.354 [histone H3]-lysine4 N-trimethyltransferaseIUBMB Comments
This entry describes several enzymes that successively methylate the L-lysine4 residue of histone H3 (H3K4), ultimately generating a trimethylated form. These modifications influence the binding of chromatin-associated proteins. In most cases the trimethylation of this position is associated with gene activation. EC 2.1.1.364, [histone H3]-lysine4 N-methyltransferase, describes enzymes that can catalyse only monomethylation of this substrate (the first sub-reaction of this entry); EC 2.1.1.370, [histone H3]-lysine4 N-dimethyltransferase, describes enzymes that catalyse only dimethylation of this substrate (the first two sub-reactions of this entry)
Specify your search results
Word Map
- 2.1.1.354
-
navigation
- methyltransferases
-
birds
-
trimethylation
-
migratory
- myeloid
-
home
-
hotspot
-
meiotic
-
student
-
school
-
intellectual
-
homing
-
earth
-
moral
-
whole-exome
-
youth
- nucleosome
-
landmark
- rivaroxaban
-
mixed-lineage
-
cryptochrome
-
desert
- pigeon
- pik3ca
-
polycomb
-
journey
-
leukemogenesis
-
ontario
- crebbp
- heterochromatin
- butterfly
-
h3k4me2
-
songbird
-
migrant
-
azimuth
- suv39h1
-
arid1a
- demethylases
-
zeste
-
magnetite
-
cdkn2a
-
alberta
-
writer
-
euchromatic
-
homeotic
-
histone-modifying
- setdb1
-
chromatin-modifying
-
school-based
- medicine
The taxonomic range for the selected organisms is: Homo sapiens
The expected taxonomic range for this enzyme is: Eukaryota, Bacteria
The expected taxonomic range for this enzyme is: Eukaryota, Bacteria
Reaction Schemes
Synonyms
compass, dot1l, smyd3, kmt2d, prdm9, kmt2a, smyd2, kmt2c, ash2l, setd1a, 
more
topPlease wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
Ash1L
-
-
-
-
KMT2A
-
-
-
-
KMT2B
-
-
-
-
KMT2C
-
-
-
-
KMT2D
-
-
-
-
KMT2E
-
-
-
-
KMT2F
-
-
-
-
KMT2G
-
-
-
-
KMT2H
-
-
-
-
KMT3C
-
-
-
-
KMT3E
-
-
-
-
MLL1
-
-
-
-
MLL2
-
-
-
-
MLL3
MLL4
MLL5
-
-
-
-
PRDM7
Prdm9
-
-
-
-
Setd1A
SMYD1
-
-
-
-
Smyd2
-
-
-
-
Smyd3
-
-
-
-
MLL3
-
-
-
-
MLL4
-
-
-
-
PRDM7
-
-
-
-
Setd1A
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION
REACTION DIAGRAM
COMMENTARY
ORGANISM
UNIPROT
LITERATURE
S-adenosyl-L-methionine + histone L-lysine = S-adenosyl-L-homocysteine + histone N6-methyl-L-lysine
S-adenosyl-L-methionine + histone L-lysine = S-adenosyl-L-homocysteine + histone N6-methyl-L-lysine
enzyme is encoded on genes containing the SET-domain sequence, substrate specificity is connected to SET sequence
-
S-adenosyl-L-methionine + histone L-lysine = S-adenosyl-L-homocysteine + histone N6-methyl-L-lysine
SET structure
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYSTEMATIC NAME
IUBMB Comments
S-adenosyl-L-methionine:[histone H3]-L-lysine4 N6-methyltransferase
This entry describes several enzymes that successively methylate the L-lysine4 residue of histone H3 (H3K4), ultimately generating a trimethylated form. These modifications influence the binding of chromatin-associated proteins. In most cases the trimethylation of this position is associated with gene activation. EC 2.1.1.364, [histone H3]-lysine4 N-methyltransferase, describes enzymes that can catalyse only monomethylation of this substrate (the first sub-reaction of this entry); EC 2.1.1.370, [histone H3]-lysine4 N-dimethyltransferase, describes enzymes that catalyse only dimethylation of this substrate (the first two sub-reactions of this entry)
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
3 S-adenosyl-L-methionine + a [histone H3]-L-lysine4
3 S-adenosyl-L-homocysteine + a [histone H3]-N6,N6,N6-trimethyl-L-lysine4
overall reaction
-
-
?
S-adenosyl-L-methionine + a [histone H3]-L-lysine4
S-adenosyl-L-homocysteine + a [histone H3]-N6-methyl-L-lysine4
-
-
-
?
S-adenosyl-L-methionine + a [histone H3]-N6,N6-dimethyl-L-lysine4
S-adenosyl-L-homocysteine + a [histone H3]-N6,N6,N6-trimethyl-L-lysine4
-
-
-
?
S-adenosyl-L-methionine + a [histone H3]-N6-methyl-L-lysine4
S-adenosyl-L-homocysteine + a [histone H3]-N6,N6-dimethyl-L-lysine4
-
-
-
?
3 S-adenosyl-L-methionine + a [histone H3]-L-lysine4
3 S-adenosyl-L-homocysteine + a [histone H3]-N6,N6,N6-trimethyl-L-lysine4
overall reaction
-
-
?
S-adenosyl-L-methionine + a [histone H3]-L-lysine4
S-adenosyl-L-homocysteine + a [histone H3]-N6-methyl-L-lysine4
-
-
-
?
S-adenosyl-L-methionine + a [histone H3]-N6,N6-dimethyl-L-lysine4
S-adenosyl-L-homocysteine + a [histone H3]-N6,N6,N6-trimethyl-L-lysine4
-
-
-
?
S-adenosyl-L-methionine + a [histone H3]-N6-methyl-L-lysine4
S-adenosyl-L-homocysteine + a [histone H3]-N6,N6-dimethyl-L-lysine4
-
-
-
?
S-adenosyl-L-methionine + ART(Kme1)QTARKSTGGKAPRKQLATKAA-GK-biotin
S-adenosyl-L-homocysteine + ART(Kme2)QTARKSTGGKAPRKQLATKAA-GK-biotin
-
-
-
?
S-adenosyl-L-methionine + ART(Kme2)QTARKSTGGKAPRKQLATKAA-GK-biotin
S-adenosyl-L-homocysteine + ART(Kme3)QTARKSTGGKAPRKQLATKAA-GK-biotin
highest activity
-
-
?
S-adenosyl-L-methionine + ARTKQTARKSTGGKAPRKQLATKAA-GK-biotin
S-adenosyl-L-homocysteine + ART(Kme1)QTARKSTGGKAPRKQLATKAA-GK-biotin
-
-
-
?
S-adenosyl-L-methionine + histone L-lysine
S-adenosyl-L-homocysteine + histone N6-methyl-L-lysine
-
-
-
?
additional information
?
-
Set1/CXXC finger protein 1 complex transfers tritiated methyl groups onto both purified core histones and recombinant histone H3, fails to catalyze methylation of histone H4, specificity for histone H3-Lys4 methylation
-
-
?
additional information
?
-
-
Set1/CXXC finger protein 1 complex transfers tritiated methyl groups onto both purified core histones and recombinant histone H3, fails to catalyze methylation of histone H4, specificity for histone H3-Lys4 methylation
-
-
?
additional information
?
-
-
CXXC finger protein 1 is a component of the Setd1A and Setd1B histone H3K4 methyltransferase complex
-
-
?
additional information
?
-
no activity with ARTAQTARKSTGGKAPRKQLATKAA-GK-biotin, ATKAARKSAPATGGVKKPHRYRPG-GK-biotin, ATKAARKSAPATGGV(Kme1)KPHRYRPGGK-biotin, and ATKAARKSAPATGGV(Kme2)KPHRYRPG-GK-biotin
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
3 S-adenosyl-L-methionine + a [histone H3]-L-lysine4
3 S-adenosyl-L-homocysteine + a [histone H3]-N6,N6,N6-trimethyl-L-lysine4
overall reaction
-
-
?
S-adenosyl-L-methionine + a [histone H3]-L-lysine4
S-adenosyl-L-homocysteine + a [histone H3]-N6-methyl-L-lysine4
-
-
-
?
S-adenosyl-L-methionine + a [histone H3]-N6,N6-dimethyl-L-lysine4
S-adenosyl-L-homocysteine + a [histone H3]-N6,N6,N6-trimethyl-L-lysine4
-
-
-
?
S-adenosyl-L-methionine + a [histone H3]-N6-methyl-L-lysine4
S-adenosyl-L-homocysteine + a [histone H3]-N6,N6-dimethyl-L-lysine4
-
-
-
?
3 S-adenosyl-L-methionine + a [histone H3]-L-lysine4
3 S-adenosyl-L-homocysteine + a [histone H3]-N6,N6,N6-trimethyl-L-lysine4
overall reaction
-
-
?
S-adenosyl-L-methionine + a [histone H3]-L-lysine4
S-adenosyl-L-homocysteine + a [histone H3]-N6-methyl-L-lysine4
-
-
-
?
S-adenosyl-L-methionine + a [histone H3]-N6,N6-dimethyl-L-lysine4
S-adenosyl-L-homocysteine + a [histone H3]-N6,N6,N6-trimethyl-L-lysine4
-
-
-
?
S-adenosyl-L-methionine + a [histone H3]-N6-methyl-L-lysine4
S-adenosyl-L-homocysteine + a [histone H3]-N6,N6-dimethyl-L-lysine4
-
-
-
?
S-adenosyl-L-methionine + histone L-lysine
S-adenosyl-L-homocysteine + histone N6-methyl-L-lysine
-
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acquired Immunodeficiency Syndrome
AIDS and volunteer associations: perspectives on social and individual change.
Acquired Immunodeficiency Syndrome
The elephant from the other side of silence (or HIV news from four compass points). XV International AIDS Conference, Bangkok, 11-16 July 2004.
Acquired Immunodeficiency Syndrome
[Remarks on the paper: present means of lokalising intra-ocular foreign bodies, by M. Severin (author's transl)]
Acute Coronary Syndrome
Rivaroxaban in Acute Coronary Syndromes: We Have a Compass and an Atlas, But Where Are We Headed?
Acute Coronary Syndrome
[Antithrombotic therapy after acute coronary syndromes: is it possible to identify the PEGASUS and COMPASS patient?]
Adamantinoma
Comprehensive Molecular Characterization of Adamantinoma and OFD-like Adamantinoma Bone Tumors.
Adenocarcinoma
A novel nuclear Src and p300 signaling axis controls migratory and invasive behavior in pancreatic cancer.
Adenocarcinoma
Copy-number variation and protein expression of DOT1L in pancreatic adenocarcinoma as a potential drug target.
Adenocarcinoma
Feasibility and Safety of Transhiatal Approach and D2 Total Gastrectomy after Neoadjuvant Chemotherapy for Adenocarcinoma of the Esophago-Gastric Junction: A Subset Analysis of the COMPASS Trial.
Adenocarcinoma
Genetic characteristics of gastric-type mucinous carcinoma of the uterine cervix.
Adenocarcinoma
Integrative molecular characterization of Chinese prostate cancer specimens.
Adenocarcinoma
KMT2C Mutations in Diffuse-Type Gastric Adenocarcinoma Promote Epithelial-to-Mesenchymal Transition.
Adenocarcinoma
KMT2D deficiency enhances the anti-cancer activity of L48H37 in pancreatic ductal adenocarcinoma.
Adenocarcinoma
Molecular Genetic Features of Primary Nonurachal Enteric-type Adenocarcinoma, Urachal Adenocarcinoma, Mucinous Adenocarcinoma, and Intestinal Metaplasia/Adenoma: Review of the Literature and Next-generation Sequencing Study.
Adenocarcinoma
Reduced Expression of Histone Methyltransferases KMT2C and KMT2D Correlates with Improved Outcome in Pancreatic Ductal Adenocarcinoma.
Adenocarcinoma
Thymic adenocarcinoma accompanied by type A thymoma and pulmonary minimally invasive adenocarcinoma and harboring distinct gene alterations: A case report.
Adenocarcinoma
Transformation of advanced lung adenocarcinoma to acquired T790M resistance mutation adenosquamous carcinoma following tyrosine kinase inhibitor: a case report.
Adenocarcinoma
Validation of a targeted next-generation sequencing approach to detect mismatch repair deficiency in colorectal adenocarcinoma.
Adenocarcinoma of Lung
Comprehensive analysis of age-related somatic mutation profiles in Chinese young lung adenocarcinoma patients.
Adenocarcinoma of Lung
Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib.
Adenocarcinoma of Lung
Epigenetic Role of Histone Lysine Methyltransferase and Demethylase on the Expression of Transcription Factors Associated with the Epithelial-to-Mesenchymal Transition of Lung Adenocarcinoma Metastasis to the Brain.
Adenocarcinoma of Lung
H3K4 Methylation Status and Lysine Specific Methyltransferase KMT2C Expression Correlate with Prognosis in Lung Adenocarcinoma.
Adenocarcinoma of Lung
Hit identification of SMYD3 enzyme inhibitors using structure-based pharmacophore modeling.
Adenocarcinoma of Lung
SMYD2 promotes tumorigenesis and metastasis of lung adenocarcinoma through RPS7.
Adenoma
miR-142-3p down-regulation contributes to thyroid follicular tumorigenesis by targeting ASH1L and MLL1.
Adenoma
Molecular Genetic Features of Primary Nonurachal Enteric-type Adenocarcinoma, Urachal Adenocarcinoma, Mucinous Adenocarcinoma, and Intestinal Metaplasia/Adenoma: Review of the Literature and Next-generation Sequencing Study.
Adenomatous Polyposis Coli
SMYD2 suppresses APC2 expression to activate the Wnt/?-catenin pathway and promotes epithelial-mesenchymal transition in colorectal cancer.
Agammaglobulinemia
Defects of B-cell terminal differentiation in patients with type-1 Kabuki syndrome.
Alzheimer Disease
Adjusting the compass: new insights into the role of angiogenesis in Alzheimer's disease.
Alzheimer Disease
COMPASS: A computational model to predict changes in MMSE scores 24-months after initial assessment of Alzheimer's disease.
Alzheimer Disease
Dominantly inherited Alzheimer's disease: a compass for drug development.
Anemia, Aplastic
A Patient with Kabuki Syndrome Mutation Presenting with Very Severe Aplastic Anemia.
Anemia, Hemolytic, Autoimmune
Autoimmune Cytopenias in Chronic Lymphocytic Leukemia: Focus on Molecular Aspects.
Anemia, Hemolytic, Autoimmune
Frequent somatic mutations of KMT2D (MLL2) and CARD11 genes in primary cold agglutinin disease.
Anosmia
Bilateral participation of the hippocampus in familiar landmark navigation by homing pigeons.
Aortic Aneurysm, Abdominal
Replication of Newly Identified Genetic Associations Between Abdominal Aortic Aneurysm and SMYD2, LINC00540, PCIF1/MMP9/ZNF335, and ERG.
Asthma
Direct healthcare cost comparison of Fluticasone propionate/Salmeterol vs Budesonide/Formoterol Maintenance And Reliever Therapy for moderate/severe asthma: Results from Thailand.
Asthma
Direct healthcare costs associated with management of asthma: comparison of two treatment regimens in Indonesia, Thailand and Vietnam.
Astigmatism
[Postoperative astigmatism in senile cataract operation performed with the compass keratome and pre-placed sutures]
Atherosclerosis
Deficiency of histone lysine methyltransferase SETDB2 in hematopoietic cells promotes vascular inflammation and accelerates atherosclerosis.
Atherosclerosis
Mortality benefit in the COMPASS trial: is it related to superior statistical power or better efficacy and safety?
Atherosclerosis
Myocardin-Related Transcription Factor A Mediates LPS-Induced iNOS Transactivation.
Atherosclerosis
Non-vitamin K antagonist oral anticoagulants (NOACs) in the treatment of coronary and peripheral atherosclerosis. Expert Consensus.
Atherosclerosis
[Do the patients with peripheral atherosclerosis need to a medical therapy before the revascularization?]
Atrial Fibrillation
Compass Mapping, Double Potentials, Activation Patterns Can Identify and Track Rotational Activity Sites in the Left Atrium of Humans with Persistent Atrial Fibrillation.
Atrial Fibrillation
Non-vitamin K antagonist oral anticoagulants beyond atrial fibrillation: what did we learn from COMPASS and COMMANDER-HF?
Atrial Fibrillation
Rivaroxaban in patients with ischaemic chronic cardiomyopathy and obstructive peripheral arterial disease: rationale for treatment and results.
Atypical Squamous Cells of the Cervix
MoSnt2-dependent deacetylation of histone H3 mediates MoTor-dependent autophagy and plant infection by the rice blast fungus Magnaporthe oryzae.
Autoimmune Diseases
Ash1l and lnc-Smad3 coordinate Smad3 locus accessibility to modulate iTreg polarization and T cell autoimmunity.
Autoimmune Diseases
Histone methyltransferase ash1l suppresses interleukin-6 production and inflammatory autoimmune diseases by inducing the ubiquitin-editing enzyme a20.
Azoospermia
Novel karyotypes of partial monosomy 21 and partial monosomy 1 and underlying etiology.
Azoospermia
PRDM9 gene polymorphism may not be associated with defective spermatogenesis in the Chinese Han population.
Azoospermia
Single Nucleotide Polymorphisms in PRDM9 (MEISETZ) in Patients with Nonobstructive Azoospermia.
Azoospermia
Two single nucleotide polymorphisms in PRDM9 (MEISETZ) gene may be a genetic risk factor for Japanese patients with azoospermia by meiotic arrest.
Brain Infarction
Correction to: Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy.
Brain Infarction
Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial.
Brain Infarction
Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy.
Brain Neoplasms
The epigenetic factor Kmt2a/Mll1 regulates neural progenitor proliferation and neuronal and glial differentiation.
Breast Neoplasms
A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5' flanking region of SMYD3 is a risk factor for human cancers.
Breast Neoplasms
Aberrant expression of SETD1A promotes survival and migration of estrogen receptor ?-positive breast cancer cells.
Breast Neoplasms
Absent, small or homeotic 2-like protein (ASH2L) enhances the transcription of the estrogen receptor ? gene through GATA-binding protein 3 (GATA3).
Breast Neoplasms
Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway.
Breast Neoplasms
Analysis of Circulating Tumor DNA to Predict Neoadjuvant Therapy Effectiveness and Breast Cancer Recurrence.
Breast Neoplasms
Association between histone lysine methyltransferase KMT2C mutation and clinicopathological factors in breast cancer.
Breast Neoplasms
Breast cancer cell detection and characterization from breast milk-derived cells.
Breast Neoplasms
Breast cancer information and support needs for women with intellectual disabilities: a scoping study.
Breast Neoplasms
Comprehensive Analysis of Metabolic Genes in Breast Cancer Based on Multi-Omics Data.
Breast Neoplasms
Comprehensive Cohort Analysis of Mutational Spectrum in Early Onset Breast Cancer Patients.
Breast Neoplasms
Copy-number variation and protein expression of DOT1L in pancreatic adenocarcinoma as a potential drug target.
Breast Neoplasms
Correlation between a variable number tandem repeat (VNTR) polymorphism in SMYD3 gene and breast cancer: A genotype-phenotype study.
Breast Neoplasms
Cross-talk between CDK4/6 and SMYD2 regulates gene transcription, tubulin methylation, and ciliogenesis.
Breast Neoplasms
DOT1L cooperates with the c-Myc-p300 complex to epigenetically derepress CDH1 transcription factors in breast cancer progression.
Breast Neoplasms
DOT1L histone methyltransferase regulates the expression of BCAT1 and is involved in sphere formation and cell migration of breast cancer cell lines.
Breast Neoplasms
Dysregulation of AKT Pathway by SMYD2-Mediated Lysine Methylation on PTEN.
Breast Neoplasms
Dysregulation of non-histone molecule miR205 and LRG1 post-transcriptional de-regulation by SETD1A in triple negative breast cancer.
Breast Neoplasms
Effect of SMYD3 on the microRNA expression profile of MCF-7 breast cancer cells.
Breast Neoplasms
Effects of SMYD3 over-expression on cell cycle acceleration and cell proliferation in MDA-MB-231 human breast cancer cells.
Breast Neoplasms
Enhanced methyltransferase activity of SMYD3 by the cleavage of its N-terminal region in human cancer cells.
Breast Neoplasms
Enhanced SMYD3 expression is essential for the growth of breast cancer cells.
Breast Neoplasms
Expression Levels of KMT2C and SLC20A1 Identified by Information-theoretical Analysis Are Powerful Prognostic Biomarkers in Estrogen Receptor-positive Breast Cancer.
Breast Neoplasms
Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcome.
Breast Neoplasms
Gene trio signatures as molecular markers to predict response to doxorubicin cyclophosphamide neoadjuvant chemotherapy in breast cancer patients.
Breast Neoplasms
Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors.
Breast Neoplasms
Histone methyltransferase SMYD3 promotes MRTF-A-mediated transactivation of MYL9 and migration of MCF-7 breast cancer cells.
Breast Neoplasms
In Silico/In Vitro Hit-to-Lead Methodology Yields SMYD3 Inhibitor That Eliminates Unrestrained Proliferation of Breast Carcinoma Cells.
Breast Neoplasms
Inhibition of histone H3K79 methylation selectively inhibits proliferation, self-renewal and metastatic potential of breast cancer.
Breast Neoplasms
Inhibition of histone methyltransferase DOT1L silences ER? gene and blocks proliferation of antiestrogen-resistant breast cancer cells.
Breast Neoplasms
KMT2C is a potential biomarker of prognosis and chemotherapy sensitivity in breast cancer.
Breast Neoplasms
KMT2C mediates the estrogen dependence of breast cancer through regulation of ER? enhancer function.
Breast Neoplasms
LncRNA GAS6-AS1 facilitates the progression of breast cancer by targeting the miR-324-3p/SETD1A axis to activate the PI3K/AKT pathway.
Breast Neoplasms
Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression.
Breast Neoplasms
Novobiocin decreases SMYD3 expression and inhibits the migration of MDA-MB-231 human breast cancer cells.
Breast Neoplasms
PI3K Inhibition Activates SGK1 via a Feedback Loop to Promote Chromatin-Based Regulation of ER-Dependent Gene Expression.
Breast Neoplasms
PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D.
Breast Neoplasms
Protein lysine methyltransferase SMYD3 is involved in tumorigenesis through regulation of HER2 homodimerization.
Breast Neoplasms
Regulation of estrogen receptor ? by histone methyltransferase SMYD2-mediated protein methylation.
Breast Neoplasms
Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis.
Breast Neoplasms
Regulation of IL-20 Expression by Estradiol through KMT2B-Mediated Epigenetic Modification.
Breast Neoplasms
Requirement of histone methyltransferase SMYD3 for estrogen receptor-mediated transcription.
Breast Neoplasms
SET and MYND domain-containing protein 3 inhibits tumor cell sensitivity to cisplatin.
Breast Neoplasms
SET and MYND domain-containing protein 3 is overexpressed in human glioma and contributes to tumorigenicity.
Breast Neoplasms
SETD1A protects from senescence through regulation of the mitotic gene expression program.
Breast Neoplasms
SMYD3 tandem repeats polymorphism is not associated with the occurrence and metastasis of hepatocellular carcinoma in a Chinese population.
Breast Neoplasms
SMYD3-Mediated H2A.Z.1 Methylation Promotes Cell Cycle and Cancer Proliferation.
Breast Neoplasms
Synthesis and biological activity of selenopsammaplin A and its analogues as antitumor agents with DOT1L inhibitory activity.
Breast Neoplasms
Targeting Histone Methyltransferase DOT1L by a Novel Psammaplin A Analog Inhibits Growth and Metastasis of Triple-Negative Breast Cancer.
Breast Neoplasms
Targeting SMYD3 to Sensitize Homologous Recombination-Proficient Tumors to PARP-Mediated Synthetic Lethality.
Breast Neoplasms
The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3.
Breast Neoplasms
Variable number of tandem repeats polymorphism in the SMYD3 promoter region and the risk of familial breast cancer.
Bronchitis, Chronic
Investigation of the Clinical, Radiological and Biological Factors Associated with Disease Progression, Phenotypes and Endotypes of COPD in China (COMPASS): study design, protocol and rationale.
Burkitt Lymphoma
Burkitt lymphoma in a patient with Kabuki syndrome carrying a novel KMT2D mutation.
Burkitt Lymphoma
Hijacking a key chromatin modulator creates epigenetic vulnerability for MYC-driven cancer.
Burkitt Lymphoma
Role of Dot1L and H3K79 methylation in regulating somatic hypermutation of immunoglobulin genes.
Candidiasis, Invasive
Candida albicans SET1 encodes a histone 3 lysine 4 methyltransferase that contributes to the pathogenesis of invasive candidiasis.
Carcinogenesis
A conserved interaction between the SDI domain of Bre2 and the Dpy-30 domain of Sdc1 is required for histone methylation and gene expression.
Carcinogenesis
A virome-wide clonal integration analysis platform for discovering cancer viral etiology.
Carcinogenesis
Analysis of SET and MYND Domain-Containing Protein 3 (SMYD3) Expression in Gallbladder Cancer: a Pilot Study.
Carcinogenesis
Association of the variable number of tandem repeats polymorphism in the promoter region of the SMYD3 gene with risk of esophageal squamous cell carcinoma in relation to tobacco smoking.
Carcinogenesis
C-terminal domain of SMYD3 serves as a unique HSP90-regulated motif in oncogenesis.
Carcinogenesis
Cancer-epigenetic function of the histone methyltransferase KMT2D and therapeutic opportunities for the treatment of KMT2D-deficient tumors.
Carcinogenesis
Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer.
Carcinogenesis
Comprehensive Molecular Characterization of Adamantinoma and OFD-like Adamantinoma Bone Tumors.
Carcinogenesis
Computer-aided screening for suppressor of variegation 4-20 homolog 1 inhibitors and their preliminary activity validation in human osteosarcoma.
Carcinogenesis
Crystal structures of histone and p53 methyltransferase SmyD2 reveal a conformational flexibility of the autoinhibitory C-terminal domain.
Carcinogenesis
Depletion of H3K79 methyltransferase Dot1L promotes cell invasion and cancer stem-like cell property in ovarian cancer.
Carcinogenesis
Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis.
Carcinogenesis
Downregulation of KMT2D suppresses proliferation and induces apoptosis of gastric cancer.
Carcinogenesis
Downregulation of MMSET impairs breast cancer proliferation and metastasis through inhibiting Wnt/?-catenin signaling.
Carcinogenesis
Enhanced SMYD3 expression is essential for the growth of breast cancer cells.
Carcinogenesis
Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma.
Carcinogenesis
Euchromatic histone lysine methyltransferase 1 regulates cancer development in human gastric cancer by regulating E-cadherin.
Carcinogenesis
Exome sequencing identifies novel mutation signatures of UV radiation and trichostatin A in primary human keratinocytes.
Carcinogenesis
Exploration of the Substrate Preference of Lysine Methyltransferase SMYD3 by Molecular Dynamics Simulations.
Carcinogenesis
Genomic and transcriptomic characterisation of undifferentiated pleomorphic sarcoma of bone.
Carcinogenesis
Genomic profiling in advanced stage non-small-cell lung cancer patients with platinum-based chemotherapy identifies germline variants with prognostic value in SMYD2.
Carcinogenesis
Hepatitis B virus X protein upregulates expression of SMYD3 and C-MYC in HepG2 cells.
Carcinogenesis
High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2.
Carcinogenesis
Histone lysine methyltransferase SETD8 promotes carcinogenesis by deregulating PCNA expression.
Carcinogenesis
Histone lysine methyltransferase Wolf-Hirschhorn syndrome candidate 1 is involved in human carcinogenesis through regulation of the Wnt pathway.
Carcinogenesis
Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4.
Carcinogenesis
Histone Methyltransferase SETD1A Induces Epithelial-Mesenchymal Transition to Promote Invasion and Metastasis Through Epigenetic Reprogramming of Snail in Gastric Cancer.
Carcinogenesis
In Vivo Genetic Screens of Patient-Derived Tumors Revealed Unexpected Frailty of the Transformed Phenotype.
Carcinogenesis
Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma.
Carcinogenesis
Integrated Molecular Analysis of Papillary Renal Cell Carcinoma and Precursor Lesions Unfolds Evolutionary Process from Kidney Progenitor-Like Cells.
Carcinogenesis
Kmt2a cooperates with menin to suppress tumorigenesis in mouse pancreatic islets.
Carcinogenesis
KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer.
Carcinogenesis
LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2.
Carcinogenesis
Mechanism of the Conformational Change of the Protein Methyltransferase SMYD3: A Molecular Dynamics Simulation Study.
Carcinogenesis
miR-142-3p down-regulation contributes to thyroid follicular tumorigenesis by targeting ASH1L and MLL1.
Carcinogenesis
miRNA-584-3p inhibits gastric cancer progression by repressing Yin Yang 1- facilitated MMP-14 expression.
Carcinogenesis
Multiple myeloma-related WHSC1/MMSET isoform RE-IIBP is a histone methyltransferase with transcriptional repression activity.
Carcinogenesis
Network analyses elucidate the role of SMYD3 in esophageal squamous cell carcinoma.
Carcinogenesis
Novobiocin decreases SMYD3 expression and inhibits the migration of MDA-MB-231 human breast cancer cells.
Carcinogenesis
Playing on the Dark Side: SMYD3 Acts as a Cancer Genome Keeper in Gastrointestinal Malignancies.
Carcinogenesis
Protein lysine methyltransferase SMYD3 is involved in tumorigenesis through regulation of HER2 homodimerization.
Carcinogenesis
Resetting the epigenetic balance of Polycomb and COMPASS function at enhancers for cancer therapy.
Carcinogenesis
Role of the SMYD3 histone methyltransferase in tumorigenesis: local or global effects?
Carcinogenesis
SET and MYND domain-containing protein 3 is overexpressed in human glioma and contributes to tumorigenicity.
Carcinogenesis
SETD1A modulates cell cycle progression through a miRNA network that regulates p53 target genes.
Carcinogenesis
Silencing SMYD3 in hepatoma demethylates RIZI promoter induces apoptosis and inhibits cell proliferation and migration.
Carcinogenesis
SMYD2 promotes tumorigenesis and metastasis of lung adenocarcinoma through RPS7.
Carcinogenesis
SMYD2-dependent HSP90 methylation promotes cancer cell proliferation by regulating the chaperone complex formation.
Carcinogenesis
SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3.
Carcinogenesis
SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells.
Carcinogenesis
Smyd3 Is a Transcriptional Potentiator of Multiple Cancer-Promoting Genes and Required for Liver and Colon Cancer Development.
Carcinogenesis
Smyd3 is required for the development of cardiac and skeletal muscle in zebrafish.
Carcinogenesis
SMYD3 overexpression was a risk factor in the biological behavior and prognosis of gastric carcinoma.
Carcinogenesis
SMYD3 promotes hepatocellular carcinoma progression by methylating S1PR1 promoters.
Carcinogenesis
SMYD3: An Oncogenic Driver Targeting Epigenetic Regulation and Signaling Pathways.
Carcinogenesis
Smyd5 plays pivotal roles in both primitive and definitive hematopoiesis during zebrafish embryogenesis.
Carcinogenesis
Substituted purine and 7-deazapurine compounds as modulators of epigenetic enzymes: a patent evaluation (WO2012075381).
Carcinogenesis
Targeting SMYD3 to Sensitize Homologous Recombination-Proficient Tumors to PARP-Mediated Synthetic Lethality.
Carcinogenesis
The histone methyltransferase DOT1L promotes neuroblastoma by regulating gene transcription.
Carcinogenesis
The Histone Methyltransferase SMYD2 Methylates PARP1 and Promotes Poly(ADP-ribosyl)ation Activity in Cancer Cells.
Carcinogenesis
The Lysine Methylase SMYD3 Modulates Mesendodermal Commitment during Development.
Carcinogenesis
The nuclear-cytoplasmic trafficking of a chromatin-modifying and remodelling protein (KMT2C), in osteosarcoma.
Carcinogenesis
Thymic adenocarcinoma accompanied by type A thymoma and pulmonary minimally invasive adenocarcinoma and harboring distinct gene alterations: A case report.
Carcinogenesis
Upregulation of SMYD3 and SMYD3 VNTR 3/3 polymorphism increase the risk of hepatocellular carcinoma.
Carcinogenesis
Whole-Exome Sequencing Reveals Frequent Mutations in Chromatin Remodeling Genes in Mammary and Extramammary Paget's Diseases.
Carcinoma
Acquired Cystic Kidney Disease-associated Renal Cell Carcinoma (ACKD-RCC) Harbor Recurrent Mutations in KMT2C and TSC2 Genes.
Carcinoma
Association of the variable number of tandem repeats polymorphism in the promoter region of the SMYD3 gene with risk of esophageal squamous cell carcinoma in relation to tobacco smoking.
Carcinoma
ATM Signaling Pathway Is Implicated in the SMYD3-mediated Proliferation and Migration of Gastric Cancer Cells.
Carcinoma
Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib.
Carcinoma
Comprehensive pharmacogenomic profiling of human papillomavirus-positive and -negative squamous cell carcinoma identifies sensitivity to aurora kinase inhibition in KMT2D mutants.
Carcinoma
Copy-number variation and protein expression of DOT1L in pancreatic adenocarcinoma as a potential drug target.
Carcinoma
Dot1l expression predicts adverse postoperative prognosis of patients with clear-cell renal cell carcinoma.
Carcinoma
Effect of the downregulation of SMYD3 expression by RNAi on RIZ1 expression and proliferation of esophageal squamous cell carcinoma.
Carcinoma
Expression and clinical significance of COMPASS family of histone methyltransferases in clear cell renal cell carcinoma.
Carcinoma
Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer.
Carcinoma
Genomic Analyses of Metaplastic or Sarcomatoid Carcinomas From Different Organs Revealed Frequent Mutations in KMT2D.
Carcinoma
Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas.
Carcinoma
Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma.
Carcinoma
Investigation of Genetic Mutations in High-risk and Low-risk Basal Cell Carcinoma in a Non-Caucasian Population by Whole Exome Sequencing.
Carcinoma
Knockdown of SMYD3 by RNA interference down-regulates c-Met expression and inhibits cells migration and invasion induced by HGF.
Carcinoma
Knockdown of SMYD3 by RNA interference inhibits cervical carcinoma cell growth and invasion in vitro.
Carcinoma
LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2.
Carcinoma
Merkel Cell Polyomavirus in Merkel Cell Carcinoma: Integration Sites and Involvement of the KMT2D Tumor Suppressor Gene.
Carcinoma
miR-142-3p down-regulation contributes to thyroid follicular tumorigenesis by targeting ASH1L and MLL1.
Carcinoma
Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations.
Carcinoma
Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas.
Carcinoma
Network analyses elucidate the role of SMYD3 in esophageal squamous cell carcinoma.
Carcinoma
Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous-cell carcinoma.
Carcinoma
Quantitative Profiling of the Activity of Protein Lysine Methyltransferase SMYD2 Using SILAC-Based Proteomics.
Carcinoma
RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation.
Carcinoma
SETD2 mutation in renal clear cell carcinoma suppress autophagy via regulation of ATG12.
Carcinoma
SETD2, GIGYF2, FGFR3, BCR, KMT2C, and TSC2 as candidate genes for differentiating multilocular cystic renal neoplasm of low malignant potential from clear cell renal cell carcinoma with cystic change.
Carcinoma
SMYD2 overexpression is associated with tumor cell proliferation and a worse outcome in human papillomavirus-unrelated nonmultiple head and neck carcinomas.
Carcinoma
SMYD3 overexpression was a risk factor in the biological behavior and prognosis of gastric carcinoma.
Carcinoma
SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters.
Carcinoma
SMYD3 stimulates EZR and LOXL2 transcription to enhance proliferation, migration and invasion in esophageal squamous cell carcinoma.
Carcinoma
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Carcinoma
The histone methyltransferase SMYD2 is a novel therapeutic target for the induction of apoptosis in ovarian clear cell carcinoma cells.
Carcinoma
Upregulation of histone methyltransferase, DOT1L by matrix hyaluronan promotes MicroRNA-10 expression leading to tumor cell invasion and chemoresistance in cancer stem cells from head and neck squamous cell carcinoma.
Carcinoma
VHL-HIF-2? axis-induced SMYD3 upregulation drives renal cell carcinoma progression via direct trans-activation of EGFR.
Carcinoma
Whole Exome Sequencing of Ulcerative Colitis-associated Colorectal Cancer Based on Novel Somatic Mutations Identified in Chinese Patients.
Carcinoma in Situ
Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.
Carcinoma, Adenoid Cystic
Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer.
Carcinoma, Adenosquamous
Transformation of advanced lung adenocarcinoma to acquired T790M resistance mutation adenosquamous carcinoma following tyrosine kinase inhibitor: a case report.
Carcinoma, Basal Cell
Investigation of Genetic Mutations in High-risk and Low-risk Basal Cell Carcinoma in a Non-Caucasian Population by Whole Exome Sequencing.
Carcinoma, Hepatocellular
A Novel lncRNA IHS Promotes Tumor Proliferation and Metastasis in HCC by Regulating the ERK- and AKT/GSK-3?-Signaling Pathways.
Carcinoma, Hepatocellular
A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5' flanking region of SMYD3 is a risk factor for human cancers.
Carcinoma, Hepatocellular
Amplification of SMYD3 promotes tumorigenicity and intrahepatic metastasis of hepatocellular carcinoma via upregulation of CDK2 and MMP2.
Carcinoma, Hepatocellular
ANKHD1 is required for SMYD3 to promote tumor metastasis in hepatocellular carcinoma.
Carcinoma, Hepatocellular
C/EBPalphap30 plays transcriptional regulatory roles distinct from C/EBPalphap42.
Carcinoma, Hepatocellular
Correction: SMYD3 promotes hepatocellular carcinoma progression by methylating S1PR1 promoters.
Carcinoma, Hepatocellular
Diffuse Adenomatosis and Hepatocellular Carcinoma Treated with Liver Transplantation in an Adolescent Female with Kabuki Syndrome with a Novel KMT2D Gene Mutation.
Carcinoma, Hepatocellular
Divergent viral presentation among human tumors and adjacent normal tissues.
Carcinoma, Hepatocellular
Enhanced SMYD3 expression is essential for the growth of breast cancer cells.
Carcinoma, Hepatocellular
Hepatitis B virus X protein regulates the mEZH2 promoter via the E2F1-binding site in AML12 cells.
Carcinoma, Hepatocellular
Hepatitis B virus X protein upregulates expression of SMYD3 and C-MYC in HepG2 cells.
Carcinoma, Hepatocellular
High?level SETD1B gene expression is associated with unfavorable prognosis in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Histone H3K4 trimethylation by MLL3 as part of ASCOM complex is critical for NR activation of bile acid transporter genes and is downregulated in cholestasis.
Carcinoma, Hepatocellular
Histone lysine methyltransferase SUV39H1 is a potent target for epigenetic therapy of hepatocellular carcinoma.
Carcinoma, Hepatocellular
In Silico/In Vitro Hit-to-Lead Methodology Yields SMYD3 Inhibitor That Eliminates Unrestrained Proliferation of Breast Carcinoma Cells.
Carcinoma, Hepatocellular
MiR-346 suppresses cell proliferation through SMYD3 dependent approach in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Overexpression of SMYD3 Is Predictive of Unfavorable Prognosis in Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Positive Expression of SMYD2 is Associated with Poor Prognosis in Patients with Primary Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Silencing SMYD3 in hepatoma demethylates RIZI promoter induces apoptosis and inhibits cell proliferation and migration.
Carcinoma, Hepatocellular
SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells.
Carcinoma, Hepatocellular
SMYD3 promotes hepatocellular carcinoma progression by methylating S1PR1 promoters.
Carcinoma, Hepatocellular
SMYD3 tandem repeats polymorphism is not associated with the occurrence and metastasis of hepatocellular carcinoma in a Chinese population.
Carcinoma, Hepatocellular
Targeting Smyd3 by next-generation antisense oligonucleotides suppresses liver tumor growth.
Carcinoma, Hepatocellular
The SMYD3 VNTR 3/3 polymorphism confers an increased risk and poor prognosis of hepatocellular carcinoma in a Chinese population.
Carcinoma, Hepatocellular
Upregulation of SMYD3 and SMYD3 VNTR 3/3 polymorphism increase the risk of hepatocellular carcinoma.
Carcinoma, Hepatocellular
ZNF479 downregulates metallothionein-1 expression by regulating ASH2L and DNMT1 in hepatocellular carcinoma.
Carcinoma, Hepatocellular
[Experimental research of therapeutic effect on hepatocellular carcinoma of targeting SMYD3 gene inhibition by RNA interference]
Carcinoma, Hepatocellular
[Inhibition of SMYD3 gene expression by RNA interference induces apoptosis in human hepatocellular carcinoma cell line HepG2]
Carcinoma, Hepatocellular
[Suppression of SMYD3 expression in HepG2 cell by shRNA interference.]
Carcinoma, Merkel Cell
Merkel Cell Polyomavirus in Merkel Cell Carcinoma: Integration Sites and Involvement of the KMT2D Tumor Suppressor Gene.
Carcinoma, Non-Small-Cell Lung
Inhibition of SMYD2 Sensitized Cisplatin to Resistant Cells in NSCLC Through Activating p53 Pathway.
Carcinoma, Non-Small-Cell Lung
KMT2C promoter methylation in plasma-circulating tumor DNA is a prognostic biomarker in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Loss of histone lysine methyltransferase EZH2 confers resistance to tyrosine kinase inhibitors in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
The H3K4 methyltransferase SETD1A is required for proliferation of non-small cell lung cancer cells by promoting S-phase progression.
Carcinoma, Ovarian Epithelial
SMYD3 promotes epithelial ovarian cancer metastasis by down-regulating p53 protein stability and promoting p53 ubiquitination.
Carcinoma, Renal Cell
Acquired Cystic Kidney Disease-associated Renal Cell Carcinoma (ACKD-RCC) Harbor Recurrent Mutations in KMT2C and TSC2 Genes.
Carcinoma, Renal Cell
Dot1l expression predicts adverse postoperative prognosis of patients with clear-cell renal cell carcinoma.
Carcinoma, Renal Cell
Expression and clinical significance of COMPASS family of histone methyltransferases in clear cell renal cell carcinoma.
Carcinoma, Renal Cell
Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma.
Carcinoma, Renal Cell
SETD2 mutation in renal clear cell carcinoma suppress autophagy via regulation of ATG12.
Carcinoma, Renal Cell
SETD2, GIGYF2, FGFR3, BCR, KMT2C, and TSC2 as candidate genes for differentiating multilocular cystic renal neoplasm of low malignant potential from clear cell renal cell carcinoma with cystic change.
Carcinoma, Renal Cell
VHL-HIF-2? axis-induced SMYD3 upregulation drives renal cell carcinoma progression via direct trans-activation of EGFR.
Carcinoma, Squamous Cell
Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib.
Carcinoma, Squamous Cell
Comprehensive pharmacogenomic profiling of human papillomavirus-positive and -negative squamous cell carcinoma identifies sensitivity to aurora kinase inhibition in KMT2D mutants.
Carcinoma, Squamous Cell
KMT2A regulates cervical cancer cell growth through targeting VDAC1.
Carcinoma, Squamous Cell
Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations.
Carcinoma, Squamous Cell
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Carcinoma, Squamous Cell
Upregulation of histone methyltransferase, DOT1L by matrix hyaluronan promotes MicroRNA-10 expression leading to tumor cell invasion and chemoresistance in cancer stem cells from head and neck squamous cell carcinoma.
Cardiomegaly
A crosstalk between chromatin remodeling and histone H3K4 methyltransferase complexes in endothelial cells regulates angiotensin II-induced cardiac hypertrophy.
Cardiomyopathy, Dilated
TALEN-Mediated FLAG-Tagging of Endogenous Histone Methyltransferase DOT1L.
Cardiomyopathy, Dilated
Targeted disruption of the histone lysine 79 methyltransferase Dot1L in nephron progenitors causes congenital renal dysplasia.
Cardiomyopathy, Hypertrophic
A de novo mutation of SMYD1 (p.F272L) is responsible for hypertrophic cardiomyopathy in a Chinese patient.
Cardiovascular Diseases
A critical analysis of the COMPASS trial with respect to benefit-risk assessment using the numbers needed to treat: Applicability and relevance in Indian patients with stable cardiovascular disease.
Cardiovascular Diseases
Crystal structure of cardiac specific histone methyltransferase SmyD1 reveals unusual active site architecture.
Cardiovascular Diseases
Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial.
Cardiovascular Diseases
Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease.
Cardiovascular Diseases
Large-Scale Implementation of Collaborative Care Management for Depression and Diabetes and/or Cardiovascular Disease.
Cardiovascular Diseases
Review of article: Rivaroxaban with or without aspirin in stable cardiovascular disease. Eikelboom JW, Connolly SJ, Bosch J, et al. for the COMPASS investigators.
Cardiovascular Diseases
Rivaroxaban With or Without Aspirin for the Secondary Prevention of Cardiovascular Disease: Clinical Implications of the COMPASS Trial.
Cardiovascular Diseases
Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial.
Cardiovascular Diseases
Sustainable care coordination: a qualitative study of primary care provider, administrator, and insurer perspectives.
Cardiovascular Diseases
The COMPASS initiative: description of a nationwide collaborative approach to the care of patients with depression and diabetes and/or cardiovascular disease.
Cardiovascular Diseases
The Global Burden of Cardiovascular Diseases and Risks: A Compass for Global Action.
Cardiovascular Diseases
Usefulness of Coronary Artery Calcium to Identify Adults of Sufficiently High Risk for Atherothrombotic Cardiovascular Events to Consider Low-Dose Rivaroxaban Thromboprophylaxis (from MESA).
Cardiovascular Diseases
[Atherosclerotic Cardiovascular Diseases and Type 2 Diabetes Mellitus - new Developments in the Treatment].
Cardiovascular Diseases
[Combined Antithrombotic Therapy in Patients with a Stable Atherosclerotic Cardiovascular Diseases: What Direction did COMPASS Show?]
Carotid Artery Diseases
Clinical factors associated with peripheral artery disease in patients with documented coronary artery disease: A post hoc analysis of the COMPASS trial.
Carotid Artery Diseases
Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective.
Cataract
Circular RNA circ KMT2E is up-regulated in diabetic cataract lenses and is associated with miR-204-5p sponge function.
Cataract
Corneal Endothelial Cell Density and Morphology After Phacoemulsification in Patients With Primary Open-Angle Glaucoma and Cataracts: 2-Year Results of a Randomized Multicenter Trial.
Cataract
Two-Year COMPASS Trial Results: Supraciliary Microstenting with Phacoemulsification in Patients with Open-Angle Glaucoma and Cataracts.
Cataract
[Considerations on the opening of the anterior chamber in the cataract operation. Compass keratome]
Cataract
[Postoperative astigmatism in senile cataract operation performed with the compass keratome and pre-placed sutures]
Central Nervous System Diseases
Histone lysine methyltransferase SETDB1 as a novel target for central nervous system diseases.
Cerebellar Ataxia
Novel KMT2B mutation causes cerebellar ataxia: Expanding the clinical phenotype.
Chagas Disease
Antiproliferative effects of delta 24(25) sterol methyl transferase inhibitors on Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies.
CHARGE Syndrome
KMT2D p.Gln3575His segregating in a family with autosomal dominant choanal atresia strengthens the Kabuki/CHARGE connection.
Choanal Atresia
KMT2D p.Gln3575His segregating in a family with autosomal dominant choanal atresia strengthens the Kabuki/CHARGE connection.
Cholangiocarcinoma
Epigenetic regulation of miR-124 by Hepatitis C Virus core protein promotes migration and invasion of intrahepatic cholangiocarcinoma cells by targeting SMYD3.
Cholangiocarcinoma
Hepatitis C virus core upregulates the methylation status of the RASSF1A promoter through regulation of SMYD3 in hilar cholangiocarcinoma cells.
Cholelithiasis
Analysis of SET and MYND Domain-Containing Protein 3 (SMYD3) Expression in Gallbladder Cancer: a Pilot Study.
Cleft Palate
The KMT2D Kabuki syndrome histone methylase controls neural crest cell differentiation and facial morphology.
Colitis
Ash1l and lnc-Smad3 coordinate Smad3 locus accessibility to modulate iTreg polarization and T cell autoimmunity.
Colonic Neoplasms
CBP mediated DOT1L acetylation confers DOT1L stability and promotes cancer metastasis.
Colonic Neoplasms
NSD2 promotes osteosarcoma cell proliferation and metastasis by inhibiting E-cadherin expression.
Colonic Neoplasms
Overexpression of histone deacetylases in cancer cells is controlled by interplay of transcription factors and epigenetic modulators.
Colonic Neoplasms
RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.
Colonic Neoplasms
Regulation of Wnt signaling target gene expression by the histone methyltransferase DOT1L.
Colonic Neoplasms
SMYD2 facilitates cancer cell malignancy and xenograft tumor development through ERBB2-mediated FUT4 expression in colon cancer.
Colonic Neoplasms
Smyd3 Is a Transcriptional Potentiator of Multiple Cancer-Promoting Genes and Required for Liver and Colon Cancer Development.
Colonic Neoplasms
SMYD3 promotes colon adenocarcinoma (COAD) progression by mediating cell proliferation and apoptosis.
Colonic Neoplasms
WDR5 supports colon cancer cells by promoting methylation of H3K4 and suppressing DNA damage.
Colorectal Neoplasms
A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5' flanking region of SMYD3 is a risk factor for human cancers.
Colorectal Neoplasms
CBP mediated DOT1L acetylation confers DOT1L stability and promotes cancer metastasis.
Colorectal Neoplasms
Copy number analysis of whole-genome data using BIC-seq2 and its application to detection of cancer susceptibility variants.
Colorectal Neoplasms
Enhanced SMYD3 expression is essential for the growth of breast cancer cells.
Colorectal Neoplasms
Frameshift mutation of a histone methylation-related gene SETD1B and its regional heterogeneity in gastric and colorectal cancers with high microsatellite instability.
Colorectal Neoplasms
IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L.
Colorectal Neoplasms
KMT2A histone methyltransferase contributes to colorectal cancer development by promoting cathepsin Z transcriptional activation.
Colorectal Neoplasms
miR-133b suppresses colorectal cancer cell stemness and chemoresistance by targeting methyltransferase DOT1L.
Colorectal Neoplasms
Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer.
Colorectal Neoplasms
Prognosis model of colorectal cancer patients based on NOTCH3, KMT2C, and CREBBP mutations.
Colorectal Neoplasms
Prognostic significance of stromal SMYD3 expression in colorectal cancer of TNM stage I-III.
Colorectal Neoplasms
Restoration of KMT2C/MLL3 in human colorectal cancer cells reinforces genome-wide H3K4me1 profiles and influences cell growth and gene expression.
Colorectal Neoplasms
Silencing or inhibition of H3K79 methyltransferase DOT1L induces cell cycle arrest by epigenetically modulating c-Myc expression in colorectal cancer.
Colorectal Neoplasms
SMYD2 suppresses APC2 expression to activate the Wnt/?-catenin pathway and promotes epithelial-mesenchymal transition in colorectal cancer.
Colorectal Neoplasms
SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells.
Colorectal Neoplasms
SMYD3 promoter hypomethylation is associated with the risk of colorectal cancer.
Colorectal Neoplasms
SMYD3 tandem repeats polymorphism is not associated with the occurrence and metastasis of hepatocellular carcinoma in a Chinese population.
Colorectal Neoplasms
The histone methyltransferase DOT1L is required for proper DNA damage response, DNA repair, and modulates chemotherapy responsiveness.
Colorectal Neoplasms
The leukemia-associated Mllt10/Af10-Dot1l are Tcf4/?-catenin coactivators essential for intestinal homeostasis.
Communicable Diseases
Correction to: PK-PD Compass: bringing infectious diseases pharmacometrics to the patient's bedside.
Communicable Diseases
PK-PD Compass: bringing infectious diseases pharmacometrics to the patient's bedside.
Confusion
Looking for the compass in a case of developmental topographical disorientation: a behavioral and neuroimaging study.
Confusion
The role of ethics in science: a systematic literature review from the first wave of COVID-19.
Congenital Abnormalities
Distal Tibial Tuberosity Focal Dome Osteotomy Combined With Intra-Articular Condylar Osteotomy (Focal Dome Condylar Osteotomy) for Medial Osteoarthritis of the Knee Joint.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Identification of KMT2D and KDM6A variants by targeted sequencing from patients with Kabuki syndrome and other congenital disorders.
Contracture
Chronic flexion contracture of proximal interphalangeal joint treated with the compass hinge external fixator. A consecutive series of 27 cases.
Corneal Injuries
Dot1l Aggravates Keratitis Induced by Herpes Simplex Virus Type 1 in Mice via p38 MAPK-Mediated Oxidative Stress.
Corneal Opacity
Bilateral Congenital Corneal Opacities as an Early-Onset Ocular Feature of Kabuki Syndrome.
Coronary Artery Disease
A Blood Based Gene Expression Test for Obstructive Coronary Artery Disease Tested in Symptomatic Non-Diabetic Patients Referred for Myocardial Perfusion Imaging: The COMPASS Study.
Coronary Artery Disease
Assessment of patients with coronary artery disease who may benefit from the use of rivaroxaban in the real world: implementation of the COMPASS trial criteria in the TERCET registry population.
Coronary Artery Disease
Balloon angioplasty plus cilostazol administration versus primary stenting of small coronary artery disease: final results of COMPASS.
Coronary Artery Disease
Biological and analytical stability of a peripheral blood gene expression score for obstructive coronary artery disease in the PREDICT and COMPASS studies.
Coronary Artery Disease
Clinical characteristics and outcomes of COMPASS eligible patients in France. An analysis from the REACH Registry.
Coronary Artery Disease
Clinical factors associated with peripheral artery disease in patients with documented coronary artery disease: A post hoc analysis of the COMPASS trial.
Coronary Artery Disease
COMPASS criteria applied to a contemporary cohort of unselected patients with stable coronary artery diseases: insights from the START registry.
Coronary Artery Disease
Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease.
Coronary Artery Disease
External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry.
Coronary Artery Disease
External applicability of the COMPASS trial: the Western Denmark Heart Registry.
Coronary Artery Disease
Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease.
Coronary Artery Disease
Medical management of stable peripheral artery disease: the COMPASS trial. Perspectives from a vascular standpoint.
Coronary Artery Disease
Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial.
Coronary Artery Disease
Risk stratification of cardiovascular complications using CHA2DS2-VASc and CHADS2 scores in chronic atherosclerotic cardiovascular disease.
Coronary Artery Disease
Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial.
Coronary Artery Disease
Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease.
Coronary Artery Disease
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Coronary Artery Disease
Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease.
Coronary Artery Disease
The COMPASS trial: practical considerations for application after coronary artery bypass surgery.
Coronary Disease
[Do the patients with peripheral atherosclerosis need to a medical therapy before the revascularization?]
Coronary Disease
[Health and disease in the Netherlands: the Dutch National Public Health Compass as a source of information]
COVID-19
Differences in COVID-19 Vaccine Concerns Among Asian Americans and Pacific Islanders: The COMPASS Survey.
COVID-19
Examining the impact of the early stages of the COVID-19 pandemic period on youth cannabis use: adjusted annual changes between the pre-COVID and initial COVID-lockdown waves of the COMPASS study.
COVID-19
Motivating Developers to Use Interoperable Standards for Data in Pandemic Health Apps.
COVID-19
Single-Cell RNA Sequencing Analysis of the Immunometabolic Rewiring and Immunopathogenesis of Coronavirus Disease 2019.
COVID-19
The 2020 APSA Robert E. Gross Lecture: Pediatric Surgery, COVID 19, and the moral compass.
COVID-19
The role of ethics in science: a systematic literature review from the first wave of COVID-19.
COVID-19
Value-based medicine, a compass to guide healthcare decisions in the COVID-19 aftermath.
Craniosynostoses
On the significance of craniosynostosis in a case of Kabuki syndrome with a concomitant KMT2D mutation and 3.2?Mbp de novo 10q22.3q23.1 deletion.
Cysts
Lysine methyltransferase SMYD2 promotes cyst growth in autosomal dominant polycystic kidney disease.
Cysts
Single-cell RNA sequencing reveals regulation of fetal ovary development in the monkey (Macaca fascicularis).
Cytomegalovirus Infections
Three de novo variants in KMT2A (MLL) identified by whole exome sequencing in patients with Wiedemann-Steiner syndrome.
Dandy-Walker Syndrome
Cancer Management in Kabuki Syndrome: The First Case of Wilms Tumor and a Literature Review.
Dementia
CoMPASs: IOn programme (Care Of Memory Problems in Advanced Stages of dementia: Improving Our Knowledge): protocol for a mixed methods study.
Dementia
The battle of Alzheimer's Disease - the beginning of the future Unleashing the potential of academic discoveries.
Dermatitis
Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer.
Dermatitis, Allergic Contact
Benign summer light eruption and polymorphic light eruption: genetic and functional studies suggest that a revised nomenclature is required.
Diabetes Mellitus
Efficacy and Safety of Long-Term Antithrombotic Strategies in Patients With Chronic Coronary Syndrome: A Network Meta-analysis of Randomized Controlled Trials.
Diabetes Mellitus
Impact of structured self-monitoring of blood glucose on the quality of life of insulin-treated Chinese patients with type 2 diabetes mellitus: Results from the COMPASS study.
Diabetes Mellitus
Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial.
Diabetes Mellitus
[New possibilities of antithrombotic therapy improving prognosis in patients with stenosing atherosclerosis of carotid arteries].
Diabetes Mellitus, Type 2
Combination of Composite Autonomic Symptom Score 31 and Heart Rate Variability for Diagnosis of Cardiovascular Autonomic Neuropathy in People with Type 2 Diabetes.
Diabetes Mellitus, Type 2
Glycemic control and self-monitoring of blood glucose in Chinese patients with type 2 diabetes on insulin: Baseline results from the COMPASS study.
Diabetes Mellitus, Type 2
Impact of structured self-monitoring of blood glucose on the quality of life of insulin-treated Chinese patients with type 2 diabetes mellitus: Results from the COMPASS study.
Diabetes Mellitus, Type 2
Mutations in Mll2, an H3K4 methyltransferase, result in insulin resistance and impaired glucose tolerance in mice.
Diabetic Neuropathies
The diagnostic usefulness of the combined COMPASS 31 questionnaire and electrochemical skin conductance for diabetic cardiovascular autonomic neuropathy and diabetic polyneuropathy.
Diabetic Neuropathies
Validation of the Composite Autonomic Symptom Score 31 (COMPASS 31) for the assessment of symptoms of autonomic neuropathy in people with diabetes.
Diverticulum
[The aorto-mesenteric compass in the etiopathogenesis of the duodenal diverticulum caused by pressure]
Down Syndrome
Outcome of Childhood Acute Megakaryoblastic Leukemia: Children's Cancer Hospital Egypt 57357 Experience.
Down Syndrome
The genetic landscape of paediatric de novo acute myeloid leukaemia as defined by single nucleotide polymorphism array and exon sequencing of 100 candidate genes.
Down Syndrome
Variation in the Zinc Finger of PRDM9 is Associated with the Absence of Recombination along Nondisjoined Chromosomes 21 of Maternal Origin.
Dyspnea
Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure: COMPASS: Carperitide Effects Observed Through Monitoring Dyspnea in Acute Decompensated Heart Failure Study.
Dystonia
A novel, in-frame KMT2B deletion in a patient with apparently isolated, generalized dystonia.
Dystonia
An inherited KMT2B duplication variant in a Chinese family with dystonia and/or development delay.
Dystonia
Childhood-onset dystonia-causing KMT2B variants result in a distinctive genomic hypermethylation profile.
Dystonia
Clinical phenotypes, genotypes and treatment in Chinese dystonia patients with KMT2B variants.
Dystonia
Correction to: Novel mutations in KMT2B offer pathophysiological insights on childhood-onset progressive dystonia.
Dystonia
Corrigendum: Mutations in the histone methyltransferase gene KMT2B cause complex early-onset dystonia.
Dystonia
De-novo KMT2B mutation in a consanguineous family: 15-Year follow-up of an Afghan dystonia patient.
Dystonia
Frequency and phenotypic spectrum of KMT2B dystonia in childhood: A single-center cohort study.
Dystonia
Generalized dystonia associated with mutation in the histone methyltransferase gene KMT2B (DYT28) and white matter abnormalities.
Dystonia
Genotype-Phenotype Relations for Isolated Dystonia Genes: MDSGene Systematic Review.
Dystonia
Haploinsufficiency of KMT2B, Encoding the Lysine-Specific Histone Methyltransferase 2B, Results in Early-Onset Generalized Dystonia.
Dystonia
Identification of a novel de novo KMT2B variant in a Greek dystonia patient via exome sequencing genotype-phenotype correlations of all published cases.
Dystonia
Identification of Novel KMT2B Variants in Chinese Dystonia Patients via Whole-Exome Sequencing.
Dystonia
KMT2B and Neuronal Transdifferentiation: Bridging Basic Chromatin Mechanisms to Disease Actionability.
Dystonia
KMT2B Is Selectively Required for Neuronal Transdifferentiation, and Its Loss Exposes Dystonia Candidate Genes.
Dystonia
KMT2B-related disorders: expansion of the phenotypic spectrum and long-term efficacy of deep brain stimulation.
Dystonia
Mutations in the histone methyltransferase gene KMT2B cause complex early-onset dystonia.
Dystonia
Novel mutations in KMT2B offer pathophysiological insights into childhood-onset progressive dystonia.
Dystonia
Radiofrequency ablation for DYT-28 dystonia: short term follow-up of three adult cases.
Dystonia
Review of the phenotype of early-onset generalised progressive dystonia due to mutations in KMT2B.
Eczema
Benign summer light eruption and polymorphic light eruption: genetic and functional studies suggest that a revised nomenclature is required.
Endocardial Fibroelastosis
Three de novo variants in KMT2A (MLL) identified by whole exome sequencing in patients with Wiedemann-Steiner syndrome.
Endometrial Neoplasms
ASH2L is involved in promotion of endometrial cancer progression via upregulation of PAX2 transcription.
Endometrial Neoplasms
Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma.
Eosinophilia
A novel deletion mutation in KMT2A identified in a child with ID/DD and blood eosinophilia.
Epilepsies, Partial
Facial Dysmorphisms, Macrodontia, Focal Epilepsy, and Thinning of the Corpus Callosum: A Rare Mild Form of Kabuki Syndrome.
Epilepsy
An atypical 12q24.31 microdeletion implicates six genes including a histone demethylase KDM2B and a histone methyltransferase SETD1B in syndromic intellectual disability.
Epilepsy
Characteristics of epilepsy in patients with Kabuki syndrome with KMT2D mutations.
Epilepsy
Congenital immunodeficiency in an individual with Wiedemann-Steiner syndrome due to a novel missense mutation in KMT2A.
Epilepsy
De novo variants in SETD1B are associated with intellectual disability, epilepsy and autism.
Epilepsy
De novo variants in SETD1B cause intellectual disability, autism spectrum disorder, and epilepsy with myoclonic absences.
Epilepsy
Heterozygous Variants in KMT2E Cause a Spectrum of Neurodevelopmental Disorders and Epilepsy.
Epilepsy
Identification of De Novo DNMT3A Mutations That Cause West Syndrome by Using Whole-Exome Sequencing.
Epilepsy
Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-release to a once-daily extended-release formulation in subjects with epilepsy (The COMPASS Study).
Esophageal Neoplasms
Associations of the variable number of tandem repeats polymorphism in the SMYD3 gene with risk and prognosis of esophageal cancer: a case-control study.
Esophageal Squamous Cell Carcinoma
Association of the variable number of tandem repeats polymorphism in the promoter region of the SMYD3 gene with risk of esophageal squamous cell carcinoma in relation to tobacco smoking.
Esophageal Squamous Cell Carcinoma
Effect of the downregulation of SMYD3 expression by RNAi on RIZ1 expression and proliferation of esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Network analyses elucidate the role of SMYD3 in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Quantitative Profiling of the Activity of Protein Lysine Methyltransferase SMYD2 Using SILAC-Based Proteomics.
Esophageal Squamous Cell Carcinoma
SMYD3 stimulates EZR and LOXL2 transcription to enhance proliferation, migration and invasion in esophageal squamous cell carcinoma.
Fanconi Anemia
An uncommon t(9;11)(p24;q22) with monoallelic loss of ATM and KMT2A genes in a child with myelodysplastic syndrome/acute myeloid leukemia who evolved from Fanconi anemia.
Fibromyalgia
Autonomic Dysfunction in Fibromyalgia Assessed by the Composite Autonomic Symptoms Scale (COMPASS).
Fibromyalgia
Clinical Assessment of Autonomic Function in Fibromyalgia by the Refined and Abbreviated Composite Autonomic Symptom Score (COMPASS 31): A Case-Controlled Study.
Fibromyalgia
Heart Rate Variability for Quantification of Autonomic Dysfunction in Fibromyalgia.
Fibrosarcoma
Recurrent Fusions Between YAP1 and KMT2A in Morphologically Distinct Neoplasms Within the Spectrum of Low-grade Fibromyxoid Sarcoma and Sclerosing Epithelioid Fibrosarcoma.
Fibrosarcoma
Recurrent YAP1 and KMT2A Gene Rearrangements in a Subset of MUC4-negative Sclerosing Epithelioid Fibrosarcoma.
Fibrosarcoma
SMYD3 promotes cancer invasion by epigenetic upregulation of the metalloproteinase MMP-9.
Fracture Dislocation
Management of a proximal interphalangeal joint fracture dislocation with a compass proximal interphalangeal joint hinge and therapy: a case report.
Friedreich Ataxia
HMTase Inhibitors as a Potential Epigenetic-Based Therapeutic Approach for Friedreich's Ataxia.
Gallbladder Neoplasms
Analysis of SET and MYND Domain-Containing Protein 3 (SMYD3) Expression in Gallbladder Cancer: a Pilot Study.
Genetic Diseases, Inborn
An unusual presentation of Kabuki syndrome with orbital cysts, microphthalmia, and cholestasis with bile duct paucity.
Genetic Diseases, Inborn
Broad neurodevelopmental features and cortical anomalies associated with a novel de novo KMT2A variant in Wiedemann-Steiner syndrome.
Genetic Diseases, Inborn
Burkitt lymphoma in a patient with Kabuki syndrome carrying a novel KMT2D mutation.
Genetic Diseases, Inborn
De novo loss-of-function variants of ASH1L are associated with an emergent neurodevelopmental disorder.
Genetic Diseases, Inborn
Description of the molecular and phenotypic spectrum of Wiedemann-Steiner syndrome in Chinese patients.
Genetic Diseases, Inborn
On the significance of craniosynostosis in a case of Kabuki syndrome with a concomitant KMT2D mutation and 3.2?Mbp de novo 10q22.3q23.1 deletion.
Genetic Diseases, Inborn
Ophthalmic manifestations in Kabuki (make-up) syndrome: A single-center pediatric cohort and systematic review of the literature.
Genetic Diseases, Inborn
Wiedemann-Steiner syndrome with a novel pathogenic variant in KMT2A: a case report.
Glaucoma
Agreement between Compass Fundus Perimeter New Grid and 10-2 Testing Protocols for Detecting Central Visual Field Defects.
Glaucoma
Comparing the Performance of Compass Perimetry With Humphrey Field Analyzer in Eyes With Glaucoma.
Glaucoma
Intraocular Pressure Following Prerandomization Glaucoma Medication Washout in the HORIZON and COMPASS Trials.
Glaucoma
Management of Persistent Hypotony after Supraciliary CyPass® Implantation Using Argon Laser.
Glaucoma
Visual Field Endpoints Based on Subgroups of Points May Be Useful in Glaucoma Clinical Trials: A Study With the Humphrey Field Analyzer and Compass Perimeter.
Glaucoma, Open-Angle
Comparison of the structure-function relationship between compass microperimetry and Humphrey field analyser in myopic open-angle glaucoma eyes.
Glaucoma, Open-Angle
Corneal Endothelial Cell Density and Morphology After Phacoemulsification in Patients With Primary Open-Angle Glaucoma and Cataracts: 2-Year Results of a Randomized Multicenter Trial.
Glaucoma, Open-Angle
Intraocular Pressure Following Prerandomization Glaucoma Medication Washout in the HORIZON and COMPASS Trials.
Glaucoma, Open-Angle
Safety and Effectiveness of CyPass Supraciliary Micro-Stent in Primary Open-Angle Glaucoma: Five-Year Results from the COMPASS XT Study.
Glaucoma, Open-Angle
Two-Year COMPASS Trial Results: Supraciliary Microstenting with Phacoemulsification in Patients with Open-Angle Glaucoma and Cataracts.
Glioblastoma
Epigenetic regulation of NOTCH1 and NOTCH3 by KMT2A inhibits glioma proliferation.
Glioblastoma
Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT promoter.
Glioblastoma
NF1 glioblastoma clonal profiling reveals KMT2B mutations as potential somatic oncogenic events.
Glioma
EGFR promoter exhibits dynamic histone modifications and binding of ASH2L and P300 in human germinal matrix and gliomas.
Glioma
EZH2-, CHD4-, and IDH-linked epigenetic perturbation and its association with survival in glioma patients.
Glioma
Identification of an epigenetic prognostic signature for patients with lower-grade gliomas.
Glioma
MicroRNA-769-5p Promotes The Growth Of Glioma Cells By Targeting Lysine Methyltransferase 2A.
Glioma
SET and MYND domain-containing protein 3 is overexpressed in human glioma and contributes to tumorigenicity.
Glucose Intolerance
Mutations in Mll2, an H3K4 methyltransferase, result in insulin resistance and impaired glucose tolerance in mice.
Graft vs Host Disease
DOT1L inhibition attenuates graft-versus-host disease by allogeneic T cells in adoptive immunotherapy models.
Head and Neck Neoplasms
Radiogenomics in head and neck cancer: correlation of radiomic heterogeneity and somatic mutations in TP53, FAT1 and KMT2D.
Hearing Loss
Inhibition of Histone Methyltransferase G9a Attenuates Noise-Induced Cochlear Synaptopathy and Hearing Loss.
Hearing Loss
[One novel pathologic variation in KMT2D cause Kabuki syndrome with hearing loss as the main phenotype and related research on types of deafness].
Heart Defects, Congenital
Clinical presentation and genetic profiles of Chinese patients with velocardiofacial syndrome in a large referral centre.
Heart Defects, Congenital
COMPASS: A Novel Risk-Adjustment Model for Catheter Ablation in Pediatric and Congenital Heart Disease Patients.
Heart Defects, Congenital
KMT2D regulates specific programs in heart development via histone H3 lysine 4 di-methylation.
Heart Defects, Congenital
Loss of function of Kmt2d, a gene mutated in Kabuki syndrome, affects heart development in Xenopus laevis.
Heart Defects, Congenital
Prenatal diagnosis of a familial 5p14.3-p14.1 deletion encompassing CDH18, CDH12, PMCHL1, PRDM9 and CDH10 in a fetus with congenital heart disease on prenatal ultrasound.
Heart Diseases
Anticoagulation in Patients with Ischaemic Heart Disease and Peripheral Arterial Disease: Clinical Implications of COMPASS Study.
Heart Diseases
Democratizing health system data to impact social and environmental health contexts: a novel collaborative community data-sharing model.
Heart Diseases
Use of direct oral anticoagulant in ischaemic heart disease: the COMPASS study.
Heart Diseases
[New possibilities of antithrombotic therapy improving prognosis in patients with stenosing atherosclerosis of carotid arteries].
Heart Failure
Clinical trials update from the American College of Cardiology meeting: CARE-HF and the remission of heart failure, Women's Health Study, TNT, COMPASS-HF, VERITAS, CANPAP, PEECH and PREMIER.
Heart Failure
Heart Transplantation from Biventricular Support in Infant with Novel SMYD1 Mutation.
Heart Failure
Histone methyltransferase Smyd1 regulates mitochondrial energetics in the heart.
Heart Failure
Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure: COMPASS: Carperitide Effects Observed Through Monitoring Dyspnea in Acute Decompensated Heart Failure Study.
Heart Failure
Theodore E. Woodward Award: Coming in out of the rain relieving congestion in heart failure.
Heart Septal Defects, Ventricular
Clinical application of targeted next-generation sequencing on fetuses with congenital heart defects.
Hematologic Neoplasms
Cryptic recurrent ACIN1-NUTM1 fusions in non KMT2A-rearranged infant acute lymphoblastic leukemia.
Hematologic Neoplasms
Distinct functions of histone H3, lysine 4 methyltransferases in normal and malignant hematopoiesis.
Hematologic Neoplasms
Specific inhibition of DPY30 activity by ASH2L-derived peptides suppresses blood cancer cell growth.
Hematologic Neoplasms
t(11;16)(q23;p13)/KMT2A-CREBBP in hematologic malignancies: presumptive evidence of myelodysplasia or therapy-related neoplasm?
Hematoma, Subdural
Oral factor Xa inhibitors and risk of subdural hematoma: COMPASS trial results and meta-analysis.
Hepatitis B
A Novel lncRNA IHS Promotes Tumor Proliferation and Metastasis in HCC by Regulating the ERK- and AKT/GSK-3?-Signaling Pathways.
Hepatitis B
A virome-wide clonal integration analysis platform for discovering cancer viral etiology.
Hepatitis B
Hepatitis B virus X protein upregulates expression of SMYD3 and C-MYC in HepG2 cells.
Hepatitis B
Overexpression of SMYD3 Is Predictive of Unfavorable Prognosis in Hepatocellular Carcinoma.
Hepatitis B
The SMYD3 VNTR 3/3 polymorphism confers an increased risk and poor prognosis of hepatocellular carcinoma in a Chinese population.
Hepatitis B
Upregulation of SMYD3 and SMYD3 VNTR 3/3 polymorphism increase the risk of hepatocellular carcinoma.
Hepatitis C
Epigenetic regulation of miR-124 by Hepatitis C Virus core protein promotes migration and invasion of intrahepatic cholangiocarcinoma cells by targeting SMYD3.
Hepatitis C
Hepatitis C virus core upregulates the methylation status of the RASSF1A promoter through regulation of SMYD3 in hilar cholangiocarcinoma cells.
Hepatitis C
The lysine methyltransferase SMYD3 interacts with hepatitis C virus NS5A and is a negative regulator of viral particle production.
Herpes Simplex
Barrier-to-Autointegration Factor 1 (BAF/BANF1) Promotes Association of the SETD1A Histone Methyltransferase with Herpes Simplex Virus Immediate-Early Gene Promoters.
Herpes Simplex
Dot1l Aggravates Keratitis Induced by Herpes Simplex Virus Type 1 in Mice via p38 MAPK-Mediated Oxidative Stress.
Histiocytic Sarcoma
Primary splenic histiocytic sarcoma associated with hemophagocytic lymphohistiocytosis: A case report and review of literature of next-generation sequencing involving FLT3, NOTCH2, and KMT2A mutations.
Hodgkin Disease
ASH2L drives proliferation and sensitivity to bleomycin and other genotoxins in Hodgkin's lymphoma and testicular cancer cells.
Hodgkin Disease
Correction to: ASH2L drives proliferation and sensitivity to bleomycin and other genotoxins in Hodgkin's lymphoma and testicular cancer cells.
Hodgkin Disease
Interim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials?
Hyperglycinemia, Nonketotic
Identification of a RAI1-associated disease network through integration of exome sequencing, transcriptomics, and 3D genomics.
Hypersensitivity
ASH1L histone methyltransferase regulates the handoff between damage recognition factors in global-genome nucleotide excision repair.
Hypersensitivity
Histone methyltransferase DOT1L drives recovery of gene expression after a genotoxic attack.
Hypersensitivity
SMYD3 Promotes Homologous Recombination via Regulation of H3K4-mediated Gene Expression.
Hypertension
Navigating the uncharted waters of combination therapy in pulmonary arterial hypertension: COMPASS or dead-reckoning.
Hypertension, Pulmonary
Megakaryocytic leukemia 1 directs a histone h3 lysine 4 methyltransferase complex to regulate hypoxic pulmonary hypertension.
Hypertrichosis
A de novo Mutation in KMT2A (MLL) in monozygotic twins with Wiedemann-Steiner syndrome.
Hypertrichosis
Advanced bone age in a girl with Wiedemann-Steiner syndrome and an exonic deletion in KMT2A (MLL).
Hypertrichosis
Broad neurodevelopmental features and cortical anomalies associated with a novel de novo KMT2A variant in Wiedemann-Steiner syndrome.
Hypertrichosis
Expanding the genotypic and phenotypic spectrum in a diverse cohort of 104 individuals with Wiedemann-Steiner syndrome.
Hypertrichosis
Further delineation of the phenotype of truncating KMT2A mutations: The extended Wiedemann-Steiner syndrome.
Hypertrichosis
Growth hormone deficiency as a cause for short stature in Wiedemann-Steiner Syndrome.
Hypertrichosis
RNA Sequencing and Pathway Analysis Identify Important Pathways Involved in Hypertrichosis and Intellectual Disability in Patients with Wiedemann-Steiner Syndrome.
Hypertrichosis
Wiedemann-Steiner syndrome with a novel pathogenic variant in KMT2A: a case report.
Hypertriglyceridemia
Significant Quality of Life Improvement Observed in a Patient With FCS Associated With a Marked Reduction in Triglycerides.
Hypoglycemia
Hypoglycemia and Dandy-Walker variant in a Kabuki syndrome patient: a case report.
Hypoglycemia
Neonatal case of novel KMT2D mutation in Kabuki syndrome with severe hypoglycemia.
Hypoglycemia
Neonatal hyperinsulinemic hypoglycemia: case report of kabuki syndrome due to a novel KMT2D splicing-site mutation.
Hypogonadism
Peripheral Precocious Puberty of Ovarian Origin in a Series of 18 Girls: Exome Study Finds Variants in Genes Responsible for Hypogonadotropic Hypogonadism.
Hypoplastic Left Heart Syndrome
Cancer Management in Kabuki Syndrome: The First Case of Wilms Tumor and a Literature Review.
Hypothyroidism
A de novo KMT2D mutation in a girl with Kabuki syndrome associated with endocrine symptoms: a case report.
IgA Deficiency
Defects of B-cell terminal differentiation in patients with type-1 Kabuki syndrome.
Infections
Barrier-to-Autointegration Factor 1 (BAF/BANF1) Promotes Association of the SETD1A Histone Methyltransferase with Herpes Simplex Virus Immediate-Early Gene Promoters.
Infections
Dot1l Aggravates Keratitis Induced by Herpes Simplex Virus Type 1 in Mice via p38 MAPK-Mediated Oxidative Stress.
Infections
Exploring new targets for the treatment of hepatitis-B virus and hepatitis-B virus-associated hepatocellular carcinoma: A new perspective in bioinformatics.
Infections
Hepatitis C virus core upregulates the methylation status of the RASSF1A promoter through regulation of SMYD3 in hilar cholangiocarcinoma cells.
Infections
Interferon-? Stimulation Elicited by the Influenza Virus Is Regulated by the Histone Methylase Dot1L through the RIG-I-TRIM25 Signaling Axis.
Infections
Notch ligand Delta-like 4 induces epigenetic regulation of Treg cell differentiation and function in viral infection.
Infections
Quantitative Proteomic Discovery of Dynamic Epigenome Changes that Control Human Cytomegalovirus (HCMV) Infection.
Infections
Regulation of disease-responsive genes mediated by epigenetic factors: interaction of Arabidopsis-Pseudomonas.
Infections
SMYD3 promotes cancer invasion by epigenetic upregulation of the metalloproteinase MMP-9.
Infections
Targeting the Histone Methyltransferase Disruptor of Telomeric Silencing 1-Like Restricts Avian Leukosis Virus Subgroup J Replication by Restoring the Innate Immune Response in Chicken Macrophages.
Infections
The DOT1L inhibitor Pinometostat decreases the host-response against infections: Considerations about its use in human therapy.
Infections
The Methyltransferase DOT1L Controls Activation and Lineage Integrity in CD4+ T Cells during Infection and Inflammation.
Infections
The SMYD3 VNTR 3/3 polymorphism confers an increased risk and poor prognosis of hepatocellular carcinoma in a Chinese population.
Infections
Upregulation of SMYD3 and SMYD3 VNTR 3/3 polymorphism increase the risk of hepatocellular carcinoma.
Infertility
Accelerated evolution of the Prdm9 speciation gene across diverse metazoan taxa.
Infertility
Construction of PRDM9 allele-specific recombination maps in cattle using large-scale pedigree analysis and genome-wide single sperm genomics.
Infertility
Copy-number variation introduced by long transgenes compromises mouse male fertility independently of pachytene checkpoints.
Infertility
Evolutionary dynamics of meiotic recombination hotspots regulator PRDM9 in bovids.
Infertility
Genomic and chromatin features shaping meiotic double-strand break formation and repair in mice.
Infertility
Hybrid sterility genes in mice (Mus musculus): a peculiar case of PRDM9 incompatibility.
Infertility
Hybrid Sterility Locus on Chromosome X Controls Meiotic Recombination Rate in Mouse.
Infertility
Interallelic and intergenic incompatibilities of the Prdm9 (Hst1) gene in mouse hybrid sterility.
Infertility
Molecular Basis for the Regulation of the H3K4 Methyltransferase Activity of PRDM9.
Infertility
Prdm9 incompatibility controls oligospermia and delayed fertility but no selfish transmission in mouse intersubspecific hybrids.
Infertility
Rat PRDM9 shapes recombination landscapes, duration of meiosis, gametogenesis, and age of fertility.
Infertility
Reverse genetics reveals single gene of every candidate on Hybrid sterility, X Chromosome QTL 2 (Hstx2) are dispensable for spermatogenesis.
Infertility
Single Nucleotide Polymorphisms in PRDM9 (MEISETZ) in Patients with Nonobstructive Azoospermia.
Infertility
X marks the spot: PRDM9 rescues hybrid sterility by finding hidden treasure in the genome.
Infertility
Zinc Finger Domain of the PRDM9 Gene on Chromosome 1 Exhibits High Diversity in Ruminants but Its Paralog PRDM7 Contains Multiple Disruptive Mutations.
Infertility, Female
Setd1b, encoding a histone 3 lysine 4 methyltransferase, is a maternal effect gene required for the oogenic gene expression program.
Infertility, Male
Accelerated evolution of the Prdm9 speciation gene across diverse metazoan taxa.
Infertility, Male
Bos taurus-indicus hybridization correlates with intralocus sexual-conflict effects of PRDM9 on male and female fertility in Holstein cattle.
Infertility, Male
Cisplatin-induced DNA double-strand breaks promote meiotic chromosome synapsis in PRDM9-controlled mouse hybrid sterility.
Infertility, Male
Genetic Dissection of Hybrid Male Sterility Across Stages of Spermatogenesis.
Infertility, Male
Genomic Structure of Hstx2 Modifier of Prdm9-Dependent Hybrid Male Sterility in Mice.
Infertility, Male
Prdm9 inter-subspecific interactions in hybrid male sterility of house mouse.
Infertility, Male
X chromosome control of meiotic chromosome synapsis in mouse inter-subspecific hybrids.
Influenza, Human
Epigenetic control of influenza virus: role of H3K79 methylation in interferon-induced antiviral response.
Influenza, Human
Interferon-? Stimulation Elicited by the Influenza Virus Is Regulated by the Histone Methylase Dot1L through the RIG-I-TRIM25 Signaling Axis.
Influenza, Human
The DOT1L inhibitor Pinometostat decreases the host-response against infections: Considerations about its use in human therapy.
Insulin Resistance
Mutations in Mll2, an H3K4 methyltransferase, result in insulin resistance and impaired glucose tolerance in mice.
Intellectual Disability
A chromosome 1q22 microdeletion including ASH1L is associated with intellectual disability in a Chinese family.
Intellectual Disability
A novel deletion mutation in KMT2A identified in a child with ID/DD and blood eosinophilia.
Intellectual Disability
An atypical 12q24.31 microdeletion implicates six genes including a histone demethylase KDM2B and a histone methyltransferase SETD1B in syndromic intellectual disability.
Intellectual Disability
ASH1L mutation caused seizures and intellectual disability in twin sisters.
Intellectual Disability
Breast cancer information and support needs for women with intellectual disabilities: a scoping study.
Intellectual Disability
Clinical Characteristics and Genotype-Phenotype Correlation in Children with KMT2E Gene-Related Neurodevelopmental Disorders: Report of Two New Cases and Review of Published Literature.
Intellectual Disability
De novo loss-of-function variants of ASH1L are associated with an emergent neurodevelopmental disorder.
Intellectual Disability
De novo variants in SETD1B are associated with intellectual disability, epilepsy and autism.
Intellectual Disability
De novo variants in SETD1B cause intellectual disability, autism spectrum disorder, and epilepsy with myoclonic absences.
Intellectual Disability
Delineating the molecular and phenotypic spectrum of the SETD1B-related syndrome.
Intellectual Disability
Expanding the genotypic and phenotypic spectrum in a diverse cohort of 104 individuals with Wiedemann-Steiner syndrome.
Intellectual Disability
Frequency and phenotypic spectrum of KMT2B dystonia in childhood: A single-center cohort study.
Intellectual Disability
Functional convergence of histone methyltransferases EHMT1 and KMT2C involved in intellectual disability and autism spectrum disorder.
Intellectual Disability
Growth hormone deficiency as a cause for short stature in Wiedemann-Steiner Syndrome.
Intellectual Disability
Histone Lysine Methylases and Demethylases in the Landscape of Human Developmental Disorders.
Intellectual Disability
Identification of a RAI1-associated disease network through integration of exome sequencing, transcriptomics, and 3D genomics.
Intellectual Disability
Loss of histone methyltransferase ASH1L in the developing mouse brain causes autistic-like behaviors.
Intellectual Disability
Molecular and cellular issues of KMT2A variants involved in Wiedemann-Steiner syndrome.
Intellectual Disability
Mutually suppressive roles of KMT2A and KDM5C in behaviour, neuronal structure, and histone H3K4 methylation.
Intellectual Disability
Novel karyotypes of partial monosomy 21 and partial monosomy 1 and underlying etiology.
Intellectual Disability
RNA Sequencing and Pathway Analysis Identify Important Pathways Involved in Hypertrichosis and Intellectual Disability in Patients with Wiedemann-Steiner Syndrome.
Intellectual Disability
Role of Ash1l in Tourette syndrome and other neurodevelopmental disorders.
Intellectual Disability
Wiedemann-Steiner syndrome with a novel pathogenic variant in KMT2A: a case report.
Intracranial Hemorrhages
Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic events in coronary artery disease, peripheral artery disease, or both.
Ischemic Attack, Transient
COMPASS-CP: An Electronic Application to Capture Patient-Reported Outcomes to Develop Actionable Stroke and Transient Ischemic Attack Care Plans.
Ischemic Attack, Transient
Hospital recruitment for a pragmatic cluster-randomized clinical trial: Lessons learned from the COMPASS study.
Ischemic Attack, Transient
Patient Factors Associated With Attendance at a Comprehensive Postacute Stroke Visit: Insight From the Vanguard Site.
Ischemic Stroke
Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes: A Secondary Analysis of the COMPASS Trial.
Ischemic Stroke
External applicability of the COMPASS trial: the Western Denmark Heart Registry.
Ischemic Stroke
Meta-Analysis of Genome-Wide Association Studies Identifies Genetic Risk Factors for Stroke in African Americans.
Keratitis
Dot1l Aggravates Keratitis Induced by Herpes Simplex Virus Type 1 in Mice via p38 MAPK-Mediated Oxidative Stress.
Keratitis, Herpetic
Dot1l Aggravates Keratitis Induced by Herpes Simplex Virus Type 1 in Mice via p38 MAPK-Mediated Oxidative Stress.
Kidney Diseases
Critical roles of SMYD2 lysine methyltransferase in mediating renal fibroblast activation and kidney fibrosis.
Kidney Diseases, Cystic
Acquired Cystic Kidney Disease-associated Renal Cell Carcinoma (ACKD-RCC) Harbor Recurrent Mutations in KMT2C and TSC2 Genes.
Kidney Neoplasms
Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma.
Kidney Neoplasms
SETD2, GIGYF2, FGFR3, BCR, KMT2C, and TSC2 as candidate genes for differentiating multilocular cystic renal neoplasm of low malignant potential from clear cell renal cell carcinoma with cystic change.
Klatskin Tumor
Hepatitis C virus core upregulates the methylation status of the RASSF1A promoter through regulation of SMYD3 in hilar cholangiocarcinoma cells.
Kyphosis
Goniometer evaluation of thoracic kyphosis and lumbar lordosis in subjects during growth age: a validity study.
Language Development Disorders
Clinical Characteristics and Genotype-Phenotype Correlation in Children with KMT2E Gene-Related Neurodevelopmental Disorders: Report of Two New Cases and Review of Published Literature.
Language Development Disorders
Delineating the molecular and phenotypic spectrum of the SETD1B-related syndrome.
Leukemia
A case of pediatric acute myeloid leukemia with t(11;16)(q23;q24) leading to a novel KMT2A-USP10 fusion gene.
Leukemia
A higher-order configuration of the heterodimeric DOT1L-AF10 coiled-coil domains potentiates their leukemogenenic activity.
Leukemia
A KMT2A-AFF1 gene regulatory network highlights the role of core transcription factors and reveals the regulatory logic of key downstream target genes.
Leukemia
A Medicinal Chemistry Perspective for Targeting Histone H3 Lysine-79 Methyltransferase DOT1L.
Leukemia
A new variant of KMT2A(MLL)-FLNA fusion transcript in acute myeloid leukemia with ins(X;11)(q28;q23q23).
Leukemia
A novel non-SET domain multi-subunit methyltransferase required for sequential nucleosomal histone H3 methylation by the mixed lineage leukemia protein-1 (MLL1) core complex.
Leukemia
A Patient with Kabuki Syndrome Mutation Presenting with Very Severe Aplastic Anemia.
Leukemia
A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial.
Leukemia
A subset of mixed lineage leukemia proteins has plant homeodomain (PHD)-mediated E3 ligase activity.
Leukemia
A systems biology approach for elucidating the interaction of curcumin with Fanconi anemia FANC G protein and the key disease targets of leukemia.
Leukemia
Aberrant Activity of Histone-Lysine N-Methyltransferase 2 (KMT2) Complexes in Oncogenesis.
Leukemia
Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l.
Leukemia
Activation of the lysosome-associated membrane protein LAMP5 by DOT1L serves as a bodyguard for MLL fusion oncoproteins to evade degradation in leukemia.
Leukemia
Acute leukemias harboring KMT2A/MLLT10 fusion: a 10-year experience from a single genomics laboratory.
Leukemia
Acute lymphoblastic leukemia in infants: a quarter century of nationwide efforts in Japan.
Leukemia
Acute myeloid leukemia with t(10;11)(p11-12;q23.3): Results of Russian Pediatric AML registration study.
Leukemia
An Original Complex Rearrangement Involving Chromosomes 9, 11, and 14, Harboring a Complex KMT2A Gene Rearrangement in an Infant With Mixed-phenotype Acute Leukemia.
Leukemia
ASH2L-Promoted HOXC8 Gene Expression Plays a Role in Mixed Lineage Leukemia-Rearranged Acute Leukemia.
Leukemia
ASH2L: alternative splicing and downregulation during induced megakaryocytic differentiation of multipotential leukemia cell lines.
Leukemia
BTK, NUTM2A, and PRPF19 Are Novel KMT2A Partner Genes in Childhood Acute Leukemia.
Leukemia
C1188D mutation abolishes specific recognition between MLL1-CXXC domain and CpG site by inducing conformational switch of flexible N-terminal.
Leukemia
Case Report: Targeting 2 Antigens as a Promising Strategy in Mixed Phenotype Acute Leukemia: Combination of Blinatumomab With Gemtuzumab Ozogamicin in an Infant With a KMT2A-Rearranged Leukemia.
Leukemia
Characterization of a novel WDR5-binding site that recruits RbBP5 through a conserved motif to enhance methylation of histone H3 lysine 4 by mixed lineage leukemia protein-1.
Leukemia
Chimeric antigen receptor T-cell therapy for marrow and extramedullary relapse of infant acute lymphoblastic leukemia.
Leukemia
Cleaving for growth: threonine aspartase 1-a protease relevant for development and disease.
Leukemia
Clinicopathologic and prognostic features of TdT-negative pediatric B-lymphoblastic leukemia.
Leukemia
Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
Leukemia
Comprehensive genetic analysis of donor cell derived leukemia with KMT2A rearrangement.
Leukemia
Conformational Adaptation Drives Potent, Selective and Durable Inhibition of the Human Protein Methyltransferase DOT1L.
Leukemia
Conserved crosstalk between histone deacetylation and H3K79 methylation generates DOT1L-dose dependency in HDAC1-deficient thymic lymphoma.
Leukemia
Cooperativity in transcription factor binding to the coactivator CREB-binding protein (CBP). The mixed lineage leukemia protein (MLL) activation domain binds to an allosteric site on the KIX domain.
Leukemia
Copy-number variation and protein expression of DOT1L in pancreatic adenocarcinoma as a potential drug target.
Leukemia
Correction to: The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia.
Leukemia
Crucial roles of mixed-lineage leukemia 3 and 4 as epigenetic switches of the hepatic circadian clock controlling bile acid homeostasis in mice.
Leukemia
Cryptic and atypical KMT2A-USP2 and KMT2A-USP8 rearrangements identified by mate pair sequencing in infant and childhood leukemia.
Leukemia
Cryptic recurrent ACIN1-NUTM1 fusions in non KMT2A-rearranged infant acute lymphoblastic leukemia.
Leukemia
Cyp33 binds AU-rich RNA motifs via an extended interface that competitively disrupts the gene repressive Cyp33-MLL1 interaction in vitro.
Leukemia
Cytogenomic characterization of double minute heterogeneity in therapy related acute myeloid leukemia.
Leukemia
De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia.
Leukemia
Design, synthesis and anti leukemia cells proliferation activities of pyrimidylaminoquinoline derivatives as DOT1L inhibitors.
Leukemia
Discovery of first-in-class inhibitors of ASH1L histone methyltransferase with anti-leukemic activity.
Leukemia
Discovery of Novel Disruptor of Silencing Telomeric 1-Like (DOT1L) Inhibitors using a Target-Specific Scoring Function for the (S)-Adenosyl-l-methionine (SAM)-Dependent Methyltransferase Family.
Leukemia
Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation Approach.
Leukemia
Discovery of potent DOT1L inhibitors by AlphaLISA based High Throughput Screening assay.
Leukemia
Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach.
Leukemia
Disruptor of telomeric silencing 1-like (DOT1L): disclosing a new class of non-nucleoside inhibitors by means of ligand-based and structure-based approaches.
Leukemia
Distinct functions of histone H3, lysine 4 methyltransferases in normal and malignant hematopoiesis.
Leukemia
Disturbing the histone code in leukemia: translocations and mutations affecting histone methyl transferases.
Leukemia
DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia.
Leukemia
DOT1L complex regulates transcriptional initiation in human erythroleukemic cells.
Leukemia
DOT1L histone methyltransferase regulates the expression of BCAT1 and is involved in sphere formation and cell migration of breast cancer cell lines.
Leukemia
DOT1L inhibition is lethal for multiple myeloma due to perturbation of the endoplasmic reticulum stress pathway.
Leukemia
DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation.
Leukemia
DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells.
Leukemia
DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
Leukemia
DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis.
Leukemia
Dysregulation of the DNA Damage Response and KMT2A Rearrangement in Fetal Liver Hematopoietic Cells.
Leukemia
Elucidating the Importance of DOT1L Recruitment in MLL-AF9 Leukemia and Hematopoiesis.
Leukemia
Epigenetic changes in human model KMT2A leukemias highlight early events during leukemogenesis.
Leukemia
Epigenetic Perturbations by Arg882-Mutated DNMT3A Potentiate Aberrant Stem Cell Gene-Expression Program and Acute Leukemia Development.
Leukemia
Epigenetic silencing of SOCS5 potentiates JAK-STAT signaling and progression of T-cell acute lymphoblastic leukemia.
Leukemia
Establishment and characterization of a DOT1L inhibitor-sensitive human acute monocytic leukemia cell line YBT-5 with a novel KMT2A-MLLT3 fusion.
Leukemia
Exploring drug delivery for the DOT1L inhibitor pinometostat (EPZ-5676): Subcutaneous administration as an alternative to continuous IV infusion, in the pursuit of an epigenetic target.
Leukemia
Filamins but Not Janus Kinases Are Substrates of the ASB2? Cullin-Ring E3 Ubiquitin Ligase in Hematopoietic Cells.
Leukemia
Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
Leukemia
Functional interrogation of HOXA9 regulome in MLLr leukemia via reporter-based CRISPR/Cas9 screen.
Leukemia
Genetic mutational analysis of pediatric acute lymphoblastic leukemia from a single center in China using exon sequencing.
Leukemia
Genome-wide association and functional studies identify the DOT1L gene to be involved in cartilage thickness and hip osteoarthritis.
Leukemia
Glucocorticoids uncover a critical role for ASH2L on BCL-X expression regulation in leukemia cells.
Leukemia
High-affinity small molecular blockers of mixed lineage leukemia 1 (MLL1)-WDR5 interaction inhibit MLL1 complex H3K4 methyltransferase activity.
Leukemia
High-efficiency CRISPR induction of t(9;11) chromosomal translocations and acute leukemias in human blood stem cells.
Leukemia
Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis.
Leukemia
Histone H3K4 methyltransferase Mll1 regulates protein glycosylation and tunicamycin-induced apoptosis through transcriptional regulation.
Leukemia
Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer.
Leukemia
Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4.
Leukemia
Identification of a Cryptic Insertion ins(11;X)(q23;q28q12) Resulting in a KMT2A-FLNA Fusion in a 13-Month-Old Child with Acute Myelomonocytic Leukemia.
Leukemia
Identification of a novel KMT2A/GIMAP8 gene fusion in a pediatric patient with acute undifferentiated leukemia.
Leukemia
Identification of KMT2A-ARHGEF12 fusion in a child with a high-grade B-cell lymphoma.
Leukemia
Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT promoter.
Leukemia
Inhibition of Dot1L Alleviates Fulminant Hepatitis Through Myeloid-Derived Suppressor Cells.
Leukemia
Inhibition of DOT1L and PRMT5 promote synergistic anti-tumor activity in a human MLL leukemia model induced by CRISPR/Cas9.
Leukemia
Inhibition of Methyltransferase DOT1L Sensitizes to Sorafenib Treatment AML Cells Irrespective of MLL-Rearrangements: A Novel Therapeutic Strategy for Pediatric AML.
Leukemia
Integrated Analysis of Genetic Abnormalities of the Histone Lysine Methyltransferases in Prostate Cancer.
Leukemia
KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation.
Leukemia
Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression.
Leukemia
Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.
Leukemia
Low concentrations of permethrin and malathion induce numerical and structural abnormalities in KMT2A and IGH genes in vitro.
Leukemia
Low expression of ASH2L protein correlates with a favorable outcome in acute myeloid leukemia.
Leukemia
LSD1 inhibition exerts its anti-leukemic effect by recommissioning PU.1- and C/EBP?-dependent enhancers in AML.
Leukemia
Mechanisms of Pinometostat (EPZ-5676) Treatment-Emergent Resistance in MLL-Rearranged Leukemia.
Leukemia
Mechanisms of transcriptional regulation by MLL and its disruption in acute leukemia.
Leukemia
Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors.
Leukemia
Menin expression is regulated by transforming growth factor beta signaling in leukemia cells.
Leukemia
Menin regulates the function of hematopoietic stem cells and lymphoid progenitors.
Leukemia
MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition.
Leukemia
MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia.
Leukemia
MLL/WDR5 Complex Regulates Kif2A Localization to Ensure Chromosome Congression and Proper Spindle Assembly during Mitosis.
Leukemia
MLL4-associated condensates counterbalance Polycomb-mediated nuclear mechanical stress in Kabuki syndrome.
Leukemia
Molecular characterization of KMT2A fusion partner genes in 13 cases of pediatric leukemia with complex or cryptic karyotypes.
Leukemia
Monocytic Acute Myeloid Leukemias with KM2TA Translocations to Chromosome 17q that May Clinically Mimic Acute Promyelocytic Leukemia.
Leukemia
Neuronal Kmt2a/Mll1 histone methyltransferase is essential for prefrontal synaptic plasticity and working memory.
Leukemia
Non-canonical H3K79me2-dependent pathways promote the survival of MLL-rearranged leukemia.
Leukemia
Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor.
Leukemia
Novel DOT1L ReceptorNatural Inhibitors Involved in Mixed Lineage Leukemia: a Virtual Screening, Molecular Docking and Dynamics Simulation Study.
Leukemia
Novel SH3 protein encoded by the AF3p21 gene is fused to the mixed lineage leukemia protein in a therapy-related leukemia with t(3;11) (p21;q23).
Leukemia
Novel sub-cellular localizations and intra-molecular interactions may define new functions of Mixed Lineage Leukemia protein.
Leukemia
Perturbation of Methionine/S-adenosylmethionine Metabolism as a Novel Vulnerability in MLL Rearranged Leukemia.
Leukemia
Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells.
Leukemia
Preclinical Pharmacokinetics and Pharmacodynamics of Pinometostat (EPZ-5676), a First-in-Class, Small Molecule S-Adenosyl Methionine Competitive Inhibitor of DOT1L.
Leukemia
Protein-arginine Methyltransferase 1 (PRMT1) Methylates Ash2L, a Shared Component of Mammalian Histone H3K4 Methyltransferase Complexes.
Leukemia
Quantification of NG2-positivity for the precise prediction of KMT2A gene rearrangements in childhood acute leukemia.
Leukemia
Rapid generation of drug-resistance alleles at endogenous loci using CRISPR-Cas9 indel mutagenesis.
Leukemia
Regulation of HOXA2 gene expression by the ATP-dependent chromatin remodeling enzyme CHD8.
Leukemia
Regulation of IL-20 Expression by Estradiol through KMT2B-Mediated Epigenetic Modification.
Leukemia
Regulation of Wnt signaling target gene expression by the histone methyltransferase DOT1L.
Leukemia
Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation.
Leukemia
Requirement for MLL3 in p53 regulation of hepatic expression of small heterodimer partner and bile acid homeostasis.
Leukemia
Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia.
Leukemia
Rewiring the Epigenetic Networks in MLL-Rearranged Leukemias: Epigenetic Dysregulation and Pharmacological Interventions.
Leukemia
Selective DOT1L, LSD1, and HDAC Class I Inhibitors Reduce HOXA9 Expression in MLL-AF9 Rearranged Leukemia Cells, But Dysregulate the Expression of Many Histone-Modifying Enzymes.
Leukemia
Selective inhibitors of histone methyltransferase DOT1L: design, synthesis, and crystallographic studies.
Leukemia
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.
Leukemia
Small-molecule inhibitor of AF9/ENL-DOT1L/AF4/AFF4 interactions suppresses malignant gene expression and tumor growth.
Leukemia
SMYD2 lysine methyltransferase regulates leukemia cell growth and regeneration after genotoxic stress.
Leukemia
Somatic cancer mutations in the MLL1 histone methyltransferase modulate its enzymatic activity and dependence on the WDR5/RBBP5/ASH2L complex.
Leukemia
Somatic Mutations of the Mixed-Lineage Leukemia 3 (MLL3) Gene in Primary Breast Cancers.
Leukemia
Specific patterns of H3K79 methylation influence genetic interaction of oncogenes in AML.
Leukemia
Structural and functional analysis of the DOT1L-AF10 complex reveals mechanistic insights into MLL-AF10-associated leukemogenesis.
Leukemia
Structural Basis for Recognition of Ubiquitylated Nucleosome by Dot1L Methyltransferase.
Leukemia
Structural Characterization of the Loop at the Alpha-Subunit C-Terminus of the Mixed Lineage Leukemia Protein Activating Protease Taspase1.
Leukemia
Structure, Activity and Function of the MLL2 (KMT2B) Protein Lysine Methyltransferase.
Leukemia
Structure-guided development of YEATS domain inhibitors by targeting ?-?-? stacking.
Leukemia
Substituted purine and 7-deazapurine compounds as modulators of epigenetic enzymes: a patent evaluation (WO2012075381).
Leukemia
Suppression of Mll1-Complex by Stat3/Cebp?-Induced miR-21a/21b/181b Maintains the Accumulation, Homeostasis, and Immunosuppressive Function of Polymorphonuclear Myeloid-Derived Suppressor Cells.
Leukemia
Synthesis and Biological Activity of a Cytostatic Inhibitor of MLLr Leukemia Targeting the DOT1L Protein.
Leukemia
Synthesis and Structure-Activity Relationship Investigation of Adenosine-Containing Inhibitors of Histone Methyltransferase DOT1L.
Leukemia
Synthesis, Activity and Metabolic Stability of Non-Ribose Containing Inhibitors of Histone Methyltransferase DOT1L.
Leukemia
Targeted Disruption of the Interaction Between WD-40 Repeat Protein 5 (WDR5) and Mixed Lineage Leukemia (MLL)/SET1 Family Proteins Specifically Inhibits MLL1 and SETd1A Methyltransferase Complexes.
Leukemia
Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia.
Leukemia
Targeting DOT1L action and interactions in leukemia: the role of DOT1L in transformation and development.
Leukemia
Targeting recruitment of Disruptor Of Telomeric silencing 1-Like (DOT1L): Characterizing the interactions between DOT1L and Mixed Lineage Leukemia (MLL) fusion proteins.
Leukemia
The ability of MLL to bind RUNX1 and methylate H3K4 at PU.1 regulatory regions is impaired by MDS/AML-associated RUNX1/AML1 mutations.
Leukemia
The amino terminus of the mixed lineage leukemia protein (MLL) promotes cell cycle arrest and monocytic differentiation.
Leukemia
The combination of dibenzazepine and a DOT1L inhibitor enables a stable maintenance of human naïve-state pluripotency in non-hypoxic conditions.
Leukemia
The DOT1L inhibitor Pinometostat decreases the host-response against infections: Considerations about its use in human therapy.
Leukemia
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia.
Leukemia
The Histone H3 Lysine 4 Presenter WDR5 as an Oncogenic Protein and Novel Epigenetic Target in Cancer.
Leukemia
The histone methyltransferase DOT1L is required for proper DNA damage response, DNA repair, and modulates chemotherapy responsiveness.
Leukemia
The histone methyltransferase DOT1L: regulatory functions and a cancer therapy target.
Leukemia
The identification of novel small-molecule inhibitors targeting WDR5-MLL1 interaction through fluorescence polarization based high-throughput screening.
Leukemia
The internal interaction in RBBP5 regulates assembly and activity of MLL1 methyltransferase complex.
Leukemia
The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia.
Leukemia
The lysine methyltransferase SMYD2 is required for normal lymphocyte development and survival of hematopoietic leukemias.
Leukemia
The mechanism of binding of the KIX domain to the mixed lineage leukemia protein and its allosteric role in the recognition of c-Myb.
Leukemia
The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias.
Leukemia
The trithorax group protein Ash2l is essential for pluripotency and maintaining open chromatin in embryonic stem cells.
Leukemia
Therapy-induced Deletion in 11q23 Leading to Fusion of KMT2A With ARHGEF12 and Development of B Lineage Acute Lymphoplastic Leukemia in a Child Treated for Acute Myeloid Leukemia Caused by t(9;11)(p21;q23)/KMT2A-MLLT3.
Leukemia
Therapy-related acute lymphoblastic leukemia: Where do we stand with regards to its definition and characterization?
Leukemia
Unique Role of the WD-40 Repeat Protein 5 (WDR5) Subunit within the Mixed Lineage Leukemia 3 (MLL3) Histone Methyltransferase Complex.
Leukemia
UTX and MLL4 Coordinately Regulate Transcriptional Programs for Cell Proliferation and Invasiveness in Breast Cancer Cells.
Leukemia
[Effect of DOT1L Gene Silence on Proliferation of Acute Monocytic Leukemia Cell Line THP-1].
Leukemia, Lymphocytic, Chronic, B-Cell
CD38 as a molecular compass guiding topographical decisions of chronic lymphocytic leukemia cells.
Leukemia, Lymphocytic, Chronic, B-Cell
High incidence of MYD88 and KMT2D mutations in Chinese with chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Residual expression of SMYD2 and SMYD3 is associated with the acquisition of complex karyotype in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
STAT3 promotes chronic lymphocytic leukemia progression through upregulating SMYD3 expression.
Leukemia, Lymphocytic, Chronic, B-Cell
STAT3-induced SMYD3 transcription enhances chronic lymphocytic leukemia cell growth in vitro and in vivo.
Leukemia, Megakaryoblastic, Acute
Megakaryocytic leukemia 1 directs a histone h3 lysine 4 methyltransferase complex to regulate hypoxic pulmonary hypertension.
Leukemia, Megakaryoblastic, Acute
MKL1 mediates TNF-? induced pro-inflammatory transcription by bridging the crosstalk between BRG1 and WDR5.
Leukemia, Monocytic, Acute
Establishment and characterization of a DOT1L inhibitor-sensitive human acute monocytic leukemia cell line YBT-5 with a novel KMT2A-MLLT3 fusion.
Leukemia, Monocytic, Acute
[Effect of DOT1L Gene Silence on Proliferation of Acute Monocytic Leukemia Cell Line THP-1].
Leukemia, Myeloid
An uncommon t(9;11)(p24;q22) with monoallelic loss of ATM and KMT2A genes in a child with myelodysplastic syndrome/acute myeloid leukemia who evolved from Fanconi anemia.
Leukemia, Myeloid
DOTting the path to doom: how acceleration of histone methylation leads to leukemia.
Leukemia, Myeloid
Early-age Acute Leukemia: Revisiting Two Decades of the Brazilian Collaborative Study Group.
Leukemia, Myeloid
Glucocorticoids uncover a critical role for ASH2L on BCL-X expression regulation in leukemia cells.
Leukemia, Myeloid, Acute
A KMT2A-AFF1 gene regulatory network highlights the role of core transcription factors and reveals the regulatory logic of key downstream target genes.
Leukemia, Myeloid, Acute
A lineage switch from NPM1-mutant acute myeloid leukemia to acute T-cell lymphoblastic leukemia with KMT2D and ARID2 mutant.
Leukemia, Myeloid, Acute
A Non-catalytic Function of SETD1A Regulates Cyclin K and the DNA Damage Response.
Leukemia, Myeloid, Acute
A Novel and Cytogenetically Cryptic t(7;21)(q36.1;q22) Disrupting RUNX1 in Acute Myeloid Leukemia.
Leukemia, Myeloid, Acute
A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485.
Leukemia, Myeloid, Acute
A pediatric case of acute myeloid leukemia with KMT2A gene rearrangement t(10;11) and 16p11.2 microdeletion syndrome.
Leukemia, Myeloid, Acute
Acute myeloid leukemia with t(10;11)(p11-12;q23.3): Results of Russian Pediatric AML registration study.
Leukemia, Myeloid, Acute
Allogenic Stem Cell Transplantation Abrogates Negative Impact on Outcome of AML Patients with KMT2A Partial Tandem Duplication.
Leukemia, Myeloid, Acute
Assessing acute myeloid leukemia susceptibility in rearrangement-driven patients by DNA breakage at topoisomerase II and CCCTC-binding factor/cohesin binding sites.
Leukemia, Myeloid, Acute
Clinical Impact of KMT2C and SPRY4 Expression Levels in Intensively Treated Younger Adult Acute Myeloid Leukemia Patients.
Leukemia, Myeloid, Acute
DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia.
Leukemia, Myeloid, Acute
EPHX1 rs1051740 T>C (Tyr113His) is strongly associated with acute myeloid leukemia and KMT2A rearrangements in early age.
Leukemia, Myeloid, Acute
Epigenetic changes in human model KMT2A leukemias highlight early events during leukemogenesis.
Leukemia, Myeloid, Acute
Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Hematopoietic stem cell transplantation for pediatric acute myeloid leukemia patients with KMT2A rearrangement; A nationwide retrospective analysis in Japan.
Leukemia, Myeloid, Acute
Homogeneously staining region (hsr) on chromosome 11 is highly specific for KMT2A amplification in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Leukemia, Myeloid, Acute
KMT2A (MLL) rearrangements observed in pediatric/young adult T-lymphoblastic leukemia/lymphoma: A 10-year review from a single cytogenetic laboratory.
Leukemia, Myeloid, Acute
Kmt2c mutations enhance HSC self-renewal capacity and convey a selective advantage after chemotherapy.
Leukemia, Myeloid, Acute
Long-term remission of therapy-related acute myeloid leukemia with a new t(11;18)(q23;q21.2) translocation and KMT2A-ME2 (MLL-ME2) fusion gene.
Leukemia, Myeloid, Acute
Low expression of ASH2L protein correlates with a favorable outcome in acute myeloid leukemia.
Leukemia, Myeloid, Acute
MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia.
Leukemia, Myeloid, Acute
Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/KMT2A.
Leukemia, Myeloid, Acute
Primary acute myeloid leukemia cells with IDH1 or IDH2 mutations respond to a DOT1L inhibitor in vitro.
Leukemia, Myeloid, Acute
Smyd2 is a Myc-regulated gene critical for MLL-AF9 induced leukemogenesis.
Leukemia, Myeloid, Acute
Specific patterns of H3K79 methylation influence genetic interaction of oncogenes in AML.
Leukemia, Myeloid, Acute
The role of autophagy in targeted therapy for acute myeloid leukemia.
Leukemia, Myeloid, Acute
The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias.
Leukemia, Myeloid, Acute
Therapy-induced Deletion in 11q23 Leading to Fusion of KMT2A With ARHGEF12 and Development of B Lineage Acute Lymphoplastic Leukemia in a Child Treated for Acute Myeloid Leukemia Caused by t(9;11)(p21;q23)/KMT2A-MLLT3.
Leukemia, Myeloid, Acute
Whole transcriptome sequencing reveals a KMT2A-USP2 fusion in infant acute myeloid leukemia.
Leukemia, Myelomonocytic, Acute
Identification of a Cryptic Insertion ins(11;X)(q23;q28q12) Resulting in a KMT2A-FLNA Fusion in a 13-Month-Old Child with Acute Myelomonocytic Leukemia.
Leukemia, Promyelocytic, Acute
The role of autophagy in targeted therapy for acute myeloid leukemia.
Lipoma
A novel protein expression signature differentiates benign lipomas from well-differentiated liposarcomas.
Liposarcoma
A novel protein expression signature differentiates benign lipomas from well-differentiated liposarcomas.
Liver Cirrhosis
High?level SETD1B gene expression is associated with unfavorable prognosis in hepatocellular carcinoma.
Liver Cirrhosis
Myocardin related transcription factor A programs epigenetic activation of hepatic stellate cells.
Liver Diseases
COMPASS: A Pilot Trial of an Early Palliative Care Intervention for Patients With End-Stage Liver Disease.
Liver Diseases
Upregulation of SMYD3 and SMYD3 VNTR 3/3 polymorphism increase the risk of hepatocellular carcinoma.
Liver Neoplasms
A virome-wide clonal integration analysis platform for discovering cancer viral etiology.
Liver Neoplasms
Exploring new targets for the treatment of hepatitis-B virus and hepatitis-B virus-associated hepatocellular carcinoma: A new perspective in bioinformatics.
Liver Neoplasms
LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2.
Lordosis
Goniometer evaluation of thoracic kyphosis and lumbar lordosis in subjects during growth age: a validity study.
Lung Neoplasms
Comprehensive molecular analysis of genomic profiles and PD-L1 expression in lung adenocarcinoma with a high-grade fetal adenocarcinoma component.
Lung Neoplasms
Deficiency of H3K79 Histone Methyltransferase Dot1-like Protein (DOT1L) Inhibits Cell Proliferation.
Lung Neoplasms
DZNep, inhibitor of S-adenosylhomocysteine hydrolase, down-regulates expression of SETDB1 H3K9me3 HMTase in human lung cancer cells.
Lung Neoplasms
EHMT1 knockdown induces apoptosis and cell cycle arrest in lung cancer cells by increasing CDKN1A expression.
Lung Neoplasms
Genomic profiling in advanced stage non-small-cell lung cancer patients with platinum-based chemotherapy identifies germline variants with prognostic value in SMYD2.
Lung Neoplasms
Inhibition of SMYD2 Sensitized Cisplatin to Resistant Cells in NSCLC Through Activating p53 Pathway.
Lung Neoplasms
KMT2C promoter methylation in plasma-circulating tumor DNA is a prognostic biomarker in non-small cell lung cancer.
Lung Neoplasms
KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer.
Lung Neoplasms
KMT2D Mutation Is Associated With Poor Prognosis in Non-Small-Cell Lung Cancer.
Lung Neoplasms
Loss of histone lysine methyltransferase EZH2 confers resistance to tyrosine kinase inhibitors in non-small cell lung cancer.
Lung Neoplasms
Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L).
Lung Neoplasms
RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.
Lung Neoplasms
RNF213 gene mutation in circulating tumor DNA detected by targeted next-generation sequencing in the assisted discrimination of early-stage lung cancer from pulmonary nodules.
Lung Neoplasms
SMYD3 overexpression indicates poor prognosis and promotes cell proliferation, migration and invasion in non?small cell lung cancer.
Lung Neoplasms
Suppression of Mll1-Complex by Stat3/Cebp?-Induced miR-21a/21b/181b Maintains the Accumulation, Homeostasis, and Immunosuppressive Function of Polymorphonuclear Myeloid-Derived Suppressor Cells.
Lung Neoplasms
The H3K4 methyltransferase SETD1A is required for proliferation of non-small cell lung cancer cells by promoting S-phase progression.
Lung Neoplasms
[Health and disease in the Netherlands: the Dutch National Public Health Compass as a source of information]
Lupus Erythematosus, Systemic
Genome-wide association study on Northern Chinese identifies KLF2, DOT1L and STAB2 associated with systemic lupus erythematosus.
Lymphatic Metastasis
Elevated Levels of SET and MYND Domain-Containing Protein 3 Are Correlated with Overexpression of Transforming Growth Factor-?1 in Gastric Cancer.
Lymphatic Metastasis
High expression of SMYD3 indicates poor survival outcome and promotes tumour progression through an IGF-1R/AKT/E2F-1 positive feedback loop in bladder cancer.
Lymphatic Metastasis
Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer.
Lymphatic Metastasis
Overexpression of SET and MYND Domain-Containing Protein 2 (SMYD2) Is Associated with Tumor Progression and Poor Prognosis in Patients with Papillary Thyroid Carcinoma.
Lymphatic Metastasis
Overexpression of SMYD3 and matrix metalloproteinase-9 are associated with poor prognosis of patients with gastric cancer.
Lymphatic Metastasis
Overexpression of SMYD3 was associated with increased STAT3 activation in gastric cancer.
Lymphatic Metastasis
Overexpression of the SMYD3 Promotes Proliferation, Migration, and Invasion of Pancreatic Cancer.
Lymphatic Metastasis
Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer.
Lymphatic Metastasis
SMYD2 facilitates cancer cell malignancy and xenograft tumor development through ERBB2-mediated FUT4 expression in colon cancer.
Lymphatic Metastasis
SMYD3 overexpression was a risk factor in the biological behavior and prognosis of gastric carcinoma.
Lymphatic Metastasis
SMYD3 promoter hypomethylation is associated with the risk of colorectal cancer.
Lymphatic Metastasis
SMYD3 stimulates EZR and LOXL2 transcription to enhance proliferation, migration and invasion in esophageal squamous cell carcinoma.
Lymphatic Metastasis
The role of DOT1L in the proliferation and prognosis of gastric cancer.
Lymphohistiocytosis, Hemophagocytic
Primary splenic histiocytic sarcoma associated with hemophagocytic lymphohistiocytosis: A case report and review of literature of next-generation sequencing involving FLT3, NOTCH2, and KMT2A mutations.
Lymphoma
A Patient with Kabuki Syndrome Mutation Presenting with Very Severe Aplastic Anemia.
Lymphoma
Adult High Grade B-cell Lymphoma with Burkitt Lymphoma Signature: Genomic features and Potential Therapeutic Targets.
Lymphoma
Collaboration of MYC and RUNX2 in lymphoma simulates T-cell receptor signaling and attenuates p53 pathway activity.
Lymphoma
Conserved crosstalk between histone deacetylation and H3K79 methylation generates DOT1L-dose dependency in HDAC1-deficient thymic lymphoma.
Lymphoma
Detection of Rare Germline Variants in the Genomes of Patients with B-Cell Neoplasms.
Lymphoma
Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis.
Lymphoma
EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation.
Lymphoma
KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas.
Lymphoma
KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation.
Lymphoma
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study.
Lymphoma
Low concentrations of permethrin and malathion induce numerical and structural abnormalities in KMT2A and IGH genes in vitro.
Lymphoma
Matrix Metalloproteinase-9 gene induction by a truncated oncogenic NF-kappaB2 protein involves the recruitment of MLL1 and MLL2 H3K4 histone methyltransferase complexes.
Lymphoma
Mutational landscape of T-cell lymphoma in mice lacking the DNA mismatch repair gene Mlh1: no synergism with ionizing radiation.
Lymphoma
Plasma circulating tumor DNA assessment reveals KMT2D as a potential poor prognostic factor in extranodal NK/T-cell lymphoma.
Lymphoma
Recurrent mutations in NF-?B pathway components, KMT2D, and NOTCH1/2 in ocular adnexal MALT-type marginal zone lymphomas.
Lymphoma
Smc3 dosage regulates B cell transit through germinal centers and restricts their malignant transformation.
Lymphoma
The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development.
Lymphoma, B-Cell
Detection of new drivers of frequent B-cell lymphoid neoplasms using an integrated analysis of whole genomes.
Lymphoma, B-Cell
Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis.
Lymphoma, B-Cell
EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation.
Lymphoma, B-Cell
FBXW7 Triggers Degradation of KMT2D to Favor Growth of Diffuse Large B-cell Lymphoma Cells.
Lymphoma, B-Cell
KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas.
Lymphoma, B-Cell
Targeted next generation sequencing reveals high mutation frequency of CREBBP, BCL2 and KMT2D in high-grade B-cell lymphoma with MYC and BCL2 and /or BCL6 rearrangements.
Lymphoma, B-Cell
The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development.
Lymphoma, B-Cell
The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma.
Lymphoma, Follicular
Detection of new drivers of frequent B-cell lymphoid neoplasms using an integrated analysis of whole genomes.
Lymphoma, Follicular
Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis.
Lymphoma, Follicular
EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation.
Lymphoma, Follicular
The HDAC6-selective inhibitor is effective against non-Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma.
Lymphoma, Follicular
The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development.
Lymphoma, Large B-Cell, Diffuse
Detection of new drivers of frequent B-cell lymphoid neoplasms using an integrated analysis of whole genomes.
Lymphoma, Large B-Cell, Diffuse
Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis.
Lymphoma, Large B-Cell, Diffuse
EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation.
Lymphoma, Large B-Cell, Diffuse
FBXW7 Triggers Degradation of KMT2D to Favor Growth of Diffuse Large B-cell Lymphoma Cells.
Lymphoma, Large B-Cell, Diffuse
KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas.
Lymphoma, Large B-Cell, Diffuse
The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development.
Lymphoma, Mantle-Cell
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study.
Lymphoma, Non-Hodgkin
A virome-wide clonal integration analysis platform for discovering cancer viral etiology.
Lymphoma, Non-Hodgkin
The HDAC6-selective inhibitor is effective against non-Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma.
Lymphoma, T-Cell
A Survey of Somatic Mutations in 41 Genes in a Cohort of T-Cell Lymphomas Identifies Frequent Mutations in Genes Involved in Epigenetic Modification.
Lymphopenia
The H3K4 methyltransferase Setd1b is essential for hematopoietic stem and progenitor cell homeostasis in mice.
Lymphoproliferative Disorders
Autoimmune Cytopenias in Chronic Lymphocytic Leukemia: Focus on Molecular Aspects.
Lymphoproliferative Disorders
Chronic Active Epstein-Barr Virus Infection of T/NK-Cell Type Mimicking Classic Hodgkin Lymphoma: Clinicopathologic and Genetic Features of 8 Cases Supporting a Variant With "Hodgkin/Reed-Sternberg-like" Cells of NK Phenotype.
Lymphoproliferative Disorders
Somatic mutations in KMT2D and TET2 associated with worse prognosis in Epstein-Barr virus-associated T or natural killer-cell lymphoproliferative disorders.
Macular Degeneration
Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research.
Massive Hepatic Necrosis
Inhibition of Dot1L Alleviates Fulminant Hepatitis Through Myeloid-Derived Suppressor Cells.
Medulloblastoma
KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation.
Medulloblastoma
MLL4 Is Required to Maintain Broad H3K4me3 Peaks and Super-Enhancers at Tumor Suppressor Genes.
Melanoma
A novel germline variant in the DOT1L gene co-segregating in a Dutch family with a history of melanoma.
Melanoma
Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma.
Melanoma
Targeting the Histone Methyltransferase Disruptor of Telomeric Silencing 1-Like Restricts Avian Leukosis Virus Subgroup J Replication by Restoring the Innate Immune Response in Chicken Macrophages.
Memory Disorders
Vorinostat, a histone deacetylase inhibitor, ameliorates the sociability and cognitive memory in an Ash1L-deletion-induced ASD/ID mouse model.
Mental Retardation, X-Linked
Identification of a RAI1-associated disease network through integration of exome sequencing, transcriptomics, and 3D genomics.
Mental Retardation, X-Linked
X-Linked Mental Retardation Gene CUL4B Targets Ubiquitylation of H3K4 Methyltransferase Component WDR5 and Regulates Neuronal Gene Expression.
Mesothelioma, Malignant
Analysis of mutations of PARP1, RNF213, PAX8, KMT2C, MTRR in malignant mesothelioma of testicular tunica vaginalis testis.
Microcephaly
Characterization of SETD1A haploinsufficiency in humans and Drosophila defines a novel neurodevelopmental syndrome.
Microcephaly
Identification of a RAI1-associated disease network through integration of exome sequencing, transcriptomics, and 3D genomics.
Microcephaly
Inhibition of Notch signaling rescues cardiovascular development in Kabuki Syndrome.
Microcephaly
Quantitative phenotypic and network analysis of 1q44 microdeletion for microcephaly.
Micrognathism
Small molecule inhibition of RAS/MAPK signaling ameliorates developmental pathologies of Kabuki Syndrome.
Migraine Disorders
A novel intranasal breath-powered delivery system for sumatriptan: a review of technology and clinical application of the investigational product AVP-825 in the treatment of migraine.
Migraine Disorders
AVP-825 breath-powered intranasal delivery system containing 22?mg sumatriptan powder vs 100?mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a comparative randomized clinical trial across multiple attacks.
Migraine Disorders
Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered(®) Exhalation Delivery System (Sumatriptan Nasal Powder) vs Oral Sumatriptan.
Migraine Disorders
Evaluating Mean Level and Within-Person Consistency in Migraine Pain Intensity and Migraine-Related Disability for AVP-825 vs Oral Sumatriptan: Results from the COMPASS Study, A Randomized Trial.
Migraine Disorders
Faster Improvement in Migraine Pain Intensity and Migraine-Related Disability at Early Time Points with AVP-825 (Sumatriptan Nasal Powder Delivery System) versus Oral Sumatriptan: A Comparative Randomized Clinical Trial Across Multiple Attacks from the COMPASS Study.
Monoclonal Gammopathy of Undetermined Significance
DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signaling.
Multiple Myeloma
DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signaling.
Multiple Myeloma
DOT1L inhibition is lethal for multiple myeloma due to perturbation of the endoplasmic reticulum stress pathway.
Multiple Myeloma
Downregulation of MMSET impairs breast cancer proliferation and metastasis through inhibiting Wnt/?-catenin signaling.
Multiple Myeloma
MMSET is highly expressed and associated with aggressiveness in neuroblastoma.
Multiple Myeloma
NSD2 Is Recruited through Its PHD Domain to Oncogenic Gene Loci to Drive Multiple Myeloma.
Multiple Myeloma
NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming.
Multiple Myeloma
NSD2 promotes osteosarcoma cell proliferation and metastasis by inhibiting E-cadherin expression.
Multiple Myeloma
Overexpression of MMSET is Correlation with Poor Prognosis in Hepatocellular Carcinoma.
Multiple Myeloma
The histone methyltransferase and putative oncoprotein MMSET is overexpressed in a large variety of human tumors.
Multiple Sclerosis
Telemedicine for multiple sclerosis patients: assessment using Health Value Compass.
Muscle Hypotonia
Genetic and behavioral characterization of a Kmt2d mouse mutant, a new model for Kabuki Syndrome.
Muscle Hypotonia
Novel KDM6A (UTX) mutations and a clinical and molecular review of the X-linked Kabuki syndrome (KS2).
Muscular Atrophy
The methyltransferase SMYD3 mediates the recruitment of transcriptional cofactors at the myostatin and c-Met genes and regulates skeletal muscle atrophy.
Muscular Diseases
Mouse myofibers lacking the SMYD1 methyltransferase are susceptible to atrophy, internalization of nuclei and myofibrillar disarray.
Muscular Dystrophies
The Trithorax protein Ash1L promotes myoblast fusion by activating Cdon expression.
Muscular Dystrophy, Duchenne
The Trithorax protein Ash1L promotes myoblast fusion by activating Cdon expression.
Myelodysplastic Syndromes
Homogeneously staining region (hsr) on chromosome 11 is highly specific for KMT2A amplification in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Myelodysplastic Syndromes
Kmt2c mutations enhance HSC self-renewal capacity and convey a selective advantage after chemotherapy.
Myelodysplastic Syndromes
Severe granulocytic dysplasia with vacuolar rosettes in a myelodysplastic syndrome with low-copy KMT2A gain.
Myelodysplastic Syndromes
The role of autophagy in targeted therapy for acute myeloid leukemia.
Myocardial Infarction
Efficacy and Safety of Long-Term Antithrombotic Strategies in Patients With Chronic Coronary Syndrome: A Network Meta-analysis of Randomized Controlled Trials.
Myocardial Infarction
External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry.
Myocardial Infarction
External applicability of the COMPASS trial: the Western Denmark Heart Registry.
Myocardial Infarction
Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease.
Myocardial Infarction
Lysine methyltransferase Smyd2 suppresses p53-dependent cardiomyocyte apoptosis.
Myocardial Infarction
Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines.
Myocardial Infarction
Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS Equivalence Trial. Comparison Trial of Saruplase and Streptokinase (COMASS) Investigators.
Myocardial Infarction
Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy.
Myocardial Infarction
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Myocardial Infarction
Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASS-CABG Study.
Myocardial Infarction
The COMPASS trial: practical considerations for application after coronary artery bypass surgery.
Myocardial Infarction
The ST Compass: spatial visualization of ST-segment deviations and estimation of the ST injury vector.
Myocardial Infarction
Usefulness of Coronary Artery Calcium to Identify Adults of Sufficiently High Risk for Atherothrombotic Cardiovascular Events to Consider Low-Dose Rivaroxaban Thromboprophylaxis (from MESA).
Myocardial Infarction
[Combined Antithrombotic Therapy in Patients with a Stable Atherosclerotic Cardiovascular Diseases: What Direction did COMPASS Show?]
Myocardial Infarction
[Current opportunities for secondary prevention of atherothrombotic stroke].
Myocardial Ischemia
The ST Compass: spatial visualization of ST-segment deviations and estimation of the ST injury vector.
Myocardial Ischemia
[The Efficacy of Rivaroxaban in Reducing the Risk of Cardiovascular Events in Patients with Stable Ischemic Heart Disease and Peripheral Disease. Results of the COMPASS Trial].
Myopia
Comparison of the structure-function relationship between compass microperimetry and Humphrey field analyser in myopic open-angle glaucoma eyes.
Nasal Polyps
Autonomic dysfunction as an independent risk factor for uncontrolled inflammation in chronic rhinosinusitis following functional endoscopic sinus surgery.
Nasopharyngeal Carcinoma
Comprehensive high-throughput RNA sequencing analysis reveals contamination of multiple nasopharyngeal carcinoma cell lines with HeLa cell genomes.
Neoplasm Metastasis
A Novel lncRNA IHS Promotes Tumor Proliferation and Metastasis in HCC by Regulating the ERK- and AKT/GSK-3?-Signaling Pathways.
Neoplasm Metastasis
A novel nuclear Src and p300 signaling axis controls migratory and invasive behavior in pancreatic cancer.
Neoplasm Metastasis
Aberrant expression of SETD1A promotes survival and migration of estrogen receptor ?-positive breast cancer cells.
Neoplasm Metastasis
Amplification of SMYD3 promotes tumorigenicity and intrahepatic metastasis of hepatocellular carcinoma via upregulation of CDK2 and MMP2.
Neoplasm Metastasis
ANKHD1 is required for SMYD3 to promote tumor metastasis in hepatocellular carcinoma.
Neoplasm Metastasis
CBP mediated DOT1L acetylation confers DOT1L stability and promotes cancer metastasis.
Neoplasm Metastasis
DOT1L cooperates with the c-Myc-p300 complex to epigenetically derepress CDH1 transcription factors in breast cancer progression.
Neoplasm Metastasis
Elevated Levels of SET and MYND Domain-Containing Protein 3 Are Correlated with Overexpression of Transforming Growth Factor-?1 in Gastric Cancer.
Neoplasm Metastasis
Epigenetic Role of Histone Lysine Methyltransferase and Demethylase on the Expression of Transcription Factors Associated with the Epithelial-to-Mesenchymal Transition of Lung Adenocarcinoma Metastasis to the Brain.
Neoplasm Metastasis
Epigenetic-related gene expression profile in medullary thyroid cancer revealed the overexpression of the histone methyltransferases EZH2 and SMYD3 in aggressive tumours.
Neoplasm Metastasis
Hesperetin promotes DOT1L degradation and reduces histone H3K79 methylation to inhibit gastric cancer metastasis.
Neoplasm Metastasis
High expression of SMYD3 indicates poor survival outcome and promotes tumour progression through an IGF-1R/AKT/E2F-1 positive feedback loop in bladder cancer.
Neoplasm Metastasis
Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4.
Neoplasm Metastasis
Histone Methyltransferase SETD1A Induces Epithelial-Mesenchymal Transition to Promote Invasion and Metastasis Through Epigenetic Reprogramming of Snail in Gastric Cancer.
Neoplasm Metastasis
Histone methyltransferase SMYD3 promotes MRTF-A-mediated transactivation of MYL9 and migration of MCF-7 breast cancer cells.
Neoplasm Metastasis
Inhibition of DOT1L by Half-Selenopsammaplin A Analogs Suppresses Tumor Growth and EMT-Mediated Metastasis in Triple-Negative Breast Cancer.
Neoplasm Metastasis
KMT2A histone methyltransferase contributes to colorectal cancer development by promoting cathepsin Z transcriptional activation.
Neoplasm Metastasis
KMT2D inhibits the growth and metastasis of bladder Cancer cells by maintaining the tumor suppressor genes.
Neoplasm Metastasis
Loss of KMT2D induces prostate cancer ROS-mediated DNA damage by suppressing the enhancer activity and DNA binding of antioxidant transcription factor FOXO3.
Neoplasm Metastasis
Network analyses elucidate the role of SMYD3 in esophageal squamous cell carcinoma.
Neoplasm Metastasis
Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer.
Neoplasm Metastasis
Overexpression of SET and MYND Domain-Containing Protein 2 (SMYD2) Is Associated with Tumor Progression and Poor Prognosis in Patients with Papillary Thyroid Carcinoma.
Neoplasm Metastasis
Overexpression of SMYD3 and matrix metalloproteinase-9 are associated with poor prognosis of patients with gastric cancer.
Neoplasm Metastasis
Overexpression of SMYD3 Is Predictive of Unfavorable Prognosis in Hepatocellular Carcinoma.
Neoplasm Metastasis
Overexpression of SMYD3 was associated with increased STAT3 activation in gastric cancer.
Neoplasm Metastasis
Overexpression of the SMYD3 Promotes Proliferation, Migration, and Invasion of Pancreatic Cancer.
Neoplasm Metastasis
Role of RbBP5 and H3K4me3 in the vicinity of Snail transcription start site during epithelial- mesenchymal- transition in prostate cancer cell.
Neoplasm Metastasis
SMYD2 facilitates cancer cell malignancy and xenograft tumor development through ERBB2-mediated FUT4 expression in colon cancer.
Neoplasm Metastasis
SMYD2 promotes tumorigenesis and metastasis of lung adenocarcinoma through RPS7.
Neoplasm Metastasis
SMYD2 suppresses APC2 expression to activate the Wnt/?-catenin pathway and promotes epithelial-mesenchymal transition in colorectal cancer.
Neoplasm Metastasis
SMYD3 overexpression was a risk factor in the biological behavior and prognosis of gastric carcinoma.
Neoplasm Metastasis
SMYD3 promoter hypomethylation is associated with the risk of colorectal cancer.
Neoplasm Metastasis
SMYD3 promotes colon adenocarcinoma (COAD) progression by mediating cell proliferation and apoptosis.
Neoplasm Metastasis
SMYD3 promotes epithelial ovarian cancer metastasis by down-regulating p53 protein stability and promoting p53 ubiquitination.
Neoplasm Metastasis
SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters.
Neoplasm Metastasis
SMYD3 stimulates EZR and LOXL2 transcription to enhance proliferation, migration and invasion in esophageal squamous cell carcinoma.
Neoplasm Metastasis
SMYD3 tandem repeats polymorphism is not associated with the occurrence and metastasis of hepatocellular carcinoma in a Chinese population.
Neoplasm Metastasis
Synthesis and biological activity of selenopsammaplin A and its analogues as antitumor agents with DOT1L inhibitory activity.
Neoplasm Metastasis
Synthesis and biological evaluation of benzomorpholine derivatives as novel EZH2 inhibitors for anti-non-small cell lung cancer activity.
Neoplasm Metastasis
Targeting Histone Methyltransferase DOT1L by a Novel Psammaplin A Analog Inhibits Growth and Metastasis of Triple-Negative Breast Cancer.
Neoplasm Metastasis
The role of DOT1L in the proliferation and prognosis of gastric cancer.
Neoplasm Metastasis
Whole-exome sequencing reveals critical genes underlying metastasis in oesophageal squamous cell carcinoma.
Neoplasms
A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer.
Neoplasms
A Case of Acute Myeloid Leukemia with Novel Translocation t(6;11)(p22.2;q23) and Concurrent Insertion ins(11;9)(q23;p21.3p21.3).
Neoplasms
A comparative analysis of KMT2D missense variants in Kabuki syndrome, cancers and the general population.
Neoplasms
A compass for the cancer journey: scientific, spiritual, and practical directives.
Neoplasms
A cytoplasmic COMPASS is necessary for cell survival and triple-negative breast cancer pathogenesis by regulating metabolism.
Neoplasms
A knowledge-based framework for the discovery of cancer-predisposing variants using large-scale sequencing breast cancer data.
Neoplasms
A Medicinal Chemistry Perspective for Targeting Histone H3 Lysine-79 Methyltransferase DOT1L.
Neoplasms
A Non-catalytic Function of SETD1A Regulates Cyclin K and the DNA Damage Response.
Neoplasms
A novel nuclear Src and p300 signaling axis controls migratory and invasive behavior in pancreatic cancer.
Neoplasms
A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries.
Neoplasms
A novel protein expression signature differentiates benign lipomas from well-differentiated liposarcomas.
Neoplasms
A novel somatic mutation in ACD induces telomere lengthening and apoptosis resistance in leukemia cells.
Neoplasms
A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies.
Neoplasms
A STUDY OF THE RELATIONSHIP BETWEEN LEVELS OF METHYLTRANSFERASES IN PERIPHERAL BLOOD MONONUCLEAR CELLS AND CHARACTERISTICS OF TUMOR IN PATIENTS WITH DUCTAL INVASIVE CARCINOMA OF BREAST.
Neoplasms
A tumor suppressive coactivator complex of p53 containing ASC-2 and histone H3-lysine-4 methyltransferase MLL3 or its paralogue MLL4.
Neoplasms
A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5' flanking region of SMYD3 is a risk factor for human cancers.
Neoplasms
A virome-wide clonal integration analysis platform for discovering cancer viral etiology.
Neoplasms
Aberrant Activity of Histone-Lysine N-Methyltransferase 2 (KMT2) Complexes in Oncogenesis.
Neoplasms
Aberrant expression of SETD1A promotes survival and migration of estrogen receptor ?-positive breast cancer cells.
Neoplasms
Absent, small or homeotic 2-like protein (ASH2L) enhances the transcription of the estrogen receptor ? gene through GATA-binding protein 3 (GATA3).
Neoplasms
Adult High Grade B-cell Lymphoma with Burkitt Lymphoma Signature: Genomic features and Potential Therapeutic Targets.
Neoplasms
Altered gene expression along the glycolysis-cholesterol synthesis axis is associated with outcome in pancreatic cancer.
Neoplasms
Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification.
Neoplasms
Amplification of SMYD3 promotes tumorigenicity and intrahepatic metastasis of hepatocellular carcinoma via upregulation of CDK2 and MMP2.
Neoplasms
An Achilles' Heel for MLL-Rearranged Leukemias: Writers and Readers of H3 Lysine 36 Dimethylation.
Neoplasms
An Evolutionarily Conserved Structural Platform for PRC2 Inhibition by a Class of Ezh2 Inhibitors.
Neoplasms
An examination of the co-occurrence of modifiable risk factors associated with chronic disease among youth in the COMPASS study.
Neoplasms
An Mll4/COMPASS-Lsd1 epigenetic axis governs enhancer function and pluripotency transition in embryonic stem cells.
Neoplasms
An organoid-based drug screening identified a menin-MLL inhibitor for endometrial cancer through regulating the HIF pathway.
Neoplasms
Analysis of head and neck carcinoma progression reveals novel and relevant stage-specific changes associated with immortalisation and malignancy.
Neoplasms
Analysis of SET and MYND Domain-Containing Protein 3 (SMYD3) Expression in Gallbladder Cancer: a Pilot Study.
Neoplasms
Analysis of the role of mutations in the KMT2D histone lysine methyltransferase in bladder cancer.
Neoplasms
Analysis of the Substrate Specificity of the SMYD2 Protein Lysine Methyltransferase and Discovery of Novel Non-Histone Substrates.
Neoplasms
ANKHD1 is required for SMYD3 to promote tumor metastasis in hepatocellular carcinoma.
Neoplasms
Artificial intelligence (AI) and cancer prevention: the potential application of AI in cancer control programming needs to be explored in population laboratories such as COMPASS.
Neoplasms
ASH2L drives proliferation and sensitivity to bleomycin and other genotoxins in Hodgkin's lymphoma and testicular cancer cells.
Neoplasms
ASH2L is involved in promotion of endometrial cancer progression via upregulation of PAX2 transcription.
Neoplasms
Association analysis of KMT2D copy number variation as a positional candidate for growth traits.
Neoplasms
Association between histone lysine methyltransferase KMT2C mutation and clinicopathological factors in breast cancer.
Neoplasms
Association of the variable number of tandem repeats polymorphism in the promoter region of the SMYD3 gene with risk of esophageal squamous cell carcinoma in relation to tobacco smoking.
Neoplasms
Authoring experience: the significance and performance of storytelling in Socratic dialogue with rehabilitating cancer patients.
Neoplasms
Automated radiation targeting in head-and-neck cancer using region-based texture analysis of PET and CT images.
Neoplasms
Automethylation of SUV39H2, an oncogenic histone lysine methyltransferase, regulates its binding affinity to substrate proteins.
Neoplasms
Bisphenol A and Phthalates Modulate Peritoneal Macrophage Function in Female Mice Involving SYMD2-H3K36 Dimethylation.
Neoplasms
Breast cancer in women with neurofibromatosis type 1 (NF1): a comprehensive case series with molecular insights into its aggressive phenotype.
Neoplasms
Burkitt lymphoma in a patient with Kabuki syndrome carrying a novel KMT2D mutation.
Neoplasms
C-terminal domain of SMYD3 serves as a unique HSP90-regulated motif in oncogenesis.
Neoplasms
C/EBP? enhances platinum resistance of ovarian cancer cells by reprogramming H3K79 methylation.
Neoplasms
Cancer Management in Kabuki Syndrome: The First Case of Wilms Tumor and a Literature Review.
Neoplasms
Cancer-epigenetic function of the histone methyltransferase KMT2D and therapeutic opportunities for the treatment of KMT2D-deficient tumors.
Neoplasms
Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors.
Neoplasms
CBP mediated DOT1L acetylation confers DOT1L stability and promotes cancer metastasis.
Neoplasms
Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer.
Neoplasms
Chromosomal abnormalities and molecular landscape of metastasizing mucinous salivary adenocarcinoma.
Neoplasms
Clinical implications of prospective genomic profiling of metastatic breast cancer patients.
Neoplasms
COMPASS Ascending: Emerging clues regarding the roles of MLL3/KMT2C and MLL2/KMT2D proteins in cancer.
Neoplasms
Comprehensive assessments of germline deletion structural variants reveal the association between prognostic MUC4 and CEP72 deletions and immune response gene expression in colorectal cancer patients.
Neoplasms
Comprehensive Cancer Panel Sequencing Defines Genetic Diversity and Changes in the Mutational Characteristics of Pancreatic Cancer Patients Receiving Neoadjuvant Treatment.
Neoplasms
Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib.
Neoplasms
Comprehensive genomic profiling of small cell lung cancer in Chinese patients and the implications for therapeutic potential.
Neoplasms
Comprehensive Molecular Characterization of Adamantinoma and OFD-like Adamantinoma Bone Tumors.
Neoplasms
Comprehensive pharmacogenomic profiling of human papillomavirus-positive and -negative squamous cell carcinoma identifies sensitivity to aurora kinase inhibition in KMT2D mutants.
Neoplasms
Conformational Adaptation Drives Potent, Selective and Durable Inhibition of the Human Protein Methyltransferase DOT1L.
Neoplasms
Conservation of epigenetic regulation by the MLL3/4 tumour suppressor in planarian pluripotent stem cells.
Neoplasms
Cooperation between SMYD3 and PC4 drives a distinct transcriptional program in cancer cells.
Neoplasms
Coordination of stress signals by the lysine methyltransferase SMYD2 promotes pancreatic cancer.
Neoplasms
Copy-number variation and protein expression of DOT1L in pancreatic adenocarcinoma as a potential drug target.
Neoplasms
Corrigendum to "The cancer COMPASS: Navigating the functions of MLL complexes in cancer" [Cancer Genetics 208 (2015) pp. 178-191].
Neoplasms
CRISPR-GEMM pooled mutagenic screening identifies KMT2D as a major modulator of immune checkpoint blockade.
Neoplasms
Critical roles of SMYD2-mediated ?-catenin methylation for nuclear translocation and activation of Wnt signaling.
Neoplasms
Cross-talk between CDK4/6 and SMYD2 regulates gene transcription, tubulin methylation, and ciliogenesis.
Neoplasms
Crystal structures of histone and p53 methyltransferase SmyD2 reveal a conformational flexibility of the autoinhibitory C-terminal domain.
Neoplasms
Cytogenomic characterization of double minute heterogeneity in therapy related acute myeloid leukemia.
Neoplasms
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.
Neoplasms
Deep Targeted Sequencing and Its Potential Implication for Cancer Therapy in Chinese Patients with Gastric Adenocarcinoma.
Neoplasms
Deficiency of H3K79 Histone Methyltransferase Dot1-like Protein (DOT1L) Inhibits Cell Proliferation.
Neoplasms
Depletion of H3K79 methyltransferase Dot1L promotes cell invasion and cancer stem-like cell property in ovarian cancer.
Neoplasms
Deregulated expression of selected histone methylases and demethylases in prostate carcinoma.
Neoplasms
Design, Synthesis, and Biological Activity of Substrate Competitive SMYD2 Inhibitors.
Neoplasms
Detection of circulating sarcoma tumor cells using a microfluidic chip-type cell sorter.
Neoplasms
Detection of gene rearrangements in targeted clinical next-generation sequencing.
Neoplasms
Developing the structure of Japan's cancer survivorship guidelines using an expert panel and modified Delphi method.
Neoplasms
Development of an eHealth System to Capture and Analyze Patient Sensor and Self-Report Data: Mixed-Methods Assessment of Potential Applications to Improve Cancer Care Delivery.
Neoplasms
Discovery and Characterization of a Highly Potent and Selective Aminopyrazoline-Based in Vivo Probe (BAY-598) for the Protein Lysine Methyltransferase SMYD2.
Neoplasms
Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation Approach.
Neoplasms
Discovery of the SMYD3 Inhibitor BAY-6035 Using Thermal Shift Assay (TSA)-Based High-Throughput Screening.
Neoplasms
Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis.
Neoplasms
Disruptor of telomeric silencing 1-like promotes ovarian cancer tumor growth by stimulating pro-tumorigenic metabolic pathways and blocking apoptosis.
Neoplasms
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas.
Neoplasms
Domain swapping and SMYD1 interactions with the PWWP domain of human hepatoma-derived growth factor.
Neoplasms
DOT1L cooperates with the c-Myc-p300 complex to epigenetically derepress CDH1 transcription factors in breast cancer progression.
Neoplasms
Dot1l expression predicts adverse postoperative prognosis of patients with clear-cell renal cell carcinoma.
Neoplasms
DOT1L-controlled cell-fate determination and transcription elongation are independent of H3K79 methylation.
Neoplasms
DOTting the path to doom: how acceleration of histone methylation leads to leukemia.
Neoplasms
Downregulation of MMSET impairs breast cancer proliferation and metastasis through inhibiting Wnt/?-catenin signaling.
Neoplasms
DPY30 functions in glucose homeostasis via integrating activated histone epigenetic modifications.
Neoplasms
DPY30 is required for the enhanced proliferation, motility and epithelial-mesenchymal transition of epithelial ovarian cancer cells.
Neoplasms
Drosophila SETs its Sights on Cancer: Trr/MLL3/4 COMPASS-like complexes in Development and Disease.
Neoplasms
Editor's Choice - External Applicability of the COMPASS and VOYAGER-PAD Trials on Patients with Symptomatic Lower Extremity Artery Disease in France: The COPART Registry.
Neoplasms
Effect of the downregulation of SMYD3 expression by RNAi on RIZ1 expression and proliferation of esophageal squamous cell carcinoma.
Neoplasms
Effects of SMYD3 overexpression on transformation, serum dependence, and apoptosis sensitivity in NIH3T3 cells.
Neoplasms
Elevated Levels of SET and MYND Domain-Containing Protein 3 Are Correlated with Overexpression of Transforming Growth Factor-?1 in Gastric Cancer.
Neoplasms
Enhanced methyltransferase activity of SMYD3 by the cleavage of its N-terminal region in human cancer cells.
Neoplasms
Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma.
Neoplasms
Epigenetic-related gene expression profile in medullary thyroid cancer revealed the overexpression of the histone methyltransferases EZH2 and SMYD3 in aggressive tumours.
Neoplasms
Euchromatic histone lysine methyltransferase 1 regulates cancer development in human gastric cancer by regulating E-cadherin.
Neoplasms
Exploration of the Substrate Preference of Lysine Methyltransferase SMYD3 by Molecular Dynamics Simulations.
Neoplasms
Exploring drug delivery for the DOT1L inhibitor pinometostat (EPZ-5676): Subcutaneous administration as an alternative to continuous IV infusion, in the pursuit of an epigenetic target.
Neoplasms
Expression and clinical significance of COMPASS family of histone methyltransferases in clear cell renal cell carcinoma.
Neoplasms
Expression of histone methyltransferases as novel biomarkers for renal cell tumor diagnosis and prognostication.
Neoplasms
Expression patterns and the prognostic value of the SMYD family members in human breast carcinoma using integrative bioinformatics analysis.
Neoplasms
FBXW7 Triggers Degradation of KMT2D to Favor Growth of Diffuse Large B-cell Lymphoma Cells.
Neoplasms
Financial difficulties are associated with greater total pain and suffering among patients with advanced cancer: results from the COMPASS study.
Neoplasms
Frameshift mutation of a histone methylation-related gene SETD1B and its regional heterogeneity in gastric and colorectal cancers with high microsatellite instability.
Neoplasms
Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
Neoplasms
GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer.
Neoplasms
Genetic and epigenetic changes in fibrosis-associated hepatocarcinogenesis in mice.
Neoplasms
Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors.
Neoplasms
Genome-scale CRISPR-Cas9 screen of Wnt/?-catenin signaling identifies therapeutic targets for colorectal cancer.
Neoplasms
Genomic analyses of high-grade neuroendocrine gynecological malignancies reveal a unique mutational landscape and therapeutic vulnerabilities.
Neoplasms
Genomic Analyses of Metaplastic or Sarcomatoid Carcinomas From Different Organs Revealed Frequent Mutations in KMT2D.
Neoplasms
Genomic profile of breast sarcomas: a comparison with malignant phyllodes tumours.
Neoplasms
Genomic Profiling Identified ERCC2 E606Q Mutation in Helicase Domain Respond to Platinum-Based Neoadjuvant Therapy in Urothelial Bladder Cancer.
Neoplasms
High expression of SMYD3 indicates poor survival outcome and promotes tumour progression through an IGF-1R/AKT/E2F-1 positive feedback loop in bladder cancer.
Neoplasms
High?level SETD1B gene expression is associated with unfavorable prognosis in hepatocellular carcinoma.
Neoplasms
Hijacking a key chromatin modulator creates epigenetic vulnerability for MYC-driven cancer.
Neoplasms
Histone 3 lysine-27 demethylase KDM6A coordinates with KMT2B to play an oncogenic role in NSCLC by regulating H3K4me3.
Neoplasms
Histone lysine methyltransferase SET8 is a novel therapeutic target for cancer treatment.
Neoplasms
Histone lysine methyltransferase SETD8 promotes carcinogenesis by deregulating PCNA expression.
Neoplasms
Histone methyltransferase ash1l suppresses interleukin-6 production and inflammatory autoimmune diseases by inducing the ubiquitin-editing enzyme a20.
Neoplasms
Histone methyltransferase hSETD1A is a Novel Regulator of Metastasis in Breast Cancer.
Neoplasms
Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4.
Neoplasms
Histone Methyltransferase SETD1A Induces Epithelial-Mesenchymal Transition to Promote Invasion and Metastasis Through Epigenetic Reprogramming of Snail in Gastric Cancer.
Neoplasms
Histone methyltransferase SETD1A interacts with HIF1? to enhance glycolysis and promote cancer progression in gastric cancer.
Neoplasms
Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas.
Neoplasms
Histone methyltransferase SMYD3 regulates the expression of transcriptional factors during bovine oocyte maturation and early embryonic development.
Neoplasms
Hit identification of SMYD3 enzyme inhibitors using structure-based pharmacophore modeling.
Neoplasms
HSF2 regulates aerobic glycolysis by suppression of FBP1 in hepatocellular carcinoma.
Neoplasms
Identification of an epigenetic prognostic signature for patients with lower-grade gliomas.
Neoplasms
Identification of hub genes and key pathways associated with the progression of gynecological cancer.
Neoplasms
Identification of novel EED-EZH2 PPI inhibitors using an in silico fragment mapping method.
Neoplasms
IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L.
Neoplasms
Impaired recruitment of the histone methyltransferase DOT1L contributes to the incomplete reactivation of tumor suppressor genes upon DNA demethylation.
Neoplasms
In Silico/In Vitro Hit-to-Lead Methodology Yields SMYD3 Inhibitor That Eliminates Unrestrained Proliferation of Breast Carcinoma Cells.
Neoplasms
In Situ Proteome Profiling and Bioimaging Applications of Small-Molecule Affinity-Based Probes Derived From DOT1L Inhibitors.
Neoplasms
Inhibition of DOT1L by Half-Selenopsammaplin A Analogs Suppresses Tumor Growth and EMT-Mediated Metastasis in Triple-Negative Breast Cancer.
Neoplasms
Inhibition of Euchromatic Histone Lysine Methyltransferase 2 (EHMT2) Suppresses the Proliferation and Invasion of Cervical Cancer Cells.
Neoplasms
Inhibition of histone methyltransferase DOT1L silences ER? gene and blocks proliferation of antiestrogen-resistant breast cancer cells.
Neoplasms
Inhibition of Methyltransferase DOT1L Sensitizes to Sorafenib Treatment AML Cells Irrespective of MLL-Rearrangements: A Novel Therapeutic Strategy for Pediatric AML.
Neoplasms
Inhibition of SMYD2 Sensitized Cisplatin to Resistant Cells in NSCLC Through Activating p53 Pathway.
Neoplasms
Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma.
Neoplasms
Inhibition of the Histone Lysine Methyltransferase EZH2 for the Treatment of Cancer.
Neoplasms
Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Neoplasms
Integrative analysis of genomic alterations in triple-negative breast cancer in association with homologous recombination deficiency.
Neoplasms
Interaction of BARD1 and HP1 is required for BRCA1 retention at sites of DNA damage.
Neoplasms
Involvement of Chromatin Remodeling Genes and the Rho GTPases RhoB and CDC42 in Ovarian Clear Cell Carcinoma.
Neoplasms
In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer.
Neoplasms
KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas.
Neoplasms
Kmt2a cooperates with menin to suppress tumorigenesis in mouse pancreatic islets.
Neoplasms
KMT2A histone methyltransferase contributes to colorectal cancer development by promoting cathepsin Z transcriptional activation.
Neoplasms
KMT2C is a potential biomarker of prognosis and chemotherapy sensitivity in breast cancer.
Neoplasms
KMT2C mediates the estrogen dependence of breast cancer through regulation of ER? enhancer function.
Neoplasms
Kmt2c mutations enhance HSC self-renewal capacity and convey a selective advantage after chemotherapy.
Neoplasms
KMT2C Mutations in Diffuse-Type Gastric Adenocarcinoma Promote Epithelial-to-Mesenchymal Transition.
Neoplasms
KMT2C promoter methylation in plasma-circulating tumor DNA is a prognostic biomarker in non-small cell lung cancer.
Neoplasms
KMT2D deficiency enhances the anti-cancer activity of L48H37 in pancreatic ductal adenocarcinoma.
Neoplasms
KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer.
Neoplasms
KMT2D inhibits the growth and metastasis of bladder Cancer cells by maintaining the tumor suppressor genes.
Neoplasms
KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation.
Neoplasms
KMT2D promotes proliferation of gastric cancer cells: evidence from ctDNA sequencing.
Neoplasms
KMT2D/MLL2 inactivation is associated with recurrence in adult-type granulosa cell tumors of the ovary.
Neoplasms
Knockdown of SMYD3 by RNA interference down-regulates c-Met expression and inhibits cells migration and invasion induced by HGF.
Neoplasms
Knockdown of SMYD3 by RNA interference inhibits cervical carcinoma cell growth and invasion in vitro.
Neoplasms
LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2.
Neoplasms
Look at the compass needle and see your course - navigation as a cancer survivor.
Neoplasms
Loss of KMT2D induces prostate cancer ROS-mediated DNA damage by suppressing the enhancer activity and DNA binding of antioxidant transcription factor FOXO3.
Neoplasms
Lysine methylation in cancer: SMYD3-MAP3K2 teaches us new lessons in the Ras-ERK pathway.
Neoplasms
Lysine methyltransferase 2D regulates pancreatic carcinogenesis through metabolic reprogramming.
Neoplasms
Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression.
Neoplasms
Lysine methyltransferase Smyd2 regulates Hsp90-mediated protection of the sarcomeric titin springs and cardiac function.
Neoplasms
m6A modification-mediated CBX8 induction regulates stemness and chemosensitivity of colon cancer via upregulation of LGR5.
Neoplasms
Mcm2 deficiency results in short deletions allowing high resolution identification of genes contributing to lymphoblastic lymphoma.
Neoplasms
Mechanism of the Conformational Change of the Protein Methyltransferase SMYD3: A Molecular Dynamics Simulation Study.
Neoplasms
Merkel Cell Polyomavirus in Merkel Cell Carcinoma: Integration Sites and Involvement of the KMT2D Tumor Suppressor Gene.
Neoplasms
Meta-analysis of clinical data using human meiotic genes identifies a novel cohort of highly restricted cancer-specific marker genes.
Neoplasms
MiRNA-217 accelerates the proliferation and migration of bladder cancer via inhibiting KMT2D.
Neoplasms
MLL3/MLL4/COMPASS Family on Epigenetic Regulation of Enhancer Function and Cancer.
Neoplasms
Molecular analysis of encapsulated papillary carcinoma of the breast with and without invasion.
Neoplasms
Molecular characterization of an MLL1 fusion and its role in chromosomal instability.
Neoplasms
Molecular differences between screen-detected and interval breast cancers are largely explained by PAM50 subtypes.
Neoplasms
Multiregional sequence revealed SMARCA4 R1192C mutant clones acquired EGFR C797S mutation in the metastatic site of an EGFR-mutated NSCLC patient.
Neoplasms
Mutational analysis of uterine cervical cancer that survived multiple rounds of radiotherapy.
Neoplasms
Mutational burdens and evolutionary ages of thyroid follicular adenoma are comparable to those of follicular carcinoma.
Neoplasms
Mutational Characterization and Potential Prognostic Biomarkers of Chinese Patients with Esophageal Squamous Cell Carcinoma.
Neoplasms
Mutational Landscapes of Smoking-Related Cancers in Caucasians and African Americans: Precision Oncology Perspectives at Wake Forest Baptist Comprehensive Cancer Center.
Neoplasms
Mutational profile of papillary thyroid microcarcinoma with extensive lymph node metastasis.
Neoplasms
Network analyses elucidate the role of SMYD3 in esophageal squamous cell carcinoma.
Neoplasms
New open conformation of SMYD3 implicates conformational selection and allostery.
Neoplasms
Novel germline mutation KMT2A G3131S confers genetic susceptibility to familial myeloproliferative neoplasms.
Neoplasms
Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 Inhibitor.
Neoplasms
Novobiocin decreases SMYD3 expression and inhibits the migration of MDA-MB-231 human breast cancer cells.
Neoplasms
NSD2 promotes osteosarcoma cell proliferation and metastasis by inhibiting E-cadherin expression.
Neoplasms
Oncoproteomic and gene expression analyses identify prognostic biomarkers for second primary malignancy in patients with head and neck squamous cell carcinoma.
Neoplasms
Overexpression of SET and MYND Domain-Containing Protein 2 (SMYD2) Is Associated with Tumor Progression and Poor Prognosis in Patients with Papillary Thyroid Carcinoma.
Neoplasms
Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous-cell carcinoma.
Neoplasms
Overexpression of SMYD3 and matrix metalloproteinase-9 are associated with poor prognosis of patients with gastric cancer.
Neoplasms
Overexpression of SMYD3 in Ovarian Cancer is Associated with Ovarian Cancer Proliferation and Apoptosis via Methylating H3K4 and H4K20.
Neoplasms
Overexpression of SMYD3 Is Predictive of Unfavorable Prognosis in Hepatocellular Carcinoma.
Neoplasms
Overexpression of SMYD3 was associated with increased STAT3 activation in gastric cancer.
Neoplasms
Overview on Epigenetic Re-programming: A Potential Therapeutic Intervention in Triple Negative Breast Cancers
Neoplasms
Pan-sarcoma genomic analysis of KMT2A rearrangements reveals distinct subtypes defined by YAP1-KMT2A-YAP1 and VIM-KMT2A fusions.
Neoplasms
PAX3/7-FOXO1 fusion-negative alveolar rhabdomyosarcoma in Schuurs-Hoeijmakers syndrome.
Neoplasms
Plasma circulating tumor DNA assessment reveals KMT2D as a potential poor prognostic factor in extranodal NK/T-cell lymphoma.
Neoplasms
Playing on the Dark Side: SMYD3 Acts as a Cancer Genome Keeper in Gastrointestinal Malignancies.
Neoplasms
Primary splenic histiocytic sarcoma associated with hemophagocytic lymphohistiocytosis: A case report and review of literature of next-generation sequencing involving FLT3, NOTCH2, and KMT2A mutations.
Neoplasms
Profiles of genomic alterations in primary esophageal follicular dendritic cell sarcoma: A case report.
Neoplasms
Prognosis model of colorectal cancer patients based on NOTCH3, KMT2C, and CREBBP mutations.
Neoplasms
Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer.
Neoplasms
Prognostic significance of stromal SMYD3 expression in colorectal cancer of TNM stage I-III.
Neoplasms
Radical resection for cancer of the hypopharynx and cervical oesophagus with repair by stomach transposition.
Neoplasms
RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.
Neoplasms
RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation.
Neoplasms
Recruitment of KMT2C/MLL3 to DNA Damage Sites Mediates DNA Damage Responses and Regulates PARP Inhibitor Sensitivity in Cancer.
Neoplasms
Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas.
Neoplasms
Recurrent Fusions Between YAP1 and KMT2A in Morphologically Distinct Neoplasms Within the Spectrum of Low-grade Fibromyxoid Sarcoma and Sclerosing Epithelioid Fibrosarcoma.
Neoplasms
Recurrent mutations in NF-?B pathway components, KMT2D, and NOTCH1/2 in ocular adnexal MALT-type marginal zone lymphomas.
Neoplasms
Recurrent YAP1 and KMT2A Gene Rearrangements in a Subset of MUC4-negative Sclerosing Epithelioid Fibrosarcoma.
Neoplasms
Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis.
Neoplasms
Regulation of the DNA Damage Response and Gene Expression by the Dot1L Histone Methyltransferase and the 53Bp1 Tumour Suppressor.
Neoplasms
Requirement of histone methyltransferase SMYD3 for estrogen receptor-mediated transcription.
Neoplasms
Resetting the epigenetic balance of Polycomb and COMPASS function at enhancers for cancer therapy.
Neoplasms
Residual expression of SMYD2 and SMYD3 is associated with the acquisition of complex karyotype in chronic lymphocytic leukemia.
Neoplasms
Restoration of KMT2C/MLL3 in human colorectal cancer cells reinforces genome-wide H3K4me1 profiles and influences cell growth and gene expression.
Neoplasms
Reticuloendotheliosis virus strain T induces miR-155 which targets JARID2 and promotes cell survival.
Neoplasms
Retinoblastoma Binding Protein 5 Correlates with the Progression in Hepatocellular Carcinoma.
Neoplasms
RNA Sequencing of Hepatobiliary Cancer Cell Lines: Data and Applications to Mutational and Transcriptomic Profiling.
Neoplasms
SET and MYND domain-containing protein 3 decreases sensitivity to dexamethasone and stimulates cell adhesion and migration in NIH3T3 cells.
Neoplasms
SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma.
Neoplasms
SETD1A Promotes Proliferation of Castration-Resistant Prostate Cancer Cells via FOXM1 Transcription.
Neoplasms
SETD1A protects from senescence through regulation of the mitotic gene expression program.
Neoplasms
SETDB1 promotes gastric carcinogenesis and metastasis via upregulation of CCND1 and MMP9 expression.
Neoplasms
Silencing or inhibition of H3K79 methyltransferase DOT1L induces cell cycle arrest by epigenetically modulating c-Myc expression in colorectal cancer.
Neoplasms
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery.
Neoplasms
SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery.
Neoplasms
Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance).
Neoplasms
Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation.
Neoplasms
Smc3 dosage regulates B cell transit through germinal centers and restricts their malignant transformation.
Neoplasms
SMYD2 facilitates cancer cell malignancy and xenograft tumor development through ERBB2-mediated FUT4 expression in colon cancer.
Neoplasms
SMYD2 overexpression is associated with tumor cell proliferation and a worse outcome in human papillomavirus-unrelated nonmultiple head and neck carcinomas.
Neoplasms
SMYD2 suppresses APC2 expression to activate the Wnt/?-catenin pathway and promotes epithelial-mesenchymal transition in colorectal cancer.
Neoplasms
SMYD2-dependent HSP90 methylation promotes cancer cell proliferation by regulating the chaperone complex formation.
Neoplasms
SMYD3 controls a Wnt-responsive epigenetic switch for ASCL2 activation and cancer stem cell maintenance.
Neoplasms
SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells.
Neoplasms
Smyd3 Is a Transcriptional Potentiator of Multiple Cancer-Promoting Genes and Required for Liver and Colon Cancer Development.
Neoplasms
SMYD3 overexpression was a risk factor in the biological behavior and prognosis of gastric carcinoma.
Neoplasms
SMYD3 promotes cancer invasion by epigenetic upregulation of the metalloproteinase MMP-9.
Neoplasms
SMYD3 promotes colon adenocarcinoma (COAD) progression by mediating cell proliferation and apoptosis.
Neoplasms
SMYD3 Promotes Homologous Recombination via Regulation of H3K4-mediated Gene Expression.
Neoplasms
SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters.
Neoplasms
Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation.
Neoplasms
SMYD3 stimulates EZR and LOXL2 transcription to enhance proliferation, migration and invasion in esophageal squamous cell carcinoma.
Neoplasms
SMYD3-associated pathway is involved in the anti-tumor effects of sulforaphane on gastric carcinoma cells.
Neoplasms
SMYD3-mediated lysine methylation in the PH domain is critical for activation of AKT1.
Neoplasms
SMYD3: An Oncogenic Driver Targeting Epigenetic Regulation and Signaling Pathways.
Neoplasms
Somatic cancer mutations in the MLL1 histone methyltransferase modulate its enzymatic activity and dependence on the WDR5/RBBP5/ASH2L complex.
Neoplasms
Somatic mutations of DICER1 and KMT2D are frequent in intraocular medulloepitheliomas.
Neoplasms
Somatic Mutations of the Mixed-Lineage Leukemia 3 (MLL3) Gene in Primary Breast Cancers.
Neoplasms
Stable Form of JAB1 Enhances Proliferation and Maintenance of Hematopoietic Progenitors.
Neoplasms
Structural Basis for Substrate Preference of SMYD3, A SET Domain-containing Protein Lysine Methyltransferase.
Neoplasms
Structure of human SMYD2 protein reveals the basis of p53 tumor suppressor methylation.
Neoplasms
Structure-Based Design of a Novel SMYD3 Inhibitor that Bridges the SAM-and MEKK2-Binding Pockets.
Neoplasms
Structure-guided Discovery of a Potent and Selective Cell-active Inhibitor of SETDB1 Tudor Domain.
Neoplasms
Subsequent development of histiocytic sarcoma and follicular lymphoma: cytogenetics and next-generation sequencing analyses provide evidence for transdifferentiation of early common lymphoid precursor-a case report and review of literature.
Neoplasms
Synthesis and biological activity of selenopsammaplin A and its analogues as antitumor agents with DOT1L inhibitory activity.
Neoplasms
Synthesis and biological evaluation of benzomorpholine derivatives as novel EZH2 inhibitors for anti-non-small cell lung cancer activity.
Neoplasms
Synthesis and structure-activity relationship studies of LLY-507 analogues as SMYD2 inhibitors.
Neoplasms
Systems biology analysis of hepatitis C virus infection reveals the role of copy number increases in regions of chromosome 1q in hepatocellular carcinoma metabolism.
Neoplasms
Targeted genomic investigations in a population-based cohort of mantle cell lymphoma reveal novel clinically relevant targets.
Neoplasms
Targeted sequencing reveals the somatic mutation landscape in a Swedish breast cancer cohort.
Neoplasms
Targeting Histone Methyltransferase DOT1L by a Novel Psammaplin A Analog Inhibits Growth and Metastasis of Triple-Negative Breast Cancer.
Neoplasms
Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy.
Neoplasms
Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020).
Neoplasms
Targeting Smyd3 by next-generation antisense oligonucleotides suppresses liver tumor growth.
Neoplasms
Targeting SMYD3 to Sensitize Homologous Recombination-Proficient Tumors to PARP-Mediated Synthetic Lethality.
Neoplasms
Targeting the Atf7ip-Setdb1 complex augments antitumor immunity by boosting tumor immunogenicity.
Neoplasms
The 11q-Gain/Loss Aberration Occurs Recurrently in MYC-Negative Burkitt-like Lymphoma With 11q Aberration, as Well as MYC-Positive Burkitt Lymphoma and MYC-Positive High-Grade B-Cell Lymphoma, NOS.
Neoplasms
The Association of Modifiable Breast Cancer Risk Factors and Somatic Genomic Alterations in Breast Tumors: The Cancer Genome Atlas Network.
Neoplasms
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Neoplasms
The COMPASS study: A descriptive study on the characteristics of palliative care team consultation for cancer patients in hospitals.
Neoplasms
The epigenetic factor Kmt2a/Mll1 regulates neural progenitor proliferation and neuronal and glial differentiation.
Neoplasms
The evolution of bladder cancer genomics: What have we learned and how can we use it?
Neoplasms
The feasibility of a purpose-renewal intervention after treatment for early stage breast cancer: A brief report.
Neoplasms
The histone H3 methyltransferase G9A epigenetically activates the serine-glycine synthesis pathway to sustain cancer cell survival and proliferation.
Neoplasms
The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development.
Neoplasms
The Histone Methyltransferase DOT1L Is a Functional Component of Estrogen Receptor Alpha Signaling in Ovarian Cancer Cells.
Neoplasms
The histone methyltransferase DOT1L is required for proper DNA damage response, DNA repair, and modulates chemotherapy responsiveness.
Neoplasms
The histone methyltransferase DOT1L promotes neuroblastoma by regulating gene transcription.
Neoplasms
The histone methyltransferase DOT1L: regulatory functions and a cancer therapy target.
Neoplasms
The Histone Methyltransferase Smyd2 Is a Negative Regulator of Macrophage Activation by Suppressing Interleukin 6 (IL-6) and Tumor Necrosis Factor ? (TNF-?) Production.
Neoplasms
The Histone Methyltransferase SMYD2 Methylates PARP1 and Promotes Poly(ADP-ribosyl)ation Activity in Cancer Cells.
Neoplasms
The Lysine Methylase SMYD3 Modulates Mesendodermal Commitment during Development.
Neoplasms
The lysine-specific methyltransferase KMT2C/MLL3 regulates DNA repair components in cancer.
Neoplasms
The MLL3/4 H3K4 methyltransferase complex in establishing an active enhancer landscape.
Neoplasms
The MLL3/MLL4 branch of the COMPASS family is a major H3K4 monomethylase at enhancers.
Neoplasms
The mutational landscape of histiocytic sarcoma associated with lymphoid malignancy.
Neoplasms
The RS4;11 cell line as a model for leukaemia with t(4;11)(q21;q23): Revised characterisation of cytogenetic features.
Neoplasms
The SMYD family proteins in immunology: An update of their obvious and non-obvious relations with the immune system.
Neoplasms
The SMYD3 VNTR 3/3 polymorphism confers an increased risk and poor prognosis of hepatocellular carcinoma in a Chinese population.
Neoplasms
The telomerase reverse transcriptase (hTERT) gene is a direct target of the histone methyltransferase SMYD3.
Neoplasms
The Trithorax protein Ash1L promotes myoblast fusion by activating Cdon expression.
Neoplasms
Therapeutical potential of deregulated lysine methyltransferase SMYD3 as a safe target for novel anticancer agents.
Neoplasms
Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes.
Neoplasms
Transformation of advanced lung adenocarcinoma to acquired T790M resistance mutation adenosquamous carcinoma following tyrosine kinase inhibitor: a case report.
Neoplasms
Transposon mutagenesis identifies cooperating genetic drivers during keratinocyte transformation and cutaneous squamous cell carcinoma progression.
Neoplasms
Tubulocystic renal cell carcinoma: a distinct clinicopathologic entity with a characteristic genomic profile.
Neoplasms
Tumor slices as a model to evaluate doxorubicin in vitro treatment and expression of trios of genes PRSS11, MTSS1, CLPTM1 and PRSS11, MTSS1, SMYD2 in canine mammary gland cancer.
Neoplasms
Two Loops Undergoing Concerted Dynamics Regulate the Activity of the ASH1L Histone Methyltransferase.
Neoplasms
Two progressed malignant phyllodes tumors of the breast harbor alterations in genes frequently involved in other advanced cancers.
Neoplasms
Upregulated expression of G9a is correlated with poor prognosis of gastric cancer patients.
Neoplasms
Upregulated SMYD3 promotes bladder cancer progression by targeting BCLAF1 and activating autophagy.
Neoplasms
Upregulation of histone methyltransferase, DOT1L by matrix hyaluronan promotes MicroRNA-10 expression leading to tumor cell invasion and chemoresistance in cancer stem cells from head and neck squamous cell carcinoma.
Neoplasms
Upregulation of SMYD3 and SMYD3 VNTR 3/3 polymorphism increase the risk of hepatocellular carcinoma.
Neoplasms
UTX inhibits EMT-induced breast CSC properties by epigenetic repression of EMT genes in cooperation with LSD1 and HDAC1.
Neoplasms
Validation of biomarkers associated with 5-fluorouracil and thymidylate synthase in colorectal cancer.
Neoplasms
VHL-HIF-2? axis-induced SMYD3 upregulation drives renal cell carcinoma progression via direct trans-activation of EGFR.
Neoplasms
WDR5 supports colon cancer cells by promoting methylation of H3K4 and suppressing DNA damage.
Neoplasms
Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified.
Neoplasms
Whole-exome sequencing defines the mutational landscape of pheochromocytoma and identifies KMT2D as a recurrently mutated gene.
Neoplasms
Whole-Exome Sequencing Reveals Frequent Mutations in Chromatin Remodeling Genes in Mammary and Extramammary Paget's Diseases.
Neoplasms
XIST lost induces ovarian cancer stem cells to acquire taxol resistance via a KMT2C-dependent way.
Neoplasms
[An Analysis of contributions to the main German chat forum for cancer patients regarding palliative care].
Neoplasms
[Experimental research of therapeutic effect on hepatocellular carcinoma of targeting SMYD3 gene inhibition by RNA interference]
Neoplastic Cells, Circulating
SETD1A protects from senescence through regulation of the mitotic gene expression program.
Neuralgia
N6-Methyladenosine Demethylase FTO Contributes to Neuropathic Pain by Stabilizing G9a Expression in Primary Sensory Neurons.
Neuroblastoma
Fgfr3 is a transcriptional target of Ap2delta and Ash2l-containing histone methyltransferase complexes.
Neuroblastoma
The histone methyltransferase DOT1L promotes neuroblastoma by regulating gene transcription.
Neuroblastoma
Transcriptional Changes following Cellular Knockdown of the Schizophrenia Risk Gene SETD1A Are Enriched for Common Variant Association with the Disorder.
Neurodegenerative Diseases
Polymorphism distribution of prion protein codon 117, 129 and 171 in Taiwan.
Neuroectodermal Tumors, Primitive
Somatic mutations of DICER1 and KMT2D are frequent in intraocular medulloepitheliomas.
Neuroendocrine Tumors
Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.
Neurologic Manifestations
Refractory celiac disease type II: An atypical case highlighting limitations of the current classification system.
Obesity
A de novo KMT2D mutation in a girl with Kabuki syndrome associated with endocrine symptoms: a case report.
Obesity
Are School Substance Use Policy Violation Disciplinary Consequences Associated with Student Engagement in Cannabis?
Obesity
Changing social inequalities in smoking, obesity and cause-specific mortality: Cross-national comparisons using compass typology.
Obesity
Clustering of risk-related modifiable behaviours and their association with overweight and obesity among a large sample of youth in the COMPASS study.
Obesity
DOT1L Regulates Thermogenic Adipocyte Differentiation and Function via Modulating H3K79 Methylation.
Obesity
Evaluating the Impact of the Healthy Kids Community Challenge (HKCC) on Physical Activity of Older Youth.
Obesity
Evaluation of BMI-based classification of adolescent overweight and obesity: choice of percentage body fat cutoffs exerts a large influence. The COMPASS study.
Obesity
High School Intramural Participation and Substance Use: A Longitudinal Analysis of COMPASS Data.
Obesity
Problem Video Gaming Among Children Enrolled in Tertiary Weight Management Programs.
Obesity
Reluctancy towards Help-Seeking for Mental Health Concerns at Secondary School among Students in the COMPASS Study.
Obesity
The Combating Obesity in M?ori and Pasifika Adolescent School-Children Study: COMPASS Methodology and Study Protocol.
Obesity, Morbid
Electronic Gaming Characteristics Associated with Class 3 Severe Obesity in Youth Who Attend the Pediatric Weight Management Programs of the COMPASS Network.
Obesity, Morbid
Pilot Testing of a Patient Decision Aid for Adolescents with Severe Obesity in US Pediatric Weight Management Programs within the COMPASS Network.
Oligospermia
Prdm9 incompatibility controls oligospermia and delayed fertility but no selfish transmission in mouse intersubspecific hybrids.
Optic Nerve Diseases
A Comparison between the Compass Fundus Perimeter and the Humphrey Field Analyzer.
Orthostatic Intolerance
Association between autonomic dysfunction and fatigue in Parkinson disease.
Orthostatic Intolerance
Children with Functional Nausea-Comorbidities outside the Gastrointestinal Tract.
Orthostatic Intolerance
Clinical Assessment of Autonomic Function in Fibromyalgia by the Refined and Abbreviated Composite Autonomic Symptom Score (COMPASS 31): A Case-Controlled Study.
Orthostatic Intolerance
Prevalence and characteristics of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) in Poland: a cross-sectional study.
Orthostatic Intolerance
The composite autonomic symptom scale 31 is a useful screening tool for patients with Parkinsonism.
Orthostatic Intolerance
Time Course of Autonomic Symptoms in Postural Orthostatic Tachycardia Syndrome (POTS) Patients: Two-Year Follow-Up Results.
Orthostatic Intolerance
Translation and linguistic validation of the Composite Autonomic Symptom Score COMPASS 31.
Osteoarthritis
Increased susceptibility to develop spontaneous and post-traumatic osteoarthritis in Dot1l-deficient mice.
Osteoarthritis
Review Article: Is Wnt Signaling an Attractive Target for the Treatment of Osteoarthritis?
Osteoarthritis
The DOT1L rs12982744 polymorphism is associated with osteoarthritis of the hip with genome-wide statistical significance in males.
Osteoarthritis, Hip
Genome-wide association and functional studies identify the DOT1L gene to be involved in cartilage thickness and hip osteoarthritis.
Osteoarthritis, Hip
The DOT1L rs12982744 polymorphism is associated with osteoarthritis of the hip with genome-wide statistical significance in males.
Osteoarthritis, Knee
Analysis of Polymorphisms in the MATN3 and DOT1L Genes and CTX-II Urinary Levels in Patients with Knee Osteoarthritis in a Northeast Mexican-Mestizo Population.
Osteoarthritis, Knee
Association Between Single Nucleotide Polymorphisms of DOT1L Gene and Risk of Knee Osteoarthritis in a Chinese Han Population.
Osteoporosis
Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women.
Osteoporosis
The histone methyltransferase DOT1L inhibits osteoclastogenesis and protects against osteoporosis.
Osteosarcoma
The nuclear-cytoplasmic trafficking of a chromatin-modifying and remodelling protein (KMT2C), in osteosarcoma.
Ovarian Neoplasms
Depletion of H3K79 methyltransferase Dot1L promotes cell invasion and cancer stem-like cell property in ovarian cancer.
Ovarian Neoplasms
Disruptor of telomeric silencing 1-like promotes ovarian cancer tumor growth by stimulating pro-tumorigenic metabolic pathways and blocking apoptosis.
Ovarian Neoplasms
Overexpression of SMYD3 in Ovarian Cancer is Associated with Ovarian Cancer Proliferation and Apoptosis via Methylating H3K4 and H4K20.
Ovarian Neoplasms
Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer.
Ovarian Neoplasms
SET and MYND Domain-Containing Protein 3 (SMYD3) Polymorphism as a Risk Factor for Susceptibility and Poor Prognosis in Ovarian Cancer.
Ovarian Neoplasms
SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters.
Ovarian Neoplasms
The Histone Methyltransferase DOT1L Is a Functional Component of Estrogen Receptor Alpha Signaling in Ovarian Cancer Cells.
Ovarian Neoplasms
XIST lost induces ovarian cancer stem cells to acquire taxol resistance via a KMT2C-dependent way.
Overweight
Clustering of risk-related modifiable behaviours and their association with overweight and obesity among a large sample of youth in the COMPASS study.
Overweight
Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial.
Pancreatic Diseases
Biomarkers in the Differential Diagnosis of Pancreatic Diseases: Looking for a Compass.
Pancreatic Neoplasms
Coordination of stress signals by the lysine methyltransferase SMYD2 promotes pancreatic cancer.
Pancreatic Neoplasms
Copy number variation and cytidine analogue cytotoxicity: a genome-wide association approach.
Pancreatic Neoplasms
Copy-number variation and protein expression of DOT1L in pancreatic adenocarcinoma as a potential drug target.
Pancreatic Neoplasms
Genomic and Epigenomic Landscaping Defines New Therapeutic Targets for Adenosquamous Carcinoma of the Pancreas.
Pancreatic Neoplasms
Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial.
Pancreatic Neoplasms
Lysine methyltransferase 2D regulates pancreatic carcinogenesis through metabolic reprogramming.
Pancreatic Neoplasms
Overexpression of the SMYD3 Promotes Proliferation, Migration, and Invasion of Pancreatic Cancer.
Pancreatic Neoplasms
RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.
Pancytopenia
Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation.
Paralysis
Posterior interosseous nerve palsy following placement of the compass elbow hinge for acute instability: a case report.
Paraproteinemias
DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signaling.
Parkinsonian Disorders
Parkinsonism and Positive Dopamine Transporter Imaging in a Patient with a Novel KMT2B Variant.
Parkinsonian Disorders
The composite autonomic symptom scale 31 is a useful screening tool for patients with Parkinsonism.
Pediatric Obesity
Evaluation of BMI-based classification of adolescent overweight and obesity: choice of percentage body fat cutoffs exerts a large influence. The COMPASS study.
Perinatal Death
Increased susceptibility to develop spontaneous and post-traumatic osteoarthritis in Dot1l-deficient mice.
Perinatal Death
Loss of SMYD1 Results in Perinatal Lethality via Selective Defects within Myotonic Muscle Descendants.
Peripheral Arterial Disease
A COMPASS for VOYAGERs with revascularized peripheral artery disease.
Peripheral Arterial Disease
Anticoagulation in Patients with Ischaemic Heart Disease and Peripheral Arterial Disease: Clinical Implications of COMPASS Study.
Peripheral Arterial Disease
Clinical characteristics and outcomes of COMPASS eligible patients in France. An analysis from the REACH Registry.
Peripheral Arterial Disease
Clinical factors associated with peripheral artery disease in patients with documented coronary artery disease: A post hoc analysis of the COMPASS trial.
Peripheral Arterial Disease
Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective.
Peripheral Arterial Disease
Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease.
Peripheral Arterial Disease
External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry.
Peripheral Arterial Disease
External applicability of the COMPASS trial: the Western Denmark Heart Registry.
Peripheral Arterial Disease
Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease.
Peripheral Arterial Disease
How can the results of the COMPASS trial benefit patients with coronary or peripheral artery disease in Poland?
Peripheral Arterial Disease
Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials.
Peripheral Arterial Disease
Major Adverse Limb Events in Lower Extremity Peripheral Artery Disease: COMPASS Trial.
Peripheral Arterial Disease
Medical management of stable peripheral artery disease: the COMPASS trial. Perspectives from a vascular standpoint.
Peripheral Arterial Disease
Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial.
Peripheral Arterial Disease
Reducing residual thrombotic risk in patients with peripheral artery disease: impact of the COMPASS trial.
Peripheral Arterial Disease
Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial.
Peripheral Arterial Disease
Risk stratification of cardiovascular complications using CHA2DS2-VASc and CHADS2 scores in chronic atherosclerotic cardiovascular disease.
Peripheral Arterial Disease
Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial.
Peripheral Arterial Disease
Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial.
Peripheral Arterial Disease
Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial.
Peripheral Arterial Disease
Rivaroxaban versus Clopidogrel for Peripheral Artery Disease: A Clinico-Economic Approach of the COMPASS trial.
Peripheral Arterial Disease
Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease.
Peripheral Arterial Disease
Role of rivaroxaban in the prevention of atherosclerotic events.
Peripheral Arterial Disease
Synergistic influence of rivaroxaban on inflammation and coagulation biomarkers in patients with coronary artery disease and peripheral artery disease on aspirin therapy.
Peripheral Arterial Disease
Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease.
Peripheral Arterial Disease
[Dual Pathway Inhibition in Atherosclerosis - Which Patients Benefit?]
Peripheral Arterial Disease
[New possibilities of antithrombotic therapy improving prognosis in patients with stenosing atherosclerosis of carotid arteries].
Peripheral Nervous System Diseases
The Autonomic Symptom Profile: a new instrument to assess autonomic symptoms.
Peritoneal Fibrosis
Inhibition of the H3K4 methyltransferase SET7/9 ameliorates peritoneal fibrosis.
Pheochromocytoma
Whole-exome sequencing defines the mutational landscape of pheochromocytoma and identifies KMT2D as a recurrently mutated gene.
Photosensitivity Disorders
Benign summer light eruption and polymorphic light eruption: genetic and functional studies suggest that a revised nomenclature is required.
Pneumonia
The Methyltransferase DOT1L Controls Activation and Lineage Integrity in CD4+ T Cells during Infection and Inflammation.
Polycystic Kidney Diseases
Cross-talk between CDK4/6 and SMYD2 regulates gene transcription, tubulin methylation, and ciliogenesis.
Polycystic Kidney Diseases
Lysine methyltransferase SMYD2 promotes cyst growth in autosomal dominant polycystic kidney disease.
Polycystic Kidney Diseases
Polycystic kidney disease: SMYD2 is a novel epigenetic regulator of cyst growth.
Polycystic Kidney, Autosomal Dominant
Cross-talk between CDK4/6 and SMYD2 regulates gene transcription, tubulin methylation, and ciliogenesis.
Polycystic Kidney, Autosomal Dominant
Lysine methyltransferase SMYD2 promotes cyst growth in autosomal dominant polycystic kidney disease.
Polydactyly
Corrigendum to "Preaxial polydactyly in an individual with Wiedemann-Steiner syndrome caused by a novel nonsense mutation in KMT2A. Am J Med Genet Part A. 2017;173A:2821-2,825".
Polydactyly
Preaxial polydactyly in an individual with Wiedemann-Steiner syndrome caused by a novel nonsense mutation in KMT2A.
Prader-Willi Syndrome
Epigenetics meets GPCR: inhibition of histone H3 methyltransferase (G9a) and histamine H3 receptor for Prader-Willi Syndrome.
Pre-Eclampsia
Advocacy organisations as partners in pre-eclampsia progress: patient involvement improves outcomes.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A lineage switch from NPM1-mutant acute myeloid leukemia to acute T-cell lymphoblastic leukemia with KMT2D and ARID2 mutant.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute lymphoblastic leukemia in infants: a quarter century of nationwide efforts in Japan.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Azacitidine successfully maintained the second remission in an infant with KMT2A-rearranged acute lymphoblastic leukemia who relapsed after unrelated cord blood transplantation.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
B-cell lymphoblastic lymphoma with cutaneous involvement and a KMT2A gene rearrangement.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
DNA methylation profiling of pediatric B-cell lymphoblastic leukemia with KMT2A rearrangement identifies hypomethylation at enhancer sites.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
First case of B ALL with KMT2A-MAML2 rearrangement: a case report.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Flow cytometric predictive scoring systems for common fusions ETV6/RUNX1, BCR/ABL1, TCF3/PBX1 and rearrangements of the KMT2A gene, proposed for the initial cytogenetic approach in cases of B-acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Genetic mutational analysis of pediatric acute lymphoblastic leukemia from a single center in China using exon sequencing.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Hematopoietic stem cell transplantation for infants with high-risk KMT2A gene rearranged acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Inv(11)(q21q23); KMT2A-MAML2, a Recurrent Genetic Abnormality in T-Cell Therapy-related Acute Lymphoblastic Leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Is acute lymphoblastic leukemia with mature B-cell phenotype and KMT2A rearrangements a new entity? A systematic review and meta-analysis.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Molecular characterization of KMT2A fusion partner genes in 13 cases of pediatric leukemia with complex or cryptic karyotypes.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Outcomes of Acute Lymphoblastic Leukemia with KMT2A (MLL) rearrangement - The MD Anderson Experience.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
SMYD2 is highly expressed in pediatric acute lymphoblastic leukemia and constitutes a bad prognostic factor.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Whole transcriptome sequencing reveals a KMT2A-USP2 fusion in infant acute myeloid leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Whole-exome sequencing of a rare case of familial childhood acute lymphoblastic leukemia reveals putative predisposing mutations in Fanconi anemia genes.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
XRCC4 rs28360071 intronic variant is associated with increased risk for infant acute lymphoblastic leukemia with KMT2A rearrangements.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Epigenetic silencing of SOCS5 potentiates JAK-STAT signaling and progression of T-cell acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
The lysine methyltransferase SMYD2 is required for normal lymphocyte development and survival of hematopoietic leukemias.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes.
Primary Dysautonomias
Autonomic symptoms are common and are associated with overall symptom burden and disease activity in primary Sjogren's syndrome.
Prion Diseases
Polymorphism distribution of prion protein codon 117, 129 and 171 in Taiwan.
Progeria
The Role of Dot1l in Prenatal and Postnatal Murine Chondrocytes and Trabecular Bone.
Prostatic Neoplasms
High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer.
Prostatic Neoplasms
Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer.
Prostatic Neoplasms
Integrated Analysis of Genetic Abnormalities of the Histone Lysine Methyltransferases in Prostate Cancer.
Prostatic Neoplasms
Long and noncoding RNAs (lnc-RNAs) determine androgen receptor dependent gene expression in prostate cancer growth in vivo.
Prostatic Neoplasms
Loss of KMT2D induces prostate cancer ROS-mediated DNA damage by suppressing the enhancer activity and DNA binding of antioxidant transcription factor FOXO3.
Prostatic Neoplasms
Mutational and transcriptomic landscapes of a rare human prostate basal cell carcinoma.
Prostatic Neoplasms
Role of RbBP5 and H3K4me3 in the vicinity of Snail transcription start site during epithelial- mesenchymal- transition in prostate cancer cell.
Prostatic Neoplasms
SETD1A Promotes Proliferation of Castration-Resistant Prostate Cancer Cells via FOXM1 Transcription.
Prostatic Neoplasms
SMYD3 as an oncogenic driver in prostate cancer by stimulation of androgen receptor transcription.
Prostatic Neoplasms
SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3.
Prostatic Neoplasms
The COMPASs Study: Community Preferences for Prostate cAncer Screening. Protocol for a quantitative preference study.
Prostatic Neoplasms
Three-dimensional dose reconstruction-based pretreatment dosimetric verification in volumetric modulated arc therapy for prostate cancer.
Prostatic Neoplasms
Transcriptional regulation of 15-lipoxygenase expression by histone h3 lysine 4 methylation/demethylation.
Prurigo
Benign summer light eruption and polymorphic light eruption: genetic and functional studies suggest that a revised nomenclature is required.
Psoriasis
Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate-to-severe plaque psoriasis: the COMPASS analysis.
Pterygium
Comparison of Different Measurement Tools and Dimensional Parameters of Pterygium to Investigate its Impact on Refractive Indices and Ocular Aberrations.
Pulmonary Arterial Hypertension
Navigating the uncharted waters of combination therapy in pulmonary arterial hypertension: COMPASS or dead-reckoning.
Pulmonary Disease, Chronic Obstructive
Investigation of the Clinical, Radiological and Biological Factors Associated with Disease Progression, Phenotypes and Endotypes of COPD in China (COMPASS): study design, protocol and rationale.
Pulmonary Disease, Chronic Obstructive
SMYD3 promotes colon adenocarcinoma (COAD) progression by mediating cell proliferation and apoptosis.
Pulmonary Disease, Chronic Obstructive
[Health and disease in the Netherlands: the Dutch National Public Health Compass as a source of information]
Pulpitis
ASH1L Suppresses Matrix Metalloproteinase through Mitogen-activated Protein Kinase Signaling Pathway in Pulpitis.
Renal Insufficiency
Editor's Choice - External Applicability of the COMPASS and VOYAGER-PAD Trials on Patients with Symptomatic Lower Extremity Artery Disease in France: The COPART Registry.
Retinoblastoma
Crystal structures of histone and p53 methyltransferase SmyD2 reveal a conformational flexibility of the autoinhibitory C-terminal domain.
Retinoblastoma
Effect of the downregulation of SMYD3 expression by RNAi on RIZ1 expression and proliferation of esophageal squamous cell carcinoma.
Retinoblastoma
Lysine methyltransferase Smyd2 regulates Hsp90-mediated protection of the sarcomeric titin springs and cardiac function.
Rhabdomyosarcoma
Smyd1 And G6Pd Modulation Are Critical Events For Mir-206-Mediated Differentiation Of Rhabdomyosarcoma.
Rheumatic Diseases
[Back to school physical education despite rheumatism : Development and testing of a sport scientific-based physical education certification].
Rubinstein-Taybi Syndrome
KMT2C/D COMPASS complex-associated diseases [KCDCOM-ADs]: an emerging class of congenital regulopathies.
Sarcoma
Pan-sarcoma genomic analysis of KMT2A rearrangements reveals distinct subtypes defined by YAP1-KMT2A-YAP1 and VIM-KMT2A fusions.
Sarcoma
Recurrent Fusions Between YAP1 and KMT2A in Morphologically Distinct Neoplasms Within the Spectrum of Low-grade Fibromyxoid Sarcoma and Sclerosing Epithelioid Fibrosarcoma.
Sarcoma, Myeloid
Clinicopathological characteristics of de novo and secondary myeloid sarcoma: a monocentric retrospective study.
Sarcoma, Myeloid
Mutations within the Activation Loop Domain of FLT3 in Two Pediatric Patients with Refractory Infant Acute Myeloid Leukemia.
Sarcoma, Myeloid
Myeloid Sarcoma of the Testis in Children: Clinicopathologic and Immunohistochemical Characteristics With KMT2A (MLL) Gene Rearrangement Correlation.
Sarcoma, Myeloid
Rare myeloid sarcoma with KMT2A (MLL)-ELL fusion presenting as a vaginal wall mass.
Scoliosis
De novo loss-of-function variants of ASH1L are associated with an emergent neurodevelopmental disorder.
Seizures
Clinical Characteristics and Genotype-Phenotype Correlation in Children with KMT2E Gene-Related Neurodevelopmental Disorders: Report of Two New Cases and Review of Published Literature.
Sepsis
Histone methyltransferase ash1l suppresses interleukin-6 production and inflammatory autoimmune diseases by inducing the ubiquitin-editing enzyme a20.
Shock, Septic
Bioinformatics Analysis of Gene Expression Profiles for Risk Prediction in Patients with Septic Shock.
Skin Neoplasms
Exome sequencing identifies novel mutation signatures of UV radiation and trichostatin A in primary human keratinocytes.
Sleep Apnea Syndromes
De novo loss-of-function variants of ASH1L are associated with an emergent neurodevelopmental disorder.
Sleep Deprivation
Modifiable predictors of insufficient sleep durations: A longitudinal analysis of youth in the COMPASS study.
Small Cell Lung Carcinoma
KMT2D Mutation Is Associated With Poor Prognosis in Non-Small-Cell Lung Cancer.
Smoldering Multiple Myeloma
DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signaling.
Sotos Syndrome
Growth disrupting mutations in epigenetic regulatory molecules are associated with abnormalities of epigenetic aging.
Spondylitis
Biomechanical assessment of balance and posture in subjects with inclosing spondylitis.
Squamous Cell Carcinoma of Head and Neck
SMYD2 overexpression is associated with tumor cell proliferation and a worse outcome in human papillomavirus-unrelated nonmultiple head and neck carcinomas.
Squamous Cell Carcinoma of Head and Neck
The non-coding landscape of head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Upregulation of histone methyltransferase, DOT1L by matrix hyaluronan promotes MicroRNA-10 expression leading to tumor cell invasion and chemoresistance in cancer stem cells from head and neck squamous cell carcinoma.
Stevens-Johnson Syndrome
Using a claims database to investigate drug-induced Stevens-Johnson syndrome.
Stomach Neoplasms
ATM Signaling Pathway Is Implicated in the SMYD3-mediated Proliferation and Migration of Gastric Cancer Cells.
Stomach Neoplasms
Biomarker analysis to predict the pathological response to neoadjuvant chemotherapy in locally advanced gastric cancer: An exploratory biomarker study of COMPASS, a randomized phase II trial.
Stomach Neoplasms
Difference of molecular alterations in HER2-positive and HER2-negative gastric cancers by whole-genome sequencing analysis.
Stomach Neoplasms
Downregulation of KMT2D suppresses proliferation and induces apoptosis of gastric cancer.
Stomach Neoplasms
Euchromatic histone lysine methyltransferase 1 regulates cancer development in human gastric cancer by regulating E-cadherin.
Stomach Neoplasms
Exome sequencing reveals three novel candidate predisposition genes for diffuse gastric cancer.
Stomach Neoplasms
Expression of Concern: The role of DOT1L in the proliferation and prognosis of gastric cancer.
Stomach Neoplasms
Genomic alterations in advanced gastric cancer endoscopic biopsy samples using targeted next-generation sequencing.
Stomach Neoplasms
Hesperetin promotes DOT1L degradation and reduces histone H3K79 methylation to inhibit gastric cancer metastasis.
Stomach Neoplasms
Histone Methyltransferase SETD1A Induces Epithelial-Mesenchymal Transition to Promote Invasion and Metastasis Through Epigenetic Reprogramming of Snail in Gastric Cancer.
Stomach Neoplasms
Histone methyltransferase SETD1A interacts with HIF1? to enhance glycolysis and promote cancer progression in gastric cancer.
Stomach Neoplasms
Increased expression of EHMT2 associated with H3K9me2 level contributes to the poor prognosis of gastric cancer.
Stomach Neoplasms
Induction of a Pathological Complete Response by Four Courses of Neoadjuvant Chemotherapy for Gastric Cancer: Early Results of the Randomized Phase II COMPASS Trial.
Stomach Neoplasms
KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation.
Stomach Neoplasms
KMT2D promotes proliferation of gastric cancer cells: evidence from ctDNA sequencing.
Stomach Neoplasms
miRNA-584-3p inhibits gastric cancer progression by repressing Yin Yang 1- facilitated MMP-14 expression.
Stomach Neoplasms
Overexpression of SMYD2 contributes to malignant outcome in gastric cancer.
Stomach Neoplasms
Overexpression of SMYD3 and matrix metalloproteinase-9 are associated with poor prognosis of patients with gastric cancer.
Stomach Neoplasms
Overexpression of SMYD3 was associated with increased STAT3 activation in gastric cancer.
Stomach Neoplasms
The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors.
Stomach Neoplasms
Upregulated SMYD3 promotes bladder cancer progression by targeting BCLAF1 and activating autophagy.
Stroke
A Person-Centered Approach to Poststroke Care: The COMprehensive Post-Acute Stroke Services Model.
Stroke
Beat-by-Beat Estimation of the Left Ventricular Pressure-Volume Loop Under Clinical Conditions.
Stroke
COMPASS-CP: An Electronic Application to Capture Patient-Reported Outcomes to Develop Actionable Stroke and Transient Ischemic Attack Care Plans.
Stroke
Democratizing health system data to impact social and environmental health contexts: a novel collaborative community data-sharing model.
Stroke
Editor's Choice - External Applicability of the COMPASS and VOYAGER-PAD Trials on Patients with Symptomatic Lower Extremity Artery Disease in France: The COPART Registry.
Stroke
Ensuring respect for persons in COMPASS: a cluster randomised pragmatic clinical trial.
Stroke
External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry.
Stroke
Genome-Wide Association Study Meta-Analysis of Stroke in 22 000 Individuals of African Descent Identifies Novel Associations With Stroke.
Stroke
Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease.
Stroke
Hospital recruitment for a pragmatic cluster-randomized clinical trial: Lessons learned from the COMPASS study.
Stroke
How engagement of a diverse set of stakeholders shaped the design, implementation, and dissemination of a multicenter pragmatic trial of stroke transitional care: The COMPASS study.
Stroke
Implementation of a billable transitional care model for stroke patients: the COMPASS study.
Stroke
Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial.
Stroke
Meta-Analysis of Genome-Wide Association Studies Identifies Genetic Risk Factors for Stroke in African Americans.
Stroke
Methods guiding stakeholder engagement in planning a pragmatic study on changing stroke systems of care.
Stroke
Non-vitamin K antagonist oral anticoagulants (NOACs) in the treatment of coronary and peripheral atherosclerosis. Expert Consensus.
Stroke
Patient Factors Associated With Attendance at a Comprehensive Postacute Stroke Visit: Insight From the Vanguard Site.
Stroke
Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines.
Stroke
Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial.
Stroke
Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial.
Stroke
Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy.
Stroke
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Stroke
Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASS-CABG Study.
Stroke
The COMPASS trial: practical considerations for application after coronary artery bypass surgery.
Stroke
The Cost of Implementing and Sustaining the COMprehensive Post-Acute Stroke Services Model.
Stroke
Usefulness of Coronary Artery Calcium to Identify Adults of Sufficiently High Risk for Atherothrombotic Cardiovascular Events to Consider Low-Dose Rivaroxaban Thromboprophylaxis (from MESA).
Stroke
[Atherosclerotic Cardiovascular Diseases and Type 2 Diabetes Mellitus - new Developments in the Treatment].
Stroke
[Combined Antithrombotic Therapy in Patients with a Stable Atherosclerotic Cardiovascular Diseases: What Direction did COMPASS Show?]
Stroke
[Health and disease in the Netherlands: the Dutch National Public Health Compass as a source of information]
Stroke
[New possibilities of antithrombotic therapy improving prognosis in patients with stenosing atherosclerosis of carotid arteries].
Tachycardia, Ventricular
[Is programmed ventricular stimulation still up to date in the medicinal evaluation of ventricular tachycardia?]
Testicular Neoplasms
ASH2L drives proliferation and sensitivity to bleomycin and other genotoxins in Hodgkin's lymphoma and testicular cancer cells.
Testicular Neoplasms
Correction to: ASH2L drives proliferation and sensitivity to bleomycin and other genotoxins in Hodgkin's lymphoma and testicular cancer cells.
Thrombosis
European Society of Cardiology (ESC) Annual Congress Report From Barcelona 2017.
Thrombosis
The COMPASS trial: practical considerations for application after coronary artery bypass surgery.
Thrombosis
[New possibilities of antithrombotic therapy improving prognosis in patients with stenosing atherosclerosis of carotid arteries].
Thymoma
Pan-Cancer Landscape Analysis Reveals Recurrent KMT2A-MAML2 Gene Fusion in Aggressive Histologic Subtypes of Thymoma.
Thymoma
Thymic adenocarcinoma accompanied by type A thymoma and pulmonary minimally invasive adenocarcinoma and harboring distinct gene alterations: A case report.
Thyroid Cancer, Papillary
Overexpression of SET and MYND Domain-Containing Protein 2 (SMYD2) Is Associated with Tumor Progression and Poor Prognosis in Patients with Papillary Thyroid Carcinoma.
Thyroid Carcinoma, Anaplastic
Novel role of ASH1L histone methyltransferase in anaplastic thyroid carcinoma.
Thyroid Neoplasms
Epigenetic-related gene expression profile in medullary thyroid cancer revealed the overexpression of the histone methyltransferases EZH2 and SMYD3 in aggressive tumours.
Thyroid Neoplasms
Novel role of ASH1L histone methyltransferase in anaplastic thyroid carcinoma.
Tooth Attrition
Individual tooth macrowear pattern guides the reconstruction of Sts 52 (Australopithecus africanus) dental arches.
Tooth Loss
Dental arch perimeter changes as a result from premature loss of primary anterior teeth due to trauma: A case series in infant and pre-school children.
Tourette Syndrome
Role of Ash1l in Tourette syndrome and other neurodevelopmental disorders.
Tourette Syndrome
Spontaneous hyperactivity in Ash1l mutant mice, a new model for Tourette syndrome.
Triple Negative Breast Neoplasms
A cytoplasmic COMPASS is necessary for cell survival and triple-negative breast cancer pathogenesis by regulating metabolism.
Triple Negative Breast Neoplasms
Aberrant expression of SETD1A promotes survival and migration of estrogen receptor ?-positive breast cancer cells.
Triple Negative Breast Neoplasms
Dysregulation of non-histone molecule miR205 and LRG1 post-transcriptional de-regulation by SETD1A in triple negative breast cancer.
Triple Negative Breast Neoplasms
Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer.
Triple Negative Breast Neoplasms
Inhibition of DOT1L by Half-Selenopsammaplin A Analogs Suppresses Tumor Growth and EMT-Mediated Metastasis in Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression.
Triple Negative Breast Neoplasms
Targeting Histone Methyltransferase DOT1L by a Novel Psammaplin A Analog Inhibits Growth and Metastasis of Triple-Negative Breast Cancer.
Ureteral Obstruction
Blocking the histone lysine 79 methyltransferase DOT1L alleviates renal fibrosis through inhibition of renal fibroblast activation and epithelial-mesenchymal transition.
Ureteral Obstruction
Critical roles of SMYD2 lysine methyltransferase in mediating renal fibroblast activation and kidney fibrosis.
Urinary Bladder Neoplasms
A virome-wide clonal integration analysis platform for discovering cancer viral etiology.
Urinary Bladder Neoplasms
Analysis of the role of mutations in the KMT2D histone lysine methyltransferase in bladder cancer.
Urinary Bladder Neoplasms
Effect of SMYD3 on biological behavior and H3K4 methylation in bladder cancer.
Urinary Bladder Neoplasms
High expression of SMYD3 indicates poor survival outcome and promotes tumour progression through an IGF-1R/AKT/E2F-1 positive feedback loop in bladder cancer.
Urinary Bladder Neoplasms
KMT2D inhibits the growth and metastasis of bladder Cancer cells by maintaining the tumor suppressor genes.
Urinary Bladder Neoplasms
MiRNA-217 accelerates the proliferation and migration of bladder cancer via inhibiting KMT2D.
Urinary Bladder Neoplasms
The BBN model: a mouse bladder cancer model featuring basal-subtype gene expression and MLL3/MLL4 genetic disruption.
Urinary Bladder Neoplasms
The lysine-specific methyltransferase KMT2C/MLL3 regulates DNA repair components in cancer.
Urinary Bladder Neoplasms
Upregulated SMYD3 promotes bladder cancer progression by targeting BCLAF1 and activating autophagy.
Uterine Cervical Neoplasms
Inhibition of Euchromatic Histone Lysine Methyltransferase 2 (EHMT2) Suppresses the Proliferation and Invasion of Cervical Cancer Cells.
Uterine Cervical Neoplasms
KMT2A regulates cervical cancer cell growth through targeting VDAC1.
Uterine Cervical Neoplasms
Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.
Uterine Cervical Neoplasms
SMYD2 promotes cervical cancer growth by stimulating cell proliferation.
Uterine Cervical Neoplasms
SMYD2 suppresses p53 activity to promote glucose metabolism in cervical cancer.
Vascular Diseases
Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?
Vascular Diseases
Association of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients.
Vascular Diseases
Correction to: The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease.
Vascular Diseases
Eligibility for Low-Dose Rivaroxaban Based on the COMPASS Trial: Insights from the Veterans Affairs Healthcare System.
Vascular Diseases
Fighting residual cardiovascular risk in stable patients with atherosclerotic vascular disease: COMPASS in context.
Vascular Diseases
Rivaroxaban and Aspirin in Peripheral Vascular Disease: a Review of Implementation Strategies and Management of Common Clinical Scenarios.
Vascular Diseases
Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy.
Vascular Diseases
Rivaroxaban for the prevention of major adverse cardiovascular events in patients with coronary or peripheral artery disease.
Vascular Diseases
Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial.
Vascular Diseases
Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial.
Vascular Diseases
The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease.
Vascular Diseases
Vascular disease: Reduction in major adverse limb events in the COMPASS trial.
Vascular Diseases
[Mortality benefit with different antithrombotic therapies in patients with stable vascular disease: from pathophysiology to the clinical impact in the real world. The COMPASS study].
Vesicular Stomatitis
Interferon-? Stimulation Elicited by the Influenza Virus Is Regulated by the Histone Methylase Dot1L through the RIG-I-TRIM25 Signaling Axis.
Vesicular Stomatitis
The DOT1L inhibitor Pinometostat decreases the host-response against infections: Considerations about its use in human therapy.
Virus Diseases
A high definition picture of somatic mutations in chronic lymphoproliferative disorder of natural killer cells.
Virus Diseases
Epigenetic control of Foxp3 by SMYD3 H3K4 histone methyltransferase controls iTreg development and regulates pathogenic T-cell responses during pulmonary viral infection.
Virus Diseases
Human papillomavirus and the landscape of secondary genetic alterations in oral cancers.
Virus Diseases
Interferon-? Stimulation Elicited by the Influenza Virus Is Regulated by the Histone Methylase Dot1L through the RIG-I-TRIM25 Signaling Axis.
Virus Diseases
Methyltransferase Dot1l preferentially promotes innate IL-6 and IFN-? production by mediating H3K79me2/3 methylation in macrophages.
Virus Diseases
Notch ligand Delta-like 4 induces epigenetic regulation of Treg cell differentiation and function in viral infection.
Virus Diseases
Quantitative Proteomic Discovery of Dynamic Epigenome Changes that Control Human Cytomegalovirus (HCMV) Infection.
Waardenburg Syndrome
Triple diagnosis of Wiedemann-Steiner, Waardenburg and DLG3-related intellectual disability association found by WES: A case report.
Williams Syndrome
Evaluation of PRDM9 variation as a risk factor for recurrent genomic disorders and chromosomal non-disjunction.
Wolf-Hirschhorn Syndrome
A Scalable Platform for Producing Recombinant Nucleosomes with Codified Histone Methyltransferase Substrate Preferences.
Wolf-Hirschhorn Syndrome
Histone lysine methyltransferase Wolf-Hirschhorn syndrome candidate 1 is involved in human carcinogenesis through regulation of the Wnt pathway.
[histone h3]-lysine4 n-trimethyltransferase
deficiency
Aqp5 is a new transcriptional target of Dot1a and a regulator of Aqp2.
[histone h3]-lysine4 n-trimethyltransferase
deficiency
Ash1l controls quiescence and self-renewal potential in hematopoietic stem cells.
[histone h3]-lysine4 n-trimethyltransferase
deficiency
CRISPR-GEMM pooled mutagenic screening identifies KMT2D as a major modulator of immune checkpoint blockade.
[histone h3]-lysine4 n-trimethyltransferase
deficiency
Deficiency of H3K79 Histone Methyltransferase Dot1-like Protein (DOT1L) Inhibits Cell Proliferation.
[histone h3]-lysine4 n-trimethyltransferase
deficiency
Differentiation and localization of interneurons in the developing spinal cord depends on DOT1L expression.
[histone h3]-lysine4 n-trimethyltransferase
deficiency
Dot1l deficiency leads to increased intercalated cells and upregulation of V-ATPase B1 in mice.
[histone h3]-lysine4 n-trimethyltransferase
deficiency
Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma.
[histone h3]-lysine4 n-trimethyltransferase
deficiency
ES cell cycle progression and differentiation require the action of the histone methyltransferase Dot1L.
[histone h3]-lysine4 n-trimethyltransferase
deficiency
Histone H3 lysine K4 methylation and its role in learning and memory.
[histone h3]-lysine4 n-trimethyltransferase
deficiency
KMT2D deficiency enhances the anti-cancer activity of L48H37 in pancreatic ductal adenocarcinoma.
[histone h3]-lysine4 n-trimethyltransferase
deficiency
KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer.
[histone h3]-lysine4 n-trimethyltransferase
deficiency
KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation.
[histone h3]-lysine4 n-trimethyltransferase
deficiency
Lysine methyltransferase SMYD2 promotes cyst growth in autosomal dominant polycystic kidney disease.
[histone h3]-lysine4 n-trimethyltransferase
deficiency
Setd1a and NURF mediate chromatin dynamics and gene regulation during erythroid lineage commitment and differentiation.
[histone h3]-lysine4 n-trimethyltransferase
deficiency
SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma.
[histone h3]-lysine4 n-trimethyltransferase
deficiency
Setd1a regulates progenitor B-cell-to-precursor B-cell development through histone H3 lysine 4 trimethylation and Ig heavy-chain rearrangement.
[histone h3]-lysine4 n-trimethyltransferase
deficiency
Setd1b, encoding a histone 3 lysine 4 methyltransferase, is a maternal effect gene required for the oogenic gene expression program.
[histone h3]-lysine4 n-trimethyltransferase
deficiency
The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development.
[histone h3]-lysine4 n-trimethyltransferase
deficiency
The selective activation of p53 target genes regulated by SMYD2 in BIX-01294 induced autophagy-related cell death.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.0002
ART(Kme1)QTARKSTGGKAPRKQLATKAA-GK-biotin
mutant enzyme S289N, at pH 9.0 and 23°C
0.0003
ART(Kme1)QTARKSTGGKAPRKQLATKAA-GK-biotin
mutant enzyme S357Y, at pH 9.0 and 23°C
0.0007
ART(Kme1)QTARKSTGGKAPRKQLATKAA-GK-biotin
wild type enzyme, at pH 9.0 and 23°C
0.001
ART(Kme1)QTARKSTGGKAPRKQLATKAA-GK-biotin
mutant enzyme S312W, at pH 9.0 and 23°C
0.002
ART(Kme1)QTARKSTGGKAPRKQLATKAA-GK-biotin
mutant enzyme S289N/S312W/S357Y, at pH 9.0 and 23°C
0.00026
ART(Kme2)QTARKSTGGKAPRKQLATKAA-GK-biotin
mutant enzyme S357Y, at pH 9.0 and 23°C
0.002
ART(Kme2)QTARKSTGGKAPRKQLATKAA-GK-biotin
mutant enzyme S312W, at pH 9.0 and 23°C
0.0033
ART(Kme2)QTARKSTGGKAPRKQLATKAA-GK-biotin
mutant enzyme S289N/S312W/S357Y, at pH 9.0 and 23°C
0.0035
ART(Kme2)QTARKSTGGKAPRKQLATKAA-GK-biotin
wild type enzyme, at pH 9.0 and 23°C
0.004
ART(Kme2)QTARKSTGGKAPRKQLATKAA-GK-biotin
mutant enzyme S289N, at pH 9.0 and 23°C
0.00017
ARTKQTARKSTGGKAPRKQLATKAA-GK-biotin
mutant enzyme S357Y, at pH 9.0 and 23°C
0.0004
ARTKQTARKSTGGKAPRKQLATKAA-GK-biotin
mutant enzyme S289N, at pH 9.0 and 23°C
0.0004
ARTKQTARKSTGGKAPRKQLATKAA-GK-biotin
mutant enzyme S312W, at pH 9.0 and 23°C
0.0008
ARTKQTARKSTGGKAPRKQLATKAA-GK-biotin
wild type enzyme, at pH 9.0 and 23°C
0.0017
ARTKQTARKSTGGKAPRKQLATKAA-GK-biotin
mutant enzyme S289N/S312W/S357Y, at pH 9.0 and 23°C
0.025
S-adenosyl-L-methionine
mutant enzyme S289N/S312W/S357Y, at pH 9.0 and 23°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.0022
ART(Kme1)QTARKSTGGKAPRKQLATKAA-GK-biotin
wild type enzyme, at pH 9.0 and 23°C
0.0036
ART(Kme1)QTARKSTGGKAPRKQLATKAA-GK-biotin
mutant enzyme S289N, at pH 9.0 and 23°C
0.0333
ART(Kme1)QTARKSTGGKAPRKQLATKAA-GK-biotin
mutant enzyme S312W, at pH 9.0 and 23°C
6
ART(Kme1)QTARKSTGGKAPRKQLATKAA-GK-biotin
mutant enzyme S357Y, at pH 9.0 and 23°C
7.5
ART(Kme1)QTARKSTGGKAPRKQLATKAA-GK-biotin
mutant enzyme S289N/S312W/S357Y, at pH 9.0 and 23°C
0.0167
ART(Kme2)QTARKSTGGKAPRKQLATKAA-GK-biotin
mutant enzyme S312W, at pH 9.0 and 23°C
0.021
ART(Kme2)QTARKSTGGKAPRKQLATKAA-GK-biotin
mutant enzyme S289N, at pH 9.0 and 23°C
0.053
ART(Kme2)QTARKSTGGKAPRKQLATKAA-GK-biotin
wild type enzyme, at pH 9.0 and 23°C
4.167
ART(Kme2)QTARKSTGGKAPRKQLATKAA-GK-biotin
mutant enzyme S289N/S312W/S357Y, at pH 9.0 and 23°C
6.444
ART(Kme2)QTARKSTGGKAPRKQLATKAA-GK-biotin
mutant enzyme S357Y, at pH 9.0 and 23°C
0.0025
ARTKQTARKSTGGKAPRKQLATKAA-GK-biotin
wild type enzyme, at pH 9.0 and 23°C
0.0031
ARTKQTARKSTGGKAPRKQLATKAA-GK-biotin
mutant enzyme S289N, at pH 9.0 and 23°C
0.0139
ARTKQTARKSTGGKAPRKQLATKAA-GK-biotin
mutant enzyme S312W, at pH 9.0 and 23°C
4.806
ARTKQTARKSTGGKAPRKQLATKAA-GK-biotin
mutant enzyme S357Y, at pH 9.0 and 23°C
5.833
ARTKQTARKSTGGKAPRKQLATKAA-GK-biotin
mutant enzyme S289N/S312W/S357Y, at pH 9.0 and 23°C
3.056
S-adenosyl-L-methionine
mutant enzyme S289N/S312W/S357Y, at pH 9.0 and 23°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
SOURCE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY
GeneOntology No.
LITERATURE
SOURCE
GFP-Set1 fusion protein in nuclear speckles that are largely excluded from DAPI-bright regions, thus euchromatin localization, FLAG-CXXC finger protein 1 and GFP-Set1 colocalize to sub-nuclear regions that are distinct from regions of DAPIbright heterochromatin
brenda
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
metabolism
the enzyme is involved in calcium dependent signaling pathways through forming complexes with the phospholipase PLCB3, calcium/calmodulin dependent kinase CAMK2B, or calcineurin inhibitor RCAN3. The enzyme is involved in epigenetic transcriptional regulation
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable).
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). SMYD3_HUMAN
428
0
49097
Swiss-Prot
other Location (Reliability: 4)
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PDB
SCOP
CATH
UNIPROT
ORGANISM
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
S289N
the PRDM7 mutant loses the dimethylated substrate specificity and instead gains the ability to methylate H3K36 similar to, but less efficiently than its evolutionary predecessor PRDM9
S289N/S312W/S357Y
the PRDM7 mutant regains the substrate specificities and catalytic activities similar to its evolutionary predecessor PRDM9, including the ability to efficiently methylate histone H3 lysine 36
S312W
the PRDM7 mutant loses the dimethylated substrate specificity and instead gains the ability to methylate H3K36 similar to, but less efficiently than its evolutionary predecessor PRDM9
S357Y
the PRDM7 mutant regains the substrate specificities and catalytic activities similar to its evolutionary predecessor PRDM9, including the ability to efficiently methylate histone H3 lysine 36
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PURIFICATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Yeates, T.O.
Structures of SET domain proteins: protein lysine methyltransferases make their mark
Cell
111
5-7
2002
Homo sapiens
brenda
Lee, J.H.; Skalnik, D.G.
CpG-binding protein (CXXC finger protein 1) is a component of the mammalian Set1 histone H3-Lys4 methyltransferase complex, the analogue of the yeast Set1/COMPASS complex
J. Biol. Chem.
280
41725-41731
2005
Mus musculus, Homo sapiens (O15047), Homo sapiens
brenda
Wu, X.; Hua, X.
Menin, histone H3 methyltransferases, and regulation of cell proliferation: current knowledge and perspective
Curr. Mol. Med.
8
805-815
2008
Drosophila melanogaster, Homo sapiens
brenda
Butler, J.S.; Lee, J.H.; Skalnik, D.G.
CFP1 interacts with DNMT1 independently of association with the Setd1 histone H3K4 methyltransferase complexes
DNA Cell Biol.
27
533-543
2008
Homo sapiens
brenda
Cho, Y.W.; Hong, S.; Ge, K.
Affinity purification of MLL3/MLL4 histone H3K4 methyltransferase complex
Methods Mol. Biol.
809
465-472
2012
Homo sapiens
brenda
Blazer, L.L.; Lima-Fernandes, E.; Gibson, E.; Eram, M.S.; Loppnau, P.; Arrowsmith, C.H.; Schapira, M.; Vedadi, M.
PR domain-containing protein 7 (PRDM7) is a histone 3 lysine 4 trimethyltransferase
J. Biol. Chem.
291
13509-13519
2016
Homo sapiens (Q9NQW5)
brenda
Zhang, Y.; Li, C.; Yang, Z.
Is MYND domain-mediated assembly of SMYD3 complexes involved in calcium dependent signaling?
Front. Mol. Biosci.
6
121
2019
Homo sapiens (Q9H7B4)
brenda
EXTERNAL LINKS (specific for EC-Number 2.1.1.354)
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
About BRENDA
Social media
Help
Survey
Download
Contribution
Legal
Curated at
Member of
